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Abstract 
Title: An investigation into the risk factors of musculoskeletal diseases and the 
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Background:  A recent shift in the global burden of disease from communicable to non-
communicable has shown that a third of the global burden of disease is attributable to non-
communicable disease, with the heaviest burden affecting poor communities in urban 
areas. Musculoskeletal disease (MSD) is the most common cause of severe chronic or 
persistent pain, functional limitations, and physical disability, affecting 20-50% of adults. 
Globally, disability due to musculoskeletal disease is estimated to have increased by 45% 
from 1990 to 2010 accounting for 6.8% of total years lived with disability. Research has 
highlighted a possible co-existence of musculoskeletal disease and chronic non-
communicable diseases of lifestyle, however, there is inadequate South African evidence 
regarding these inter-relationships and possible risk factors. This highlights a gap in 
research as management may not be appropriately targeted toward risk factors and thus 
may not reduce the high prevalence rates of musculoskeletal disease. 
Aim:  The main aims of this study were firstly to determine the prevalence and patterns of 
acute and chronic musculoskeletal disease. The secondary aim was to explore the 
relationship between these factors by examining the patterns of onset of musculoskeletal 
disease, chronic diseases of lifestyle, and risk factors across gender and six age categories 
(from 18 years to 70 years and older) in patients seeking medical services at a community 
health centre in Cape Town, South Africa. It was hypothesised that if some conditions were 
found to have an earlier onset, these conditions might lay the foundation for the 
development of other chronic diseases of lifestyle and musculoskeletal disease. 
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Methodology:   A descriptive, cross-sectional, analytical study design was used at primary 
health care level at a community health centre in Cape Town, South Africa. All males and 
females aged 18 years and older, except those who were pregnant or unable to answer the 
English, Afrikaans, or isiXhosa versions of the selected questionnaires, were eligible to 
participate. The outcome measures were the Community Orientated Program for Control 
of Rheumatic Diseases (COPCORD) screening tool for musculoskeletal disease, the Brief 
Pain Inventory (BPI), the European Quality of Life-5 Dimensions (EQ-5D) health-related 
quality of life measure, the International Physical Activity Questionnaire (IPAQ), and 
anthropometric measures of weight, height, and waist and hip circumference. Data were 
collected via interview and anthropometric measurement. Responses were captured by 
online questionnaires on mobile devices using the mobile data collection application Magpi 
by DataDyne Group, LLC. Data were exported to Microsoft Office Excel spreadsheets for 
descriptive and inferential statistical analysis. Ethical permission was obtained from the 
University of Cape Town. 
Results:  This study recruited 1115 participants, with a mean age of 48.7 ± 16.8 years. A 
prevalence rate of 33.6% (95% Confidence Intervals; CI: 30.1-36.5%) for acute MSD and 
43.3%  (CI: 40.4-46.3%) for chronic MSD was found. The number of participants reporting 
an overall prevalence of any MSD was 505 (45.7%; CI: 42.8-48.7%). The highest prevalence 
of MSD was found in females aged 40-59 years. The most common anatomical sites of 
chronic MSD  were the knees (35.6%; CI: 31.5-39.9%), low back/pelvis (33.8%; CI: 29.8-
38.0%), shoulders (26.8%; CI: 23.1-30.9%), and hands/fingers (21.9%; CI: 18.5-25.7%). Of 
those with MSD, exercise was reported as the best management strategy for 
musculoskeletal pain (35.6% of 191 respondents; CI: 29.1-42.6%). Hypertension was found 
to be the most prevalent chronic disease of lifestyle (47.8%; CI: 44.8-50.7%), followed by 
type 2 diabetes mellitus (21.4%; CI: 19.1-23.9%), and hypercholesterolaemia (20.2%; CI: 
17.9-22.6%). All chronic diseases, except chronic obstructive airway disease (COAD), 
increased with age, while COAD and both acute and chronic MSD peaked around the 50-59 
age category and then decreased with age. Most females reported to be highly physically 
active (46.0%) while males reported mostly low physical activity levels (47.8%). Around the 
50-59 year old age group the proportion of participants with a ‘high’ physical activity level 
decreased while that of participants with a ‘low’ physical activity level increased at the 
same age group. A higher proportion of those without MSD reported ‘high’ levels of 
physical activity (41% compared to 32%). In the 30-39 and 40-49 age groups, low levels of 
physical activity were associated with chronic MSD (70.6% compared to 37.5% of those 
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with high levels; Chi-Square=13.833; df=2; p=0.001). Body mass index (BMI) category was 
found to be associated with MSD (p<0.001) with 73% of those with MSD being overweight 
or obese and 27% being extremely obese. There were significant differences in BMI 
between those with and without hypertension (p<0.001), hypercholesterolaemia 
(p<0.001), and type 2 diabetes mellitus (p<0.001). A trend of increasing obesity, high waist-
hip ratio and low levels of physical activity with age was observed. In smokers, being 30 
years of age or older was associated with an increased risk of MSD (42% compared to 
21.1%). Gender emerged as a risk factor in the 40-49 and 50-59 age categories with 76.2% 
of females in these categories reporting chronic MSD compared to 45.1% of the males. 
However, no risk factor seemed to track the plot of MSD. Age emerged as having the 
highest association with chronic MSD (Chi-Square=136.6; p<0.001). 
Conclusions: Bivariate associations of musculoskeletal disease and chronic diseases of 
lifestyle were detected because they all become more prevalent with age. The comorbidity 
of musculoskeletal disease and chronic disease of lifestyle appeared to almost entirely be 
due to the aging process, rather than the mutual influence that musculoskeletal disease 
and chronic diseases of lifestyle may have. Low levels of physical activity were only 
associated with musculoskeletal disease among those in the 30-49 age categories. As 
previous evidence has shown that increased levels of physical activity can reduce pain in 
chronic or persistent musculoskeletal disease, a window of opportunity is suggested where 
increasing physical activity levels in the 30-49 age group may result in a decrease in the 
prevalence of musculoskeletal disease in the older age group. The only factor that emerged 
as being predictive in the group with the highest prevalence of musculoskeletal disease, the 
40-59 age categories, was gender. Although gender is clearly not modifiable, this finding 
should inform the development of culturally appropriate intervention strategies.  
Implications: Although it was not possible to detect any evidence supporting causation, the 
co-existence of chronic musculoskeletal disease, chronic diseases of lifestyle, and risk 
factors highlights the need for holistic care to address the multiple problems experienced 
by adults, specifically as age progresses. The impact of chronic musculoskeletal disease is 
large, both in terms of prevalence and impact on health-related quality of life. The 
management of chronic musculoskeletal disease should thus focus on the most effective 
and affordable intervention strategies and healthcare systems and coherent policies for 
dealing with this condition should be developed. This management should not only be 
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based on a pharmacological model but on biopsychosocial integration emphasising self-
management. 
Funding acknowledgements: NRF Thuthuka student support grant, the University of Cape 
Town Masters Research Scholarship, and the Yeoman bequest bursary. 
Ethics approval: Approved by the Human Research Ethic Committee of the University of 
Cape Town (HREC REF: 856/2014), South Africa. 
  
xiii 
 
List of Tables 
Table 1: Musculoskeletal disease: articles on prevalence and risk factors ........................... 23 
Table 2: Classification of body mass index (BMI) ................................................................... 28 
Table 3: Association between musculoskeletal disease and chronic diseases of lifestyle: 
review articles ........................................................................................................................ 47 
Table 4: Inclusion and exclusion criteria for participation in this study ................................ 60 
Table 5: Sample size calculation ............................................................................................ 61 
Table 6: Summary of research questions and statistical tests for this study ........................ 71 
Table 7: Frequency of specific age groups and gender of study sample ............................... 76 
Table 8: Demographic characteristics of study sample ......................................................... 77 
Table 9: Reasons for CHC visits of study sample .................................................................... 78 
Table 10: Socio-economic characteristics of study sample ................................................... 79 
Table 11: Prevalence of acute and chronic MSD ................................................................... 80 
Table 12: Reported previous injuries, injury mechanisms, and injury results in participants 
with chronic MSD ................................................................................................................... 81 
Table 13: Self-reported chronic diseases of lifestyle by gender ............................................ 83 
Table 14: Self-reported chronic diseases of lifestyle with and without chronic MSD ........... 84 
Table 15: Body mass index categories of participants ........................................................... 88 
Table 16: BMI categories in those with and without chronic MSD ....................................... 91 
xiv 
 
Table 17: BMI categories in those with and without CDL ...................................................... 92 
Table 18: Physical activity level categories of participants .................................................... 94 
Table 19: Physical activity levels in participants with and without chronic MSD .................. 95 
Table 20: Physical activity levels in those with and without CDL .......................................... 95 
Table 21: Comparison of total MET between those with and without chronic conditions ... 96 
Table 22: Current and past smoking and alcohol use of participants.................................... 97 
Table 23: Smoking in participants with MSD and/or CDL ...................................................... 98 
Table 24: Pain severity and pain interference scores reported by participants with MSD 
(Brief Pain Inventory) ........................................................................................................... 105 
Table 25: Self-reported sites and description of MSD ......................................................... 107 
Table 26: Self-reported MSD management strategies ........................................................ 108 
Table 27: Characteristics of self-reported joint stiffness ..................................................... 110 
Table 28: Comparison of the EQ-5D Index and VAS scores between those with and without 
chronic health conditions. ................................................................................................... 114 
Table 29: Evaluation of this study in relation to STROBE guidelines for cross-sectional 
studies .................................................................................................................................. 129 
  
xv 
 
List of Figures 
Figure 1: The hypothesised impact of chronic musculoskeletal disease (self-designed model)
 ................................................................................................................................................. 2 
Figure 2: Flowchart indicating choice of test for binary/categorical data ............................. 68 
Figure 3: Flowchart indicating choice of test for numerical data .......................................... 69 
Figure 4: The sampling process .............................................................................................. 74 
Figure 5: Histogram of participant age .................................................................................. 75 
Figure 6: Proportion of respondents reporting presence of chronic diseases in each age 
category ................................................................................................................................. 85 
Figure 7:  Proportion of female respondents reporting health conditions in each age 
category ................................................................................................................................. 86 
Figure 8: Proportion of male respondents reporting presence of chronic diseases in each 
age category ........................................................................................................................... 87 
Figure 9: Histogram of BMI categorised by gender ............................................................... 88 
Figure 10: Scatter plot of linear correlation between age and BMI ...................................... 89 
Figure 11:Proportional changes in BMI over the adult lifespan ............................................ 90 
Figure 12: Histogram of Total MET-minutes categorised by gender ..................................... 93 
Figure 13: Change in percentage of activity levels across age categories ............................. 94 
Figure 14: Proportional changes in chronic MSD and risk factors over the adult lifespan.... 99 
Figure 15: CHAID analysis of relationship between MSD and CDL ...................................... 100 
xvi 
 
Figure 16: CHAID analysis of relationship between MSD and CDL with age included ......... 101 
Figure 17: CHAID analysis of relationship between MSD and risk factors ........................... 103 
Figure 18: CHAID analysis of relationship between MSD and risk factors including age .... 104 
Figure 19: Most common painful anatomical sites reported in participants with MSD...... 106 
Figure 20: Self-reported best management strategy for MSD ............................................ 109 
Figure 21: EQ-5D dimensions by gender .............................................................................. 110 
Figure 22: Mean EQ5D health index score by age group..................................................... 111 
Figure 23: Mean EQ5D health VAS score by age group ....................................................... 112 
Figure 24: Percentage responses to the EQ-5D dimensions for chronic MSD ..................... 112 
  
xvii 
 
List of Abbreviations 
6MWT   6-Minute Walk Test 
ACE   Angiotensin-Converting Enzyme 
AIDS   Acquired Immunodeficiency Syndrome 
ANOVA   Analysis of Variance 
AP   Apparent Prevalence 
ARB   Angiotensin-Receptor Blocker 
ASA   Acetylsalicyclic Acid 
BMI   Body Mass Index 
BMD   Bone Mineral Density 
BOD   Burden of Disease 
BP   Blood Pressure 
BPI   Brief Pain Inventory 
BPQ   Brief Pain Questionnaire 
CAD   Coronary Artery Disease  
CCB   Calcium-Channel Blocker 
CDC   Centres for Disease Control and Prevention 
CDL   Chronic Diseases of Lifestyle 
CHAID   Chi-Square Automatic Interaction Detector 
CHC   Community Health Centre 
CI   Confidence Interval 
cm   Centimetre 
xviii 
 
COPCORD  Community Orientated Program for Control of Rheumatic Diseases 
COAD   Chronic Obstructive Airway Disease 
COX   Cyclo-oxygenase 
CRPS   Complex Regional Pain Syndrome 
CSA   Computer Science and Applications, Inc 
CVD   Cardiovascular disease 
DBP   Diastolic Blood Pressure 
DI   Disability Index 
df   Degrees of Freedom 
DM   Diabetes Mellitus 
DMARDs  Disease Modifying Anti Rheumatic Drugs 
EQ-5D   European Quality of Life-5 Dimensions 
FEV1   Forced Expiratory Volume during first second of expiration 
FVC   Forced Vital Capacity 
GABA   Gamma-Aminobutyric Acid 
GAD   Generalised Anxiety Disorder 
GBD   Global Burden of Disease 
GNI   Gross National Income 
H0   Null Hypothesis 
HAQ   Stanford Health Assessment Questionnaire 
HCL    Hypercholesterolaemia 
HCTZ   Hydrochlorothiazide 
xix 
 
HDL   High Density Lipoprotein 
HIV   Human Immunodeficiency Virus 
HPT   Hypertension 
HRQoL   Health-Related Quality of Life 
HVAS   Horizontal Visual Analogue Scale 
IASP   International Association for the Study of Pain 
IBD   Inflammatory Bowel Disease 
IBS   Irritable Bowel Syndrome 
ICC Intraclass Correlation Coefficient 
ICF International Classification of Functioning, Disability and Health 
ILAR   International League of Associations of Rheumatology 
ILO International Labour Office 
IMMPACT The Initiative on Methods, Measurement and Pain Assessment in 
Clinical Trials 
IPAQ   International Physical Activity Questionnaire  
kg   Kilogram 
kg/m2   Kilogram per metre squared 
LBP   Low Back Pain 
LDL   Low Density Lipoprotein 
m   Metre 
MET Metabolic Equivalent of a Task (energy equivalent of a task/Oxygen 
consumed at rest) 
mm   Millimetre 
xx 
 
mmHg   Millimetre of Mercury 
mmol/l   Millimoles per litre 
MPQ   McGill Pain Questionnaire 
MSD   Musculoskeletal Disease 
NCD   Non-Communicable Disease 
NICE National Institute for Health and Clinical Excellence (United 
Kingdom) 
NIDDM Non-Insulin-Dependent Diabetes Mellitus 
NRS Numeric Rating Scale 
NSAIDs   Non-Steroidal Anti-Inflammatory Drugs 
OA   Osteoarthritis 
OGTT   Oral Glucose Tolerance Test 
OR   Odds Ratio 
OTC   Over-the-counter 
PA   Physical Activity 
PHC   Primary Health Care 
PIS   Pain Interference Score 
PPI   Present Pain Intensity 
PSS   Pain Severity Score 
PVD   Peripheral Vascular Disease 
r   Pearson Correlation Coefficient 
R   (South African) Rand 
xxi 
 
RA   Rheumatoid Arthritis 
RSST   Repeated Sit-to-Stand Test 
sec   Seconds   
SBP   Systolic Blood Pressure 
SD   Standard Deviation 
SE   Sensitivity of a diagnostic test 
SE   Standard Error 
SES   Socioeconomic Status 
SF-MCQ  Short-Form McGill Pain Questionnaire 
SLE   Systemic Lupus Erythematosus 
SMR   Skeletal Muscle Relaxant 
SNRI   Serotonin-Norepinephrine Reuptake Inhibitor 
SP   Specificity of a diagnostic test 
SSRI   Selective Serotonin Reuptake Inhibitor  
STROBE Strengthening the Reporting of Observational Studies in 
Epidemiology 
TB Tuberculosis 
TCA Tricyclic Antidepressant 
TP True Prevalence 
UEMSD Upper Extremity Musculoskeletal Disease 
vs   Versus 
VAS   Visual Analogue Scale 
xxii 
 
VVAS   Vertical Visual Analogue Scale 
WCDoH   Western Cape Department of Health  
WHO   World Health Organisation 
WHR   Waist-Hip Ratio 
WOMAC  Western Ontario and McMasters Universities Osteoarthritis Index 
YLDs   Years Lived with Disability 
1 
 
1 INTRODUCTION 
1.1 Background 
In recent years, there has been a global shift in the burden of disease (BOD) from 
communicable infectious disease to non-communicable or chronic diseases of lifestyle 
(CDL) which has thus seen more emphasis placed on healthier lifestyles. The non-
communicable diseases (NCDs) include musculoskeletal disease.1 
Musculoskeletal disease (MSD) refers to injuries, pain, or disorders of the musculoskeletal, 
or movement, system of the human body.2  These may result from everyday activities and 
may be acute conditions such as muscle strains and joint sprains, sub-acute conditions, or 
chronic conditions such as osteoarthritis (OA) and chronic low back pain (LBP). Acute MSD 
typically have a sudden onset and short duration. The primary goals in the management of 
acute MSD are to decrease pain intensity, facilitate recovery, and prevent the development 
of chronic pain, thus management (following a medical model of care) ends when the 
symptoms resolve.3 Chronic MSD describes musculoskeletal pain that persists for longer 
than three months or past the normal time of healing.4 The primary goal of management of 
chronic MSD is to improve function, thus a rehabilitation or disease model of management 
is utilised.5 
At some point in each individual’s lifetime, they are likely to experience some form of 
MSD.6 MSD most often manifests with the onset of pain, and may be accompanied by 
oedema, haematoma, or stiffness, and may thus result in limitations of activities of daily 
living.3 It is the most common motive behind self-medication and entry into the global 
health system,7 affecting at least one quarter of the population.6 Globally, over one quarter 
of the cost of illness is accounted for by MSD, which significantly burdens healthcare and 
social resources.6 
In peri-urban South Africa, it has been found that over 50% of primary health care (PHC) 
visits are due to pain, mostly in the head, back, and chest.8 Despite this, the complaints of 
those with musculoskeletal pain have previously been misunderstood by health care 
professionals and, therefore, patient concerns have not been well addressed and 
treatment has not been timeous and effective.6 
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Importantly, it has been shown that the prevalence of chronic MSD is higher in those with 
other chronic diseases than in those without.9 Additionally, the predominant pain 
mechanism in those with major CDL is of a musculoskeletal nature. The presence of chronic 
MSD may further negatively impact the health and wellbeing of affected individuals due to 
reduction of movement and impaired functional activities, both within the home and 
community setting.10 This may then lead to low physical activity levels and possibly obesity. 
A forced sedentary lifestyle caused by chronic MSD could eventually result in developing 
CDL such as hypertension (HPT), and type 2 diabetes mellitus (DM).11 It has been reported 
that those with chronic pain have a threefold risk of dying from heart or respiratory disease 
compared to those with no chronic pain and it is hypothesised that this may be partly 
resultant of a decreased exercise capacity in those disabled by chronic MSD.10 Therefore, it 
is hypothesised that chronic MSD may contribute to the development of a cycle of  life-
threatening and disabling CDL and if the primary medical problem, MSD, is not managed 
effectively, a cycle of secondary complications such as CDL could occur (see Figure 1 
below). 
 
 
Figure 1: The hypothesised impact of chronic musculoskeletal disease (self-designed 
model) 
 
musculoskeletal 
disease
pain & stiffness
reduced physical 
activityobesity
chronic diseases 
of lifestyle
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It can thus be deduced that other conditions that are not associated with MSD may 
contribute to the prevalence of MSD if it impacts one of the aspects in the above 
hypothesised cycle. Clinically, this suggests that an integrated approach to the evaluation 
and management of those with multiple conditions is required and MSD, especially of a 
chronic nature, cannot be managed in isolation.  
In Cape Town, primary health care (PHC) is provided at a number of community health 
centres (CHCs) and these are the primary source of health care for those living in under-
resourced communities (refer to Section 1.5 below). As the focus of this research is the 
impact of MSD and CDL on people who were previously disadvantaged by the apartheid 
system and who still have limited access to material resources, the research was targeted 
at those attending CHCs. In addition, research undertaken at similar CHC facilities has 
indicated a high prevalence of MSD in females, ranging from 36%12 reported 
musculoskeletal pain not due to injury in the past three months in Cape Town to 62%13 in 
Bloemfontein in the Free State province of South Africa. Both studies reported that MSD 
had a moderate to severe impact on health-related quality of life (HRQoL) and functional 
ability in older women.12,13 In addition, both studies recommended the need to provide a 
physiotherapy management programme which would not only address the musculoskeletal 
pain experienced by women attending CHCs, but that would also include non-
pharmaceutical management of comorbidities and risk behaviours.12,13 
 
1.2 Problem Statement and Research Questions 
A wide ranging literature search could find little South African research on the prevalence 
of MSD and the various comorbidities in under-resourced communities.  There is also a lack 
of South African evidence regarding the inter-relationships between MSD and CDL, and 
about risk factors (such as gender, obesity and physical inactivity) associated with these 
chronic diseases. Furthermore, there is insufficient evidence regarding the timing of the 
onset of these chronic diseases, information which would contribute to the understanding 
of the complex relationship between these diseases. As indicated in Figure 1 above, 
although it is likely that there is a relationship between different chronic diseases, it is 
unclear which chronic disease emerges first and may then be a causal or risk factor in the 
development of subsequent health conditions and functional impairments. This gap in 
research highlights that current management may not be targeted appropriately at risk 
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factors and thus may not reduce the high prevalence rates of MSD and possible 
comorbidities in adults.   
Furthermore, if this hypothesised impact of MSD is correct, it would suggest that affected 
individuals should be offered an integrated approach to the evaluation and management of 
multiple chronic diseases such as MSD and other common CDL. This may be in contrast to 
the current management strategies available at primary health care facilities which 
generally manage these conditions in disease specific clinics rather than in a single multi-
disciplinary clinic which would provide integrated, holistic management.   
Thus, the research questions for this study are:  
 What is the prevalence and types of MSD in adult males and females across six age 
categories (i.e. 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 
70 years and older) attending a CHC in Cape Town? 
 What comorbidities and risk factors occur in the population? 
 At which age is the onset of MSD and CDL? 
 Are these comorbidities associated with MSD? 
 What are the management and treatment strategies for MSD and CDL? 
 What is the self-reported level of physical activity in the population with MSD? 
 Is the self-reported level of activity associated with MSD and/or identified 
comorbidities? 
 What is the health-related quality of life in population with MSD and/or CDL? 
 What is the impact and association of MSD and CDL on health-related quality of life 
across various age categories? 
1.2.1 Null Hypothesis 
The null hypotheses (H0) of this study are as follows: 
 The prevalence of MSD and CDL does not increase with age.  
 The presence of chronic MSD is not associated with CDL and is not a risk factor 
for the development of CDL. 
 Age, gender, obesity and social habits are not associated with or are not risk 
factors for the development of chronic MSD and CDL. 
 Self-reported low levels of physical activity are not associated with or are not 
risk factors for the development of chronic MSD and CDL.  
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 There is no association between self-reported poor health-related quality of 
life and chronic MSD and CDL. 
 
1.3 Aims & Objectives 
1.3.1 Aims 
The aims of this study were to investigate the prevalence and patterns of onset of 
musculoskeletal disease (MSD) and chronic diseases of lifestyle (CDL) across six age 
categories (i.e. 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70 
years and older), and to identify the risk factors associated with MSD and CDL in patients 
attending a community health centre (CHC) in Cape Town, South Africa. 
1.3.2 Objectives 
The specific objectives include, within a sample of adult patients attending a CHC in Cape 
Town: 
1. To determine the proportion of people with musculoskeletal diseases and pain in 
men and women aged 18 years and older, using an adapted version of the 
COPCORD questionnaire to identify those with MSD. 
2. To determine the proportion of people with chronic diseases of lifestyle such as 
hypertension, type 2 diabetes mellitus, and cardiovascular disease.  
3. To describe the physiotherapy and medical management of MSD and CDL. 
4. To determine the proportion of respondents with MSD and/or CDL across different 
age categories ranging from 18 years and older to establish how these change over 
the adult lifespan. 
5. To determine the association between MSD and CDL and risk factors such as age, 
gender, obesity, occupations, and social habits such as smoking. 
6. To determine whether self-reported physical activity levels are associated with 
musculoskeletal disease and chronic diseases of lifestyle through investigating the 
level of self-reported physical activity, using the IPAQ (International Physical 
Activity Questionnaire). 
7. To determine the association between the health-related quality of life, health 
index score and MSD. 
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1.4 Significance of this study 
As those adults who attend CHCs are likely to be older females with limited income,12,13 
they represent a vulnerable population. Severe MSD can be particularly devastating for this 
group as they are likely to be dependent on public transport, be responsible for child care 
and reliant on physical mobility for income generation. As reported above, previous studies 
have indicated that the prevalence of MSD in similar populations is high, as is the presence 
of comorbid CDL.12,13 However, the cited studies have not included males in their samples 
and there is less information regarding the prevalence and impact of MSD and CDL in 
males. This study will assist in filing this information gap. The authors recommended that 
more appropriate methods of holistic management of MSD, together with comorbidity, be 
developed.12,13 Although comorbidity is very common, the possibility of a “cascade” of 
health conditions and functional limitations was not examined. If specific health conditions 
or risk factors consistently emerge earlier in this population, it might be possible to design 
intervention strategies which target these conditions early on, possibly disrupting the cycle 
as described earlier. Information relating to the current pharmacological and non-
pharmacological management of patients with MSD and CDL will also assist in making 
recommendations regarding appropriate management strategies. 
 
1.5 Research Setting 
The World Bank classifies country’s economies into four groups based on the country’s 
gross national income (GNI) per capita for the fiscal year, assigned on the first of July of 
each year.14 The four income economy groups are: low income, lower middle income, 
upper middle income, and high income.14 South Africa is classified as an upper middle-
income economy, with a GNI per capita of between 3956 and 12235 United States dollars.15 
Other notable countries also classified as upper middle income economies include Namibia, 
Botswana, Mauritius, Brazil, Argentina, Mexico, Turkey, Romania, Croatia, Malaysia, 
Thailand, China, and the Russian Federation.15 
In South Africa, 70.7% of households utilize public health care institutions.16–18 Thus, in the 
Western Cape province, where the City of Cape Town is situated, approximately 70% of the 
population, do not have health insurance and are reliant on public health care institutions 
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for medical services. The first point of contact within the public health care system most 
commonly occurs at CHCs which are primary health care multidisciplinary institutions.   
According to the 1978 Declaration of Alma-Ata, the World Health Organization (WHO) 
describes PHC as “essential health care based on practical, scientifically sound, and socially 
acceptable methods and technology made universally accessible to individuals and families 
in the community through their full participation and at a cost that the community and 
country can afford to maintain at every stage of their development in the spirit of self-
reliance and self-determination” (p.1).19 In the South African public health care system, as 
with that of other low to middle income countries, primary health care consists of two 
systems.20 The first level of contact for individuals, families, and communities, is a network 
of clinics and CHCs that deliver basic and preventative health care services and the second 
is the hospital care system.20 This study was conducted at primary health care level at a 
CHC in the Cape Town Metropole region of the Western Cape. 
The City of Cape Town region is constituted of 3740025 inhabitants.21 The area is serviced 
by 44 CHCs. The Mitchells Plain health district within the City of Cape Town services a 
population of 50723722 and has been identified as an under-resourced area of the Cape 
Town Metropole. The Mitchells Plain CHC within the Mitchells Plain health district provides 
health services to an area where 24.2% of the inhabitants are unemployed and 17.9% of 
households are below the poverty line, thus relying solely on public sector health care 
services.23 The CHC services 1 480 patients per day, and thus approximately 46000 patients 
per month, making it one of the busiest CHCs in the city, and the only one in the Mitchells 
Plain sub-district to offer comprehensive primary healthcare services.23  
Current daily services include, but are not limited to, trauma and medical emergency 
services, a midwife obstetric unit, general medical services, chronic disease clubs, HIV/AIDS 
services (testing, counselling, ARV treatment), reproductive health services, mental health 
services, pharmacy, physiotherapy, occupational therapy, radiology, and women and child 
health care services.23 The majority of patients seen per day partake in the chronic disease 
clubs.23 The chronic disease clubs manage those with stable CDL after they have been 
initially managed by a medical doctor.23 Clients are seen every six months, by appointment, 
where general observations, health screening, education, advice, and referral are done.23 
Thereby, the chronic disease clubs address various medical, pharmacological, and lifestyle 
factors associated with CDL.23 
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1.6 Dissertation Outline 
The first chapter provides motivation for this study by providing a contextual background 
and a statement of the problem, as well as the aim, objectives and significance of this 
study. A description of the research setting is also included. The dissertation is presented in 
five further chapters.  
Chapter 2 presents a literature review that provides additional background information on 
the burden of MSD. It contextualises the need for the investigation into its risk factors and 
association between CDL within a South African context. The prevalence of MSD is 
discussed, followed by the pathophysiology of MSD, for both acute and chronic, and risk 
factors for MSD. It also elaborates on the prevalence, pathophysiology and risk factors of 
CDL, and related intervention strategies. The review further describes the intervention 
strategies commonly used for MSD. The chapter concludes with a summary of the 
literature review. 
The following four chapters relate to the epidemiological study. Chapter 3 describes the 
research design, study sample, instrumentation, procedure of the study, ethical 
considerations, and data management and statistical analysis. In Chapter 4 the results of 
the study are presented. In Chapter 5 the results and possible reasons for associations and 
identified problems are discussed. The limitations of the study are highlighted and 
recommendations for future action are made. 
The final chapter, Chapter 6, provides a summary of the results of this study and presents 
the final conclusions and recommendations for implementation and further research. 
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2 LITERATURE REVIEW 
2.1 Introduction to the Literature Review 
The following literature review presents musculoskeletal disease (MSD) and contextualises 
the need for the investigation into its risk factors and association with chronic diseases of 
lifestyle (CDL) within a South African context. The review begins by exploring the burden of 
disease (BOD). This is followed by MSD and its prevalence, both worldwide and locally, the 
pathophysiology of MSD, both acute and chronic, and risk factors for MSD. 
Research exploring CDL, their prevalence, pathophysiology, risk factors, and intervention 
strategies are also presented. Literature on the associations between MSD and CDL is then 
presented, followed by current intervention strategies for MSD. Finally, a summary of the 
above information concludes the literature review. 
Relevant literature for this review was searched from inception to February 2019 and was 
found using the online databases Pubmed, Google Scholar, Cinahl, EBSCO, Medline, 
BioMed Central, and Science Direct. Key words entered into these databases included 
‘musculoskeletal diseases’, ‘non-communicable diseases’, ‘Africa’, ‘South Africa’, ‘physical 
activity levels’, ‘obesity’, ‘body mass index’, ‘waist-hip ratio’, ‘chronic diseases of lifestyle’, 
‘hypertension’. ‘diabetes mellitus’, ‘hypercholesterolaemia’, ‘cardiovascular disease’, and 
‘chronic obstructive airway disease’. While reading relevant articles from the above search, 
other applicable cited references were also searched for using the above method. Articles 
included in this review were limited to full text articles, freely available and published in 
English. 
 
2.2 Burden of Disease 
In recent years, there has been a shift in the global burden of disease (GBD) from 
communicable to non-communicable, with a third of the GBD attributable to non-
communicable disease (NCD) such as chronic diseases of lifestyle (CDL), which includes 
musculoskeletal disease (MSD).24 In 2008, 63% of global mortalities were due to non-
communicable diseases such as cardiovascular disease (CVD) (39%), type 2 diabetes 
mellitus (4%), various cancers (27%), and chronic respiratory and other diseases (30%).25 A 
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high percentage (80%) of mortalities in low middle-income countries were due to non-
communicable diseases as the vulnerable and socially disadvantaged population get sicker 
sooner as a result of non-communicable diseases than people of higher social positions.25 
Pain has been found to the most common reason for healthcare visitations in low-resource 
countries.26 A six-country study found that, in those with two or more CDL, the prevalence 
of pain was 59%.27 Globally, disability due to MSD is estimated to have increased by 45% 
from 1990 to 2010 with MSD accounting for 6.8% of total years lived with disability (YLDs), 
increasing from between 4% and 7% in 1990 to between 6% and 8% in 2010.28 This could 
be attributed to the rapid increase in CDL in developing countries as a consequence of the 
aging of the population29 and demographic and lifestyle changes caused by globalisation, 
urbanisation, and increasing sedentary lifestyles.25,30 This burden is gradually growing with 
the rise in age, little change over time, and an ageing world population.28 The burden of 
MSD is also one on social and health care resources as, globally, it accounts for a quarter of 
the overall cost of illness and is the second most common reason for visiting a primary 
health care physician.6 
An increase in non-communicable diseases, as well as the associated risk factors, is found in 
communities in South Africa.31 The World Health Organisation (WHO) estimates that these 
non-communicable diseases caused 29% of the total burden of disease, with the heaviest 
burden affecting poor communities in urban areas.31 In 2008, the following NCDs 
accounted for mortality in South Africa: cardiovascular disease (11%), type 2 diabetes 
mellitus (3%), cancers (7%), and other diseases including MSD (7%).32  
 
2.3 Musculoskeletal Disease and Its Prevalence 
Musculoskeletal disease encompasses a diverse group of pathophysiological conditions 
that are linked by anatomical area and association with pain and impaired physical 
function. These include a variety of conditions, ranging from those of acute onset and short 
duration to lifelong disorders such as osteoarthritis (OA), rheumatoid arthritis (RA), and 
chronic low back pain (LBP).33 Mortality associated with these conditions is generally low, 
however, MSD impacts medical costs, disability and quality of life.34 
When describing prevalence, point prevalence is said to be the proportion of a population 
that has a specific condition at a specific point in time. Relating this to biostatistics, in 
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diagnostic testing the apparent prevalence (AP) is the proportion of positive test results in 
a sample representative of a population, while true prevalence (TP) is the actual proportion 
of positive test results in a population, which may never be known unless an entire 
population is tested.35 The performance of a diagnostic test is dependent on two factors: 
the test sensitivity (SE), which is “the probability that a truly infected individual will test 
positive”(p. 2), and the test specificity (SP), which is “the probability that a truly non- 
infected individual will test negative” (p.2).35 True prevalence can be estimated using the 
following equation:  
 
 
2.3.1 Global Prevalence of Musculoskeletal Disease 
Musculoskeletal disease is the most common cause of severe chronic pain, functional 
limitations, and physical disability, affecting 20-50% of adults.33,36 Thus, MSD is globally 
common with evidence suggesting that it is becoming even more prevalent over time.37 
McBeth and Jones (2007)37 found that 50% of the general global population reported pain 
in the low back region, 20-33% reported pain in the shoulder, and an average of 8.2% 
reported chronic widespread pain.37 A Swedish population study found a prevalence of 
34.5% of chronic pain, both regional and widespread,38 while in a Brazilian, also an upper 
middle income country like South Africa, systematic review on the prevalence of MSD, 50% 
of the population reported lower limb pain, while the prevalence of arthritic pain varied 
between 9.4% and 39.6%.39  
Despite the abundance of global research on MSD, there is a paucity of epidemiological 
data on MSD within the African context. The prevalence of low back pain in Africa has been 
shown to be 16-59% among adults, potentially increasing with age.40 The wide discrepancy 
in rates could be due to the differing samples used in varying socio-economic climates or, 
despite the efforts of the Community Orientated Program for Control of Rheumatic 
Diseases (COPCORD), lack of a standard definition of what constitutes MSD.  
2.3.2 South African Prevalence of Musculoskeletal Disease 
Global literature has shown that South Africa has a higher prevalence of chronic MSD, than 
other developed and developing countries.41 In a 2010 South African study at two 
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community health centres (CHCs), 362 participants reported having non-traumatic MSD. 
This constituted a prevalence of 36% of the sample initially screened for MSD.12 A 
prevalence of osteoarthritis (10%) and rheumatoid RA (5%) was found in these participants, 
but no definitive musculoskeletal diagnosis was made for each participant, thus not 
allowing for area-specific prevalence rates.   
A  prevalence rate of 45.8% (95% CI: 40.5%-51.35%) of MSD was found in a 2013 South 
African study conducted at a CHC in Bloemfontein, Free State province.42 Three hundred 
and twenty-three male and female adult participants were recruited, where back, knee, 
wrist, elbow, and ankle pain were the most commonly reported complaints.42 This is 
supported by another study that showed similar results where a prevalence rate of 42.9% 
(95% CI: 37.4%-47.1%) of MSD was found, where chronic pain in the back, knees, ankles, 
head, shoulders and elbows were most commonly reported.43 This study was conducted in 
the rural community of Baziya in the Eastern Cape province and recruited 394 adult males 
and females.43 Further literature found a prevalence rate of 41% of MSD, where back ache 
and joint pain were most reported.44 
The Institute for Health Metrics and Evaluation found that low back and neck pain was the 
second most prevalent cause of disability behind HIV/AIDS, and notably increasing by 
22.8% between 2005 and 2016.45 Even though some studies on the prevalence of MSD 
were conducted in South Africa, there seems to be a lack of evidence regarding the onset 
of MSD according to age and whether there are any comorbidities associated with the 
presence of MSD. 
2.3.3 Age and Gender 
The prevalence of MSD has been shown to be higher among females and increasing with 
age.33,2,46 Therefore, as the average age of the population increases the impact of MSD will 
most likely increase in parallel.12,34 In adults aged 20-74 years, a prevalence rate of chronic 
MSD was also shown to be higher in females (38.3%) than in males (30.9%), with a 
significant difference between gender (p<0.002) and a peak in prevalence in females 
between ages 65-69 years and in males between ages 55-64 years.38  The same has been 
found for upper limb MSD where females had significantly higher rates of upper extremity 
musculoskeletal disease (UEMSD) than males.47 It is estimated that a prevalence rate of 
85.5% of MSD may be found in adults older than 60 years, with females being more 
affected males.39 An increase in MSD appears to be related to age, with CDL being 
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displayed more in the older population.12 A recent African study also found that age, and 
not gender, was significantly associated with MSD (p=0.043).48 In South Africa, 42% of 
adults older than 50 years reported having MSD.49 
According to Fillingim (2001),50 females are overrepresented in several chronic pain 
conditions and thus appear to be at greater risk for the symptoms of these conditions.50 
However, there is a substantial amount of evidence that demonstrates differences in the 
experience of pain between males and females.50 Mechanisms attributed for the difference 
in pain experience are largely interpreted as physiological or endogenous and psychosocial, 
as described in Section 2.6.1, which is based more on the level of analysis as opposed to 
the actual mechanism of action.50  
 
2.4 Pathophysiology and Development of Musculoskeletal Pain 
The International Association for the Study of Pain (IASP) defines pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage” (p.210).4 Thus, pain is described as a complex 
multidimensional experience that is influenced by a variety of biopsychosocial variables50 
and is always subjective as each individual applies the meaning of pain based on their own 
experiences.51 Pain is therefore thought to have a sensory dimension (“where and how 
much does it hurt?”); an emotional dimension (“how unpleasant is the experience?”); and a 
cognitive dimension (“how do we interpret the pain based on our previous experience? 
does it cause fear and anxiety? how do we respond to the threat posed by pain?”).51 
2.4.1 Classification of Pain 
There seem to be various classifications of pain which may overlap with each other. 
However, these classifications are useful as they aid in the assessment and management of 
pain. Pain may be classified by aetiology, duration, location/region, intensity, and nature, 
among others.  
Mechanisms contributing to the development of pain include: input 
mechanisms/categories such as nociceptive, inflammatory, and peripheral neuropathic; 
processing mechanisms, such as central sensitisation and the understanding and emotion 
of pain; and output mechanisms such as autonomic, motor, neuroendocrine, and immune 
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system response.52 More recently, mechanism-based classifications of musculoskeletal pain 
are being used to develop clinical criteria for diagnostic purposes.53 These mechanisms are 
nociceptive, peripheral neuropathic, and central.53 Nociceptive and neuropathic 
mechanisms will be reviewed here, while the central mechanism of musculoskeletal pain 
will be reviewed in section 2.4.3. 
2.4.1.1 Nociceptive Pain 
Nociception is the detection of noxious stimuli that aids in protection by generating a reflex 
of withdrawal and by causing an unpleasant sensation which results in avoidance behaviour 
strategies.54 Deep and superficial tissue structures receive innervations from the primary 
afferent/sensory neurones that synapse in the dorsal horn of the spinal cord.55 The noxious 
stimuli are detected by specialised transducers attached to the primary A-delta and C 
afferent/sensory fibres.56 A-delta afferent fibres are thinly myelinated, while afferent C 
fibres are unmyelinated.57 They have a high threshold and reflect changes that are 
produced by injury to the axon, activity, or inflammation.57 Thus, nociceptive pain is 
resultant of actual tissue damage or stimuli that can potentially cause actual tissue 
damage.58 
Nociceptive pain can further be classified as somatic and visceral pain. Somatic pain occurs 
in bodily tissues such as skin, muscles, and joints, and can hence be termed superficial or 
deep.59 Superficial somatic pain may feel burning, pricking, or sharp, while deep somatic 
pain may feel dull and aching.59 Somatic pain is usually localised to a specific area.59 An 
example of deep somatic pain is muscle pain due to strain.59 Visceral pain, from bodily 
organs, can be described as diffuse or poorly localised pain that is referred to other 
locations that is not always linked to all visceral injury and is also not evoked by all 
viscera.60 These characteristics are due to the relative scarcity of sensory nociceptors within 
the internal organs and cavities.60 It is usually accompanied by motor and autonomic 
reflexes, such as muscle spasm, nausea, and vomiting.60 Examples of visceral pain include 
that from functional gastrointestinal disorders such as irritable bowel syndrome (IBS),61 
indigestion,62 renal colic,62 gastroenteritis,63 appendicitis,63 cystitis,63 myocardial 
infarction,63 and pleurisy.63 
Subjective clinical indicators of nociceptive musculoskeletal pain include: “clear, 
proportionate mechanical/anatomical nature to aggravating and easing factors” (p.83), 
”pain associated with and in proportion to trauma or a pathological process (inflammatory 
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nociceptive) or movement/postural dysfunction (ischaemic nociceptive)” (p.83), ”pain 
localised to the area of injury/dysfunction” (p.83), “usually rapidly resolving” (p.83), 
“responsive to simple analgesia/NSAID’s” (p.83), “usually intermittent and sharp with 
movement” (p.83), “pain in association with other symptoms, such as swelling, redness, 
and heat (inflammatory nociceptive)” (p.83), and “pain of recent onset” (p.83).53 Objective 
clinical indicators of nociceptive musculoskeletal pain include:  “clear, consistent and 
proportionate mechanical/anatomical pattern of pain reproduction on 
movement/mechanical testing of target tissues” (p.84), “localised pain on palpation” 
(p.84), and “antalgic (i.e. pain relieving) postures/movement patterns” (p.84).53 
2.4.1.2 Neuropathic Pain 
The IASP defines neuropathic pain as “pain initiated or caused by a primary lesion or 
disease of the somatosensory system” (p.50).64 Neuropathic pain can further be divided 
into central neuropathies and peripheral neuropathies.64 Stimulation of central neuropathic 
pain is not adequate enough to stimulate peripheral sensory nerve endings.65 Examples of 
central neuropathic pain include pain related to cerebrovascular accidents and 
radiculopathy.4,64 Examples of peripheral neuropathic pain are diabetic peripheral 
neuropathy and pain owning to cancer or multiple sclerosis.58 Most notably, neuropathic 
pain does not include pain that is caused by other nervous system disorders, such as 
fibromyalgia and spinal cord injury.64  
Subjective clinical indicators of peripheral neuropathic musculoskeletal pain include: “pain 
variously described as burning, shooting, sharp, aching or electric-shock-like” (p.84), 
“history of nerve injury, pathology or mechanical compromise” (p.84), “pain in association 
with other neurological symptoms such as pins and needles, numbness, and weakness” 
(p.84), “pain referred in a dermatomal or cutaneous distribution” (p.84), “less responsive to 
simple analgesia/NSAID’s and/or more responsive to anti-epileptic/anti-depression 
medication” (p.84), “pain of high severity and irritability (i.e. easily provoked, taking longer 
to settle)” (p.84), “mechanical pattern to aggravating and easing factors involving 
activities/postures associated with movement, loading or compression of neural tissue” 
(p.84), and “pain in association with other dysaesthesias (e.g. crawling, electrical, 
heaviness)” (p.84).53 Objective clinical indicators of peripheral neuropathic musculoskeletal 
pain include: “pain/symptom provocation with mechanical/movement tests” (p.85), 
“pain/symptom provocation on palpation of relevant neural tissues” (p.85), “positive 
neurological findings” (p.85), “antalgic posturing of the affected limb/body part“ (p.85), 
16 
 
and “positive findings of hyperalgesia and/or allodynia within the distribution of pain” 
(p.85).53 
For the purpose of this study, we will refer to a duration-based classification of pain, i.e. 
acute and chronic. It must be noted that some conditions may also be classified as 
subacute, but that will not be presented or discussed in this study.  
2.4.2 Acute Musculoskeletal Pain 
Acute pain refers to episode of pain that lasts for three months or less.3 Acute 
musculoskeletal pain is often nociceptive, arising through local tissue damage51 or 
peripheral noxious stimuli of sufficient intensity to lead to or to threaten tissue57 and thus 
is perceived in a specific region of the body, and named for that region, e.g. shoulder pain, 
elbow pain, etc. The aim of acute pain is to protect the individual as an early warning when 
there is a harmful or potentially harmful process occurring in the body.5 Thus, acute pain 
usually results from acute tissue injury and inflammation and is known as a reparative 
function.66 This type of pain is mostly seen after trauma and surgical interventions.56 The 
tissues around the site of trauma or inflammation become hypersensitive or tender67 so to 
avoid contact with external stimuli.66 
Musculoskeletal pain after exertion or injury may be attributed to muscle strains or 
ligament sprains. When there is no injury, the mechanism of pathology is unknown. Pain in 
a joint does not necessarily imply pain that originates from that joint, because muscular 
pain may be referred to a joint. After injury, the thinly myelinated A-delta and 
unmyelinated C afferent (sensory)  fibres detect the nociceptive messages in the periphery 
or the site of injury,56,57,68 a process known as transduction.55 These messages or stimuli 
may be mechanical, chemical or thermal.68 The afferent A-delta and C fibre nociceptors 
innervate joint and muscle tissue, but not visceral tissue,68 which make these relatively 
significant in the generation of acute musculoskeletal pain.  The afferent/sensory neurones 
then conduct the sensory input from the periphery to the dorsal horn of the spinal cord, 
known as conduction, and also function to transfer the input transsynaptically within the 
laminae of the dorsal horn, known as transmission.55 Inflammatory mediators such as 
bradykinin, histamine, serotonin, and prostaglandins are released69 at the site of tissue 
damage. Immune cells also release mediators such as cytokines and growth factors.55 The 
release of these mediators decreases the nociceptor activation threshold and increases its 
response to noxious stimuli which is known as hyperalgesia.55,68 Allodynia is the term used 
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when normally innocuous stimuli produce pain.55 These mediators are thus released to 
alter the activity of the nociceptors which results in peripheral sensitisation.55,68 Bradykinin 
is involved in the initiation of inflammation and has been found to result in pain and 
inflammation, as well as hyperalgesia.70 Cytokines also contribute toward initiating and 
maintaining inflammation, while also stimulating the release of prostaglandins.55 
Prostaglandins are mediators of pain and fever that are synthesized by the cyclo-
oxegenase-1 (COX- 1) enzyme.55 This enzyme has a protein variant or isoform called COX-2 
enzyme.55 Neurotrophic growth factors also influence the sensitivity of neurons during the 
inflammation process.55 Thus, the changes in the sensitivity of afferent/sensory neurones 
encourages the development of hyperalgesia or hypersensitivity that occurs during the 
inflammatory stage.55 
Clinical features of acute musculoskeletal pain include pain, oedema, tenderness, and 
decreased range of motion, yet the physical examination of acute musculoskeletal pain 
lacks reliability and validity.71 These clinical features are also diagnostic criteria, but it is 
important that other more serious causes of pain should be excluded as differential 
diagnoses for acute musculoskeletal pain, such as referral of pain from visceral or vascular 
tissue as well as thromboembolism and peripheral vascular disease (PVD).71 
2.4.3 Chronic or Persistent Musculoskeletal Pain 
One of the aims of this research was to investigate the relationship between MSD and CDL. 
In a systematic review by van Hecke et al (2014),72 the interaction between chronic MSD 
and CDL was highlighted: “Those with severe chronic pain are up to three times more likely 
to die from ischaemic heart disease or respiratory disease than those with no chronic pain, 
and this may be partly a result of reduced exercise capacity in those disabled by chronic 
pain. There is evidence that several chronic physical conditions may increase the risk of 
chronic pain. This may occur directly, through increased nociception from the periphery, 
resulting in central and peripheral pathophysiological changes associated with chronic pain, 
or indirectly, by accumulated stress or load, with pro-longed activation of the stress-
regulation systems leading to breakdown of muscle, bone and neural tissue, resulting in 
more pain“ (p.210).72 
As the impact of chronic pain is considerable, this section of the review examines chronic 
pain in greater detail.  Chronic, or persistent, pain refers to an episode of pain that persists 
for longer than three months.4 Due to the unrelenting nature of chronic pain it is likely that 
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stress, environmental, and affective factors may be superimposed on the original damaged 
tissue and contribute to the intensity and persistence of pain.56 The cause of the perception 
of pain may persist irrespective of conventional medical treatments.73 Consequently, 
psychological forms of treatment such as cognitive behavioural therapies can be used to 
change the effect of pain as the brain may be capable of minimising the pain impact by 
changing the manner in which the pain-producing information is processed.73 Physiological 
and behavioural research has also shown that plasticity or learning has a role to play in the 
pain mechanism.56 
2.4.3.1 Central Sensitisation 
Alterations in central nervous system processing74 and general somatosensory system 
hypersenstivity75  characterises chronic MSD. Central sensitisation refers to this increase of 
the responsiveness to input from unimodal and polymodal receptors of the central 
neurons.74 It is defined as “an amplification of neural signalling within the central nervous 
system that elicits pain hyper-sensitivity” (p.S5).76 The descending inhibitory mechanisms is 
impaired,77 while the descending and ascending pain facilitatory pathways are 
overactive.78,79 There is also an increased efficacy in the processing of incoming nociceptive 
stimuli which is known as temporal summation of second pain79. Thus, central sensitisation 
also entails altered sensory processing in the brain79 as well as a modulated ‘pain signature’ 
arising in the brain74. Increased brain activity is shown in the areas most commonly 
involved in the acute pain sensation, except the primary or secondary somatosensory 
cortex, various brain stem nuclei, the dorsolateral frontal cortex, and the parietal 
associated cortex, as they are not involved in the acute pain sensations.80 In the absence of 
new peripheral input, central sensitisation will not resolve quickly, but will rather sustain 
the chronic nature of the MSD condition,74 however it has been shown that brain 
abnormalities in patients with chronic MSD are reversible.75 
Subjective clinical indictors of centrally sensitised musculoskeletal pain include: 
“disproportionate, non-mechanical, unpredictable pattern of pain provocation in response 
to multiple/non-specific aggravating/easing factors” (p.85), “pain persisting beyond 
expected tissue healing/pathology recovery times” (p.85), “pain disproportionate to the 
nature and extent of injury or pathology” (p.85), “widespread, non-anatomical distribution 
of pain” (p.85), “history of failed interventions (medical/surgical/therapeutic)” (p.85), 
“strong association with maladaptive psychosocial factors (e.g. negative emotions, poor 
self-efficacy, maladaptive beliefs and pain behaviours, altered family/work/social life, 
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medical conflict)” (p.85), “unresponsive to NSAID’s and/or more responsive to anti-
epileptic)/anti-depressant medication” (p.85), “reports of spontaneous (i.e. stimulus-
independent) pain and/or paroxysmal pain (i.e. sudden recurrences and intensification of 
pain)” (p.85), “pain in association with high levels of functional disability” (p.85), “more 
constant/unremitting pain” (p.85), and “night pain/disturbed sleep” (p.85).53 Objective 
clinical indicators of centrally sensitised musculoskeletal pain include: “disproportionate, 
inconsistent, non-mechanical/non-anatomical pattern of pain provocation in response to 
movement/mechanical testing” (p.86), “positive findings of hyperalgesia (primary, 
secondary) and/or allodynia within the distribution of pain” (p.86), “diffuse/non-anatomic 
areas of pain/tenderness on palpation” (p.86), and “positive identification of various 
psychosocial factors such as catastrophisation, fear-avoidance behaviour, and distress” 
(p.86).53 
Central sensitisation has been found to contribute to various clinical syndromes.76 These 
include, but are not limited to, osteoarthritis, rheumatoid arthritis, fibromyalgia, 
temporomandibular disorders, chronic neck pain and headaches, shoulder impingement 
syndrome, tennis elbow (lateral epicondylalgia), chronic low back pain, complex regional 
pain syndrome (CRPS), irritable bowel syndrome (IBS), non-cardiac chest pain, and chronic 
phantom limb pain.76 
Diagnosis of chronic musculoskeletal pain can be based on the above-mentioned 
underlying mechanisms. Widespread hypersensitivity to touch and/or mechanical pressure, 
bright light, noise, medication, and temperature (both warm and cold) are symptoms that 
aid in recognising the presence of central sensitisation.81 Where more than one of these 
symptoms are present, a clinical examination is needed to provide further evidence of 
central sensitisation.81 Other symptoms that may indicate central sensitisation, but with 
less evidence, are fatigue, sleep disturbances, non-refreshing sleep, difficulty 
concentrating, tingling and/or numbness, and a sensation of swelling in the limbs.81 The 
following clinical exam findings could indicate central sensitisation: a generalised reduction 
of the pressure pain threshold (most notably in an area not anatomically related to the 
injury site), hypersensitivity to touch, vibration, or temperature, and a heightened response 
to the brachial plexus provocation tests bilaterally.81 Notably, these symptoms should be 
assessed and interpreted within the clinical context and the presence of central 
sensitisation may only be found during treatment or rehabilitation.81 
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2.5 Measurement of Musculoskeletal Pain 
While understanding the definitions and mechanisms of pain and its related impacts is of 
utmost importance, it is also important to understand how to accurately measure and 
interpret the measure of pain. The Initiative on Methods, Measurement and Pain 
Assessment in Clinical Trials (IMMPACT) group have described core outcome measures to 
consider when measuring pain.82 These core values include pain intensity, physical 
function, emotional function, patient rating of received treatment, symptoms and adverse 
effects, and participant disposition.82 Thus, the measurement of pain should be 
multidimensional. There are many different instruments available to evaluate pain 
however, for the purpose of this study and review, frequently used instruments are 
presented below. 
2.5.1 Visual Analogue Scale and Numeric Rating Scale 
The Visual Analogue Scale (VAS) is a self-administered tool that is commonly used in 
current research to measure pain in adults.83 This is a continuous scale that is used to rate 
pain intensity and may either be used vertically (VVAS) or horizontally (HVAS).83 Only one 
item is reported on and marked by the participant with the scale being anchored at zero, 
which is equivalent to experiencing no pain, and ending at ten, or 100, on a 100mm scale, 
which is equivalent to the maximum amount of or worst pain imaginable by the 
participant.83 No numbers or descriptors are made available between these two points to 
avoid clustering of responses around any one numeric value.83 When interpreting this scale, 
it is accepted that the higher the score, the higher the intensity of the pain reported by the 
participant.83 It has been shown to be a reliable84 and valid85 tool for the measurement of 
musculoskeletal pain. 
The Numeric Rating Scale (NRS) is also a commonly used clinical and research tool that is 
based on the same structure as the VAS. However, it is more specific as it is segmented and 
contains whole numeric numbers from zero to ten, thus making it an 11-item numeric 
scale.83 It is also anchored at zero, which is equivalent to experiencing no pain, and ten, 
which is equivalent to the maximum amount of or worst pain imaginable by the 
participant.83 When interpreting this scale, it is accepted that the higher the score, the 
higher the intensity of the pain reported by the participant.83 
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It must, however, be noted that research has shown that those with chronic MSD have 
found the VAS and NRS to be too simplistic when describing their complex pain 
experiences.86 
2.5.2 McGill Pain Questionnaire  
The McGill Pain Questionnaire (MPQ) was developed in the 1970’s by Robert Melzack at 
McGill University and evaluates the quality of pain by providing information on major 
groups of descriptors of pain which include the sensory, affective and evaluative aspects of 
pain.87 It also evaluates the quantity of pain via the present pain intensity (PPI) which is 
rated from zero to five.87 This allows for the tool to be used to distinguish pain associated 
with or without a clear physical cause.88 This tool is widely used, however, due to the 78 
items or words listed as pain descriptors in the questionnaire89 it can take up to 20 minutes 
to complete83, usually via interview. This led to the development of the Short-Form McGill 
Pain Questionnaire (SF-MPQ)90 which correlates highly with the MPQ91 yet is a more 
compact version of the MPQ that can be completed in an easier and shorter manner. 
2.5.3 Brief Pain Inventory 
The Brief Pain Inventory (BPI) is a self-, or interviewer-administered questionnaire that was 
developed in the 1980’s by Charles Cleeland,92 initially named the Wisconsin Brief Pain 
Questionnaire (BPQ).93 As research progressed, a short version of the BPI became the most 
commonly used tool within clinical and research settings.92 The aim of the tool is to assess 
pain multidimensionally, although, to simplify the approach, two dimensions are captured 
– severity, or the sensory aspect of pain, and interference, the reactive aspect of pain.92 
Severity of pain is determined by asking the participant to rate their pain according to: 
“worst”, “least”, “average” and “present” pain on a numeric scale of 0 – 10.92 The four pain 
severity scores ranging from 0-10 are averaged to generate a pain severity score (PSS).92 A 
pain interference score (PIS) is also generated from the 11 questions used. The BPI 
questionnaire has been shown to be a valid and reliable tool for MSD research94,95 and is 
widely used as it assesses pain severity as well as interference with activities of daily 
living.96 The BPI has been validated for use in South African languages to measure the 
prevalence of pain, as well as pain severity and interference.97 
As can be determined from the above-mentioned literature, the pain experience, as well as 
the impact thereof, can be quite convoluted. Therefore, when measuring musculoskeletal 
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pain or disease, it is necessary to do so accurately and consider these complexities to fully 
understand how musculoskeletal disease affects each individual within their 
biopsychosocial context. The MPQ does not evaluate the effect of pain on function,98 is 
quite lengthy which increases the likelihood of error compared to the BPI, and has not been 
evaluated within the South African context. It was therefore not selected for use in this 
study. Instead the BPI, which meets all of the aforementioned criteria, was selected as a 
more relevant and applicable tool within the context of this study. 
2.5.4 Community Orientated Programme for Control of Rheumatic 
Diseases 
The Community Orientated Program for Control of Rheumatic Diseases (COPCORD) was 
launched as a collaboration between the International League of Associations of 
Rheumatology (ILAR) and the WHO in the late 1980’s.99 The purpose of the WHO-ILAR 
COPCORD is to facilitate screening of musculoskeletal pain or complaints particularly in 
developing communities and economies by focusing on recording symptoms such as pain 
and disability, instead of syndromes or diseases.99 The COPCORD is typically divided into 
three phases with phase one and two forming the basis of the questionnaire collecting 
information on musculoskeletal pain and disability while phase three is comprised of a 
rheumatological assessment which mainly requires objective evaluation.100 
The COPCORD has been used in research within the South African context, including in a 
sample similar to that used in this study.12,42 Therefore, as the COPCORD has been shown to 
be a valid and reliable tool, especially within a similar setting,12,42 phase one and two were 
selected for use in this study. 
 
2.6 Risk Factors for Musculoskeletal Disease 
Literature has shown the reporting of musculoskeletal disease is multifactorial.101 Changes 
in lifestyle, e.g. increased obesity and physical inactivity, when combined with the 
urbanisation and motorisation of the modern society has the potential to further increase 
the burden of MSD in South Africa.33 This section elaborates on potential risk factors for 
MSD as identified from literature. A summary of literature on the prevalence of MSD and 
its risk factors is shown in Table 1 below.  
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Table 1: Musculoskeletal disease: articles on prevalence and risk factors 
Author, Year 
of Publication 
Study Design Location Study 
Sample 
Outcome Measures & Results Conclusions Level of 
evidence102 
Woolf & 
Pfleger33, 2003 
Descriptive 
review 
Global Adults with 
OA, RA, 
osteoporosi
s, and LBP 
 OA: 9.6% of males and 18% of females aged 60 
years and older; prevalence increases indefinitely 
with age. Obesity is a risk factor. 
 RA: prevalence varies between 0.3% and 1%. Twice 
as many females are affected than males. Smoking 
and obesity are risk factors. 
 LBP: Lifetime prevalence of 58–84% and point 
prevalence of 4–33%. 
 
MSD affects up to 20% of the 
adult population. There is a 
higher prevalence among 
females. Prevalence increases 
with age. 
V 
McBeth & 
Jones K37, 
2007 
Review Global Adolescent 
and adult 
population  
 Point prevalence of MSD 13% - 28%. The prevalence of chronic 
MSD increases with age, is 
more common in females, in 
subjects from lower 
socioeconomic groups, and in 
psychologically stressed 
populations 
V 
Miranda et 
al39, 2012 
Systematic 
Review 
Brazil 25 studies 
reporting 
on a total 
of 116091 
elderly (60 
years of 
age or 
older) 
 Chronic MSD prevalence ranging from 14.1% to 
85.5%. 
 Statistically significant associations shown between 
chronic MSD and older age, female gender, 
married status, cognitive deficit, current or 
previous smoking, report of falls and comorbidities, 
lower education, lower income, higher BMI, 
excessive alcohol consumption, work impact, 
fatigue, depression and anxiety. 
High prevalence of Chronic 
MSD among elderly Brazilians 
This should be considered 
when addressing healthcare 
policies, especially in the 
elderly. 
II 
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Author, Year 
of Publication 
Study Design Location Study 
Sample 
Outcome Measures & Results Conclusions Level of 
evidence102 
Parker & 
Jelsma12, 2010 
Descriptive 
Cross-
Sectional 
Study 
Cape Town, 
South Africa 
 
1005 adults 
in 2 low-
income 
areas  
 COPCORD and HAQ. 
 Chronic MSD prevalence rate of 36%. 
 Back pain was the most common complaint, both 
in isolation (18.5%) and combined with peripheral 
pain (55%). 
 Most common comorbidities were HPT (59.1%), 
type 2 DM (24.8%) and heart problems (18.9%). 
 Mean DI indicated a mild to moderate functional 
impact in those with MSD; no significant difference 
between genders. 
 Positive correlation between age and DI (r=0.31; 
p<0.001). 
 
Higher prevalence of MSD 
compared to that found in 
community-based studies in 
developed and developing 
countries. In South Africa, 
both the illness and 
rehabilitation of the disability 
needs to be addressed at PHC 
level. 
II 
Igumbor et 
al43, 2011 
Descriptive 
Cross-
Sectional 
Study 
Baziya, rural 
Transkei, 
Eastern Cape, 
South Africa 
394 adults  Chronic MSD prevalence rate of 42.9%; 68.9% 
female. 
 Increase in prevalence from the age of 55 years 
onwards, with noticeably high prevalence in the 24 
and under age group. 
 Most common sites of chronic MSD: back, knee 
and ankles, head, and shoulders and elbows. 
 Female gender and being 50 years of age or older 
were the only significant variables associated with 
chronic MSD. 
 
 
High prevalence of chronic 
MSD in rural community. 
There is an urgent need for 
targeted public healthcare 
interventions, particularly 
toward females and the 
elderly. 
II 
Copley  et al42, 
2013 
Descriptive 
Cross-
Sectional 
Bloemfontein, 
Free State, 
323 adults 
attending 
 COPCORD and HAQ. 
 MSD prevalence of 45.82%. 
 Back, knee, wrist, elbow and ankle pain were the 
Prevalence of MSD higher 
than previous SA studies with 
significant functional impact 
II 
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Author, Year 
of Publication 
Study Design Location Study 
Sample 
Outcome Measures & Results Conclusions Level of 
evidence102 
Study South Africa CHC most commonly reported complaints. 
 Mean DI indicated a mild to moderate functional 
impact within those with MSD. 
of MSD. Suggestions: 
Community education 
regarding symptoms and 
management of MSD, 
(awareness campaigns, 
community empowerment, 
posters/pamphlets).  
Ruaf et al44, 
2013 
Prospective 
Cross-
Sectional 
Study 
Tshwane, 
Gauteng, 
South Africa 
1066 adults 
 
 BPI 
 Chronic MSD prevalence of 41%. 
 Chronic MSD was significantly more prevalent in 
higher age groups (p=0.001) and in women than in 
men (p=0.019). 
 Most common sites of MSD: Back (30.83%) and 
joint pains (23.48%). 
High prevalence of chronic 
MSD. Further interventions 
and training of healthcare 
professionals in appropriate 
pain management is 
suggested. 
I 
OA=Osteoarthritis; RA=Rheumatoid Arthritis; LBP=Low Back Pain; MSD=Musculoskeletal disease; BMI=Body Mass Index; COPCORD=Community Orientated Program for Control of Rheumatic 
Disease; HAQ=Stanford Health Assessment Questionnaire; DI=Disability Index; HPT=Hypertension; DM=Diabetes Mellitus; PHC=Primary Health Care; BPI=Brief Pain Inventory 
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2.6.1 Gender 
2.6.1.1 Physical Factors 
Females report more endogenous pain in more regions than males, with no underlying 
rationale for why some painful diseases are more prevalent in females or males.103 
However, pain perception is modulated by multiple internal systems, with evidence that 
these systems may be utilised differently for females and males.50 Females may be more 
pain sensitive and with a less efficient internal pain inhibitory capacity compared to 
males.104 The internal pain regulatory systems as well as other factors such as expectancies, 
conditioning, and ovarian hormones change the neurophysiology of pain and could 
attribute to the difference in the reporting of pain between males and females.50 Studies 
have previously described gender differences in sensitivity to noxious stimuli as sex 
hormones influence pain sensitivity due to variations in pain threshold and pain tolerance 
in females during the menstrual cycle.105 In the case of osteoarthritis, it is thought that the 
prevalence of the condition increases with age and in the female gender, which suggests an 
X-chromosome or oestrogen receptor genetic link, or associated female factors such as 
lower muscle strength and decreased bone density leading to osteopaenia or 
osteoporosis.106 
2.6.1.2 Psychosocial Factors 
Emotional distress, pain coping strategies, and pain-related expectancies and 
understanding have been thought to contribute to the gender differences in the reporting 
of pain.50 Females have higher levels of catastrophising compared to males which may also 
contribute to their increased risk for experiencing pain.50 Socio-cultural beliefs about 
femininity and masculinity have also been determined to have an effect on different 
gender pain responses as it is generally more socially acceptable to express pain among 
females than among males.107 This may lead to biased reporting of pain.107 
2.6.2 Obesity 
According to the WHO, obesity is a serious chronic condition of either abnormal or 
excessive accumulation in adipose which may lead to impairment of health.108 
Hypercellular obesity is typically characterised by an increase in the total number of fat 
cells and often begins in childhood.109 Hypertrophic obesity is characterised by existing fat 
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cells enlarging and producing proteins and metabolites involved in the pathophysiology of 
obesity110 and typically begins in adulthood.109  
Obesity has been identified as a growing problem in Western countries,111 but also appears 
to be affecting low to middle income countries where undernutrition co-exists with obesity, 
with urban populations more affected than rural populations.108 Globally, in 2008, the WHO 
estimated that 35% of adults aged 20 and over were overweight while 12% were obese.112  
The South African prevalence of obesity is much higher than the global equivalent and one 
of the highest in sub-Saharan Africa113 with 68% of adults aged 20 years and older found to 
be overweight (males 62.% [95% CI: 56.1-66.6%]; females 73.6% [CI: 69.5-77.1%]), and 
33.5% [CI: 30.4-36.5] found to be obese (males 23.2% [CI: 18.9-26.9]; females 42.8% [CI: 
38.2-47.2%]).114 A South African study also found a high prevalence of obesity in adults 
older than 30 years with a mean BMI of 28.7 (± 0.14) kg/m2 for females and 24.1 (± 0.11) 
kg/m2 for males.115 Among males, wealthier men are more likely to be obese than poorer 
males by 6-18%.113 
According to Aronne (2002),109 the initial step to evaluating obesity is the calculation of the 
body mass index as it significantly correlates with body fat, morbidity, mortality, and can be 
calculated quickly in a clinical setting.109 
2.6.2.1 Body Mass Index 
The body mass index (BMI) is a universally used outcome measure to determine the 
relative weight of individuals.109 BMI is calculated using total body mass, which is 
constituted by lean mass, and to a lesser extent adipose tissue.116 This is then divided by 
the individual’s height squared. 
 The following formula calculates BMI:108  BMI  =  (body weight in kg) 
                  (body height in meters)2 
 
According to the WHO, BMI can be divided into six (6) classifications,108 as shown below in 
Table 2. 
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 Table 2: Classification of body mass index (BMI) 
 
 
 
 
 
 
A BMI equal to or greater than 25kg/m2 is considered to be the accepted benchmark for 
identifying those who would be more at risk of developing obesity-related complications or 
diseases, specifically hypertension, type 2 diabetes mellitus, and cardiovascular disease.117 
It is estimated that 80% of deaths caused by comorbidities associated with obesity occur in 
patients who present with a minimum BMI of 30kg/m2.109  
Literature suggests that there is a linear relationship between increasing BMI and severe 
self-reported pain with 13.5% of BMI category III (i.e. obese III) respondents reporting 
severe pain on a regular basis.118 This trend persists despite adjustment to demographic 
and lifestyle variables.118 A BMI of 25.0kg/m2 and higher “has been found to be associated 
with an increased 12 month prevalence of musculoskeletal symptoms and being obese 
significantly increased the risk of developing musculoskeletal symptoms during 12-month 
follow-up” (p.241).119 
2.6.2.2 Waist and Hip Circumference and Waist-Hip Ratio 
The measurement of the waist circumference is regarded as a practical indicator of visceral 
abdominal or truncal fat, the distribution of which shows a correlation with the 
hypertrophic form of obesity and thus a higher risk of developing obesity.109 Waist 
circumference is measured at the end of normal expiration,120 either at the narrowest part 
of the waist or at the level of the right iliac crest, with the measuring tape being level with 
the floor and of a snug fit.109 The WHO reports that both general and abdominal obesity is 
associated with decreased glucose tolerance, reduced insulin sensitivity and adverse lipid 
profiles.121 These are risk factors for type 2 diabetes mellitus and cardiovascular disease.121 
BMI Category BMI (kg/m2) Risk of Obesity-related Diseases 
Underweight < 18.5 low 
Normal 18.5 – 24.9 low 
Overweight 25.0 – 29.9 increased 
Obese I 30.0 – 34.9 high 
Obese II 35.0 – 39.9 very high 
Obese III (extreme) ≥ 40 extremely high 
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Hence, having an alternative measure to BMI that is reflective of abdominal adiposity may 
prove to be a more effective in determining obesity. A waist measurement ≥ 94cm in 
males, and ≥ 80cm in females, indicates obesity, while a waist-hip ratio of > 1.0 in males 
and > 0.85 in females is also accepted as being indicative of obesity, particularly abdominal 
adiposity.108 A combination of BMI and waist circumference measurement, when assessing 
risk factors for obesity, may thus aid in compensating for the differences in fat 
distribution.109 
Both BMI and increased waist circumference have been found to be associated with 
chronic MSD in a population older than 70 years.46 The association between obesity and 
MSD could be attributed to an excess load being placed on musculoskeletal structures 
and/or the accompanying sedentary lifestyle leading to obesity and a weaker 
musculoskeletal system.111 This also serves to support the cycle hypothesised in Figure 1. 
2.6.3 Low Levels of Physical Activity 
Physical activity (PA) refers to “body movements that occur from skeletal muscle 
contraction resulting in increased energy expenditure above resting metabolic rate” 
(p.1205).122 However, it should be noted that physical activity is different from physical 
fitness as physical activity is behavioural and is measured across four domains (work, 
domestic, transport, discretionary time) which are representative across activities of daily 
life that are common to most people despite socioeconomic development or culture.123 
Based on available evidence, persons who are physically active are less likely to develop 
health problems compared to those who are sedentary but it is difficult to determine if this 
is due to physical activity or fitness.124  
2.6.3.1 The Impact of Low Physical Activity Levels on Musculoskeletal 
Disease 
Literature has shown that there is a significant association between physical activity and 
MSD in almost all parts of the body, where lower levels of physical activity were reported 
with more MSD.125 A recent South African study found no significant difference in the self-
reported scores for physical activity levels of subjects with chronic MSD compared to 
matched controls, where 56% of all participants were found to have low levels of physical 
activity.126 However, despite the small sample size of 24 participants, significant differences 
were found between the objective measures of those with chronic MSD and matched 
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controls.126 Those with chronic MSD scored worse on the repeated sit-to-stand test (RSST) 
and 6-minute walk test (6MWT), and had lower daily mean and total pedometer 
readings.126 It was also shown that a lack of physical activity in individuals with MSD could 
lead to secondary complications such as obesity, hypertension, and type 2 diabetes 
mellitus.11  
Thus, a lifestyle that is physically active, in both work and leisure, could decrease the 
prevalence of chronic MSD. This has been shown in literature as a 2014 longitudinal study 
found that self-reported leisure-time levels of physical activity were a significant predictor 
of pain and disability after 12 months.127 Those with a sedentary lifestyle were found to 
have more pain (4.8/10 [95% CI: 4.3-5.2/10]; p=0.001) than those who were physically 
active.127 Furthermore, females between the ages of 45 and 59 also show generally higher 
attributable factors than other age groups with 59% being physically inactive.128 This has 
also been described in South African literature where females have been shown to have 
lower physical activity levels than males, which decreases further with increased age.123 
Therefore, available evidence suggests that physical activity may aid in reducing pain and 
improving function, while having few to no adverse effects, in those with chronic MSD and 
pain.129 
2.6.3.2 Measurement of Physical Activity 
The International Physical Activity Questionnaire (IPAQ) was developed to obtain 
comparable estimates of levels of physical activity.130 It is an acceptable measurement of 
physical activity for use in adults in many settings and in different languages. Participants 
respond to questions relating to time spent being physically active in the last seven days 
during activities at work, house chores, outside of the house, to get from place to place, 
and in their spare time for recreation, exercise or sport.131 The IPAQ has been shown to be 
a valid and reliable tool for surveillance of physical activity in adults.132 The IPAQ has also 
been shown to be a valid and reliable tool when used in other South African languages.133 
Because of the reliability and validity within a South African context, the IPAQ was selected 
for use in this study to monitor and establish physical activity levels. 
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2.6.4 Other Risk Factors 
2.6.4.1 Cigarette Smoking 
Cigarette or tobacco smoking has been described to have negative effects on multiple 
bodily systems including the musculoskeletal system.134–136 Current smoking has been 
found to be significantly and independently associated with MSD in various anatomical 
sites (OR=1.69; 95% CI: 1.45-1.97).134 Cigarette smoking has two phases: the volatile phase, 
which accounts for 95% of cigarette smoke, and the particulate phase, where most of the 
carcinogenic substances are found.135 Associations between smoking and low back pain, 
spinal disc disease, and impaired soft tissue healing have been shown.135,136 Within an 
orthopaedic context, the musculoskeletal effects of smoking include decreased bone 
mineral density (BMD), as well as increased wound and fracture-healing complications.136 It 
has also been found that smoking 20 cigarettes or more increases the risk of developing 
relatively severe MSD compared to those that have never smoked before (OR=1.47).137 
From the literature it can thus be deduced that people who have a current history of 
cigarette smoking are more at risk for or prone to developing chronic MSD. 
2.6.4.2 Alcohol Consumption 
Recently, a relationship between alcohol consumption and reported widespread pain or 
fibromyalgia has been shown (males adjusted OR=2.53; 95% CI: 1.78-3.6) (females adjusted 
OR=2.11; 95% CI: 1.67-2.66).138 This has also been shown in a Brazilian study where males 
who consumed an excessive amount of alcohol were more at risk for developing MSD 
(crude risk ratio=1.59; 95% CI: 1.11–2.28; p=0.012).139 
2.6.4.3 Occupation 
Physically demanding occupations have been shown as a risk factor for the development of 
osteoarthritis in the hip and knee.106 Higher prevalences of neck and low back pain have 
also been found in those with labour intensive occupations,140 while occupations with 
repetitive movements produce a higher prevalence of upper limb MSD.141  
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2.7 Chronic Diseases of Lifestyle 
Chronic diseases of lifestyle (CDL) are non-infectious, non-transmissible, slow or 
progressive human diseases that are of long duration.30 This section provides literature on 
common CDL including prevalence, pathophysiology, risk factors, and intervention 
strategies.  
2.7.1 Prevalence of Chronic Diseases of Lifestyle 
2.7.1.1 Global Prevalence of Chronic Diseases of Lifestyle 
In recent years an increase in chronic disease trends has been shown with the WHO 
estimating that these NCDs caused 29% of the total burden of disease (BOD), with the 
heaviest burden affecting poor communities in urban areas.31 It was found that, in 2000, 
26.4% (26.6% of males and 26.1% of females) of the global adult population had 
hypertension (HPT).142 This is projected to be 29.2% (29% of males and 29.5% of females) 
by 2025.142 In sub-Saharan Africa the prevalence of type 2 diabetes mellitus has been found 
to range from to 16%, while the prevalence of hypertension has been found to range from 
6 to 48%.143 Notably, in South Africa, the prevalence of type 2 diabetes mellitus has been 
found to be significantly higher than the global mean.45 The global prevalence of chronic 
obstructive airway disease (COAD) has been found to be between 7% and 11.8%.144 
However, these prevalence estimates increase with age and in smokers.144 Mental illness is 
an umbrella term describing conditions that are, or were, undergoing psychiatric or 
psychotherapeutic diagnosis or interventions.145 The two main types of mental illness that 
appear in the global burden of disease (GBD) is major depression, with a prevalence of 
4.4%, and anxiety disorders, with a prevalence of 4%, of the global population.29,146 
Therefore, when describing mental illness, this review will focus on mood and anxiety 
disorders.  
2.7.1.2 South African Prevalence of Chronic Diseases of Lifestyle 
The increase in CDL, as well as their risk factors, is also a trend shown in South Africa.31 In 
2008, the following NCDs accounted for mortality in South Africa: cardiovascular disease 
(11%), type 2 diabetes mellitus (3%), cancers (7%), other diseases including MSD (7%).32 
The prevalence of familial hypercholesterolaemia (HCL) has also been found to be as high 
as 1% in some South African communities.147 In an African population, where more than 
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80% of the sample was South African, a history or risk of developing hypertension was 
found to be higher than the global population (OR=3.44; 95% CI: 2.64-4.48 for the African 
sample vs [versus] OR=2.49; 95% CI: 2.35-2.63 in the global study; p=0.0023).148 A 2014 
study investigated the disease profiles and prescription costs of NCDs at ten CHC’s in the 
Cape Town Metropole of the Western Cape province. Across the ten CHC’s 82.4% of 
patients reported a chronic condition, with hypertension being the most prevalent chronic 
condition (59%) followed by arthritis (21.8%) and type 2 diabetes mellitus (20%).149 Type 2 
diabetes mellitus (28.4%), hypertension (69.1%), asthma/COAD (18.5%), and arthritis 
(35.8%) were most prevalent at Mitchells Plain CHC with 94,8% of the visits being for 
chronic disease management and 71.3% of the patients having comorbidities (type 2 
diabetes mellitus, hypertension, asthma, epilepsy, arthritis, mental illness, and other), the 
most within the study.149 Previous research in a similar area of Cape Town found that that 
38.3% of participants reported respiratory symptoms of COAD.150 
A lifetime prevalence for major depression of 9.7% has been found in South Africa, where 
females were found to be 1.7 times more likely to develop the condition (95% CI: 1.3-
2.4).151,152 A lifetime prevalence for anxiety disorders of 15.8% has been found in a South 
African population, the highest of any one type of mental illness.152 Of the anxiety 
disorders, agoraphobia without panic was found to be the most prevalent (9.8%), followed 
by social anxiety (2.8%) and generalised anxiety disorder (GAD) (2.7%).152 The Western 
Cape province showed the highest prevalence of mental illness (39.4%) of which the 
majority was attributed to substance abuse (20.6%).152 The Free State province showed the 
highest prevalence of mood (14.6%) and anxiety (21.5%) disorders.152 Mood and anxiety 
disorders were found to be more common in females, while substance abuse was found to 
be more common in males.152 
2.7.2 Pathophysiology of Chronic Diseases of Lifestyle 
2.7.2.1 Hypertension, Hypercholesterolaemia, and Cardiovascular 
Disease 
Hypertension is known as a progressive cardiovascular syndrome with various related 
aetiologies, and thus can be described as a sustained increase in blood pressure (BP) with 
functional and structural vascular and cardiac abnormalities as the syndrome progresses.153 
Hypertension can be divided into two types.154 Primary or essential hypertension 
constitutes approximately 95% of hypertension cases, and is defined as hypertension 
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without any identifiable cause.154 Secondary hypertension is defined as hypertension 
caused by underlying renal or adrenal disease, and constitutes approximately 5% of 
hypertension cases.154 Balanced cardiac output and peripheral resistance results in normal 
blood pressure. Peripheral resistance is mostly implicated in hypertension as prolonged 
contraction of the smooth muscle in the walls of small arterioles lead to the thickening of 
the vessel walls and an irreversible increase in peripheral resistance.154 The contraction of 
the smooth muscle is due to an increase in calcium concentration within the cells, while the 
thickening of the vessel walls may be mediated by angiontensin.154 The autonomic nervous 
system also plays a vital role in maintaining normal BP, as it can stimulate both constriction 
and dilation of the arteriole vessel walls.154 This is why the short-term effects of stress and 
physical activity are also important.154 Other physiological mechanisms that may be 
involved in the development of primary hypertension are the rennin-angiotensin system, 
dysfunction of vascular epithelial cells, insulin sensitivity, hypercoagulability, diastolic 
dysfunction, genetic factors, and vasoactive substances that affect vascular tone as well as 
the transport of sodium.154  
Normal blood pressure ranges from around 120/80mmHg (at rest) to 140/90mmHg.153 
Therefore, hypertension is defined as “an average systolic blood pressure of 140mmHg or 
greater, and diastolic blood pressure of 90mmHg or greater” (p.217).142 Systolic blood 
pressure (SBP) refers to the pressure within arteries during contraction of the heart muscle 
and diastolic blood pressure (DBP) refers to the pressure in the arteries when the heart is 
relaxed (i.e. between heart beats). Stage one or mild hypertension is defined as SBP of 140-
159mmHg and DBP of 90-99mmHg.155 Stage two or moderate hypertension is defined as 
SBP of 160-179mmHg and DBP of 100-109mmHg.155 Stage three or severe hypertension is 
defined as SBP greater than 180 mmHg and DBP greater than 110mmHg.155 In South Africa, 
a diagnosis of hypertension may be made if repeat measurements of blood pressure have 
been performed on three separate occasions over a period of two months, where either 
the initial SBP is greater than or equal to 140mmHg, or the DBP is greater than or equal to 
90mmHg.155 
Cholesterol is a fat-like substance in the body that is used in bodily functions such as 
hormone synthesis and cell membrane build-up.156 Cholesterol is transported in the 
bloodstream via lipoproteins, which are classified into two types.156 High density 
lipoproteins (HDL) transport “good” cholesterol, whereas low density lipoproteins (LDL) 
transport “bad” cholesterol which may lead to an accumulation of plaque within arteries, 
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making the vessels narrower and decreasing blood flow to various organs.156 
Hypercholesterolaemia (high cholesterol) (HCL) is thus a type of dyslipidaemia, defined as a 
total plasma cholesterol level higher than 5mmol/l or a LDL cholesterol level higher than 
3mmol/l.147  
Hypertension and hypercholesterolaemia are both forms of cardiovascular disease (CVD). 
Others include coronary artery disease (CAD) such as angina and myocardial infarction and 
peripheral vascular disease (PVD). Most cardiovascular diseases are caused by 
atherosclerosis. 
2.7.2.2 Diabetes Mellitus 
According to the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 
diabetes mellitus (DM) is a group of metabolic diseases characterised by hyperglycaemia 
(high blood glucose level) which is resultant from a defect in insulin secretion or action, or 
both.157 This hyperglycaemia is chronic, disturbing the metabolism of carbohydrates, fat, 
and protein,158 and is thus associated with long-term damage, dysfunction, and failure of 
various organs, most significantly the eyes, kidneys, nerves, heart and blood vessels.157 
Insulin is the key hormone in the regulation of blood glucose.159 The pancreatic beta-cell 
adapts to changes in insulin action and, in diabetes mellitus, this beta-cell functions 
inadequately low, making dysfunction of the pancreatic beta-cell the critical component of 
the pathophysiology of diabetes mellitus.159 When the effect of insulin is less than 
expected, this is referred to as insulin resistance, which has been found to be strongly 
associated with obesity and physical inactivity.159 
Type 2 diabetes mellitus, also known as non-insulin-dependent diabetes mellitus (NIDDM) 
or adult-onset diabetes, is the most prevalent form of diabetes mellitus which results from 
insulin resistance with an insulin secretory defect that is insufficient to compensate for this 
insulin resistance.157 According to the WHO, someone is considered to have type 2 diabetes 
mellitus if fasting plasma glucose levels are equal to or above 7.0mmol/l or if two hours 
after an 75g oral glucose tolerance test (OGTT) plasma glucose concentration rises to 
greater than or equal to 11.1mmol/l.158 
2.7.2.3 Chronic Obstructive Airway Disease 
There are several definitions of chronic obstructive airway disease (COAD), however, it is 
characterised by reduced airflow, most notable expiratory airflow, and is a nonspecific term 
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referring to a set of conditions which vary in their disease processes and is classified into 
varying stages.160 The conditions include chronic bronchitis and emphysema, and usually 
display symptoms such as wheezing and exertional dyspnoea,160 and persistent coughing.161  
The most noted pathogenesis of COAD is continuous pulmonary inflammation162 and 
oxidative stress due to an oxidant-antioxidant imbalance.163 Thus, COAD is known as a 
progressive inflammatory disease which affects the small airways and alveoli.163 The 
inflammatory cells involved in COAD are neutrophils, lymphocytes, and macrophages, 
which do not respond to steroid treatment and result in fixed airway obstruction or 
resistance and therefore reduced airflow.163 Tobacco smoking has been found to be the 
global leading cause of COAD. Clinical symptoms of COAD are usually gradually progressive, 
starting in midlife, and include coughing, shortness of breath, and wheezing or chest 
tightness.144 A diagnosis of COAD is made using lung spirometry.163 A ratio of forced 
expiratory volume during the first second of expiration (FEV1) and forced vital capacity 
(FVC) of less than 0.7 is indicative of COAD,161,163 with the decrease in FEV1 being most 
indicative of airway obstruction.163 
2.7.2.4 Mental Illness 
For purpose of this study, the umbrella term of mental illness refers to major depressive 
and anxiety disorders, as these have been found to have the most notable impact on the 
global burden of disease.29,146 Symptoms of mental illness range from mild to severe and 
may have significant effects on daily functioning.146 Major depression is defined by the 
occurrence of depressed mood lasting a minimum of two weeks164 and may be 
persistent/long standing or recurrent, thereby significantly affecting the ability to function 
during activities of daily living.146 Symptoms of major depression include sadness, loss of 
interest or pleasure, feeling of fatigue or tiredness, low self-esteem, poor concentration, 
and disturbed sleep and/or appetite.146 Anxiety disorders refer to a group of conditions 
characterised by feelings of excessive worry, anxiety, and fear.146 These conditions include 
generalised anxiety disorder (GAD), panic disorder, post-traumatic stress disorder (PTSD), 
social anxiety disorder, phobias, and obsessive-compulsive disorder (OCD).146 
Clarity in the identification of the pathophysiological processes involved in major 
depression and anxiety disorders remains elusive.164 Therefore there are currently diverse 
theories being researched.164 Most recently the most popular theory suggests dysfunction 
of the biogenic monoamine (serotonin, norepinephrine, and dopamine) and serotonergic 
system where the monoamine neurotransmitters may be lacking, thus affecting appetite 
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regulation, aggression, and mood.164 This theory is most widely accepted due to the success 
of selective serotonin reuptake inhibitors (SSRIs) in effectively managing symptoms of 
major depression.164  
2.7.3 Risk Factors for Chronic Diseases of Lifestyle 
2.7.3.1 Age, Gender, and Ethnicity 
Along with the association to a strong genetic predisposition,122 the risk of developing type 
2 diabetes mellitus has been shown to increase with age, and occurs more in females and 
those with concurrent hypertension and hypercholesterolaemia, while variations occur in 
different racial/ethnic groups.157 As the risk of developing type 2 diabetes mellitus 
progressively increases with age, individuals aged 60 years and older have been shown to 
be six times more likely to develop type 2 diabetes mellitus than those aged 18-39 years.165 
It has also been found that being female, although the reasons for this are unclear, and of 
an older age have been found to be risk factors for developing COAD.163 In South Africa, it 
has been found that males are more at risk for developing hypertension.166 Females have 
been found to be more compliant with medication regimes and thus have significantly 
better controlled hypertension.166 In elderly with hypertension, mainly SBP is increased due 
to decreased arterial compliance.167 
2.7.3.2 Obesity and Waist Circumference 
The increased prevalence of obesity in South Africa, as described by Alaba and Chola 
(2014),113 is a major health concern for the country because of the negative impact it will 
have on the country’s resources as obesity is a risk factor for CDL and will have a 
corresponding increase effect on the burden of NCDs within the country.31,113 Being 
overweight or obese has been shown to increase the likelihood of having hypertension, 
hypercholesterolaemia, and metabolic syndrome compared to those of normal weight.168 
This has also been shown by studies in South Africa where those that are obese are shown 
to have twice the risk of developing hypertension than those with normal weight.166 A BMI 
of and above 30kg/m2 or a waist circumference more than 94cm in males and 80cm in 
females have been found to be risk factors for hypercholesterolaemia.147 Most individuals 
with type 2 diabetes mellitus have also been found to be obese or to have an increased 
percentage of body fat which is predominantly distributed in the abdominal region.157 A 
BMI of 30kg/m2 or more has been shown to be associated with a 15 times increased risk of 
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type 2 diabetes mellitus.165 Obesity plays a key role in the dysfunction of pancreatic beta-
cell and insulin resistance.169  
Waist circumference also explains obesity-related health risk.168 Large hip and thigh 
circumferences have been shown to be associated with a lower risk (independent of age 
and BMI) of type 2 diabetes mellitus, whereas a larger waist circumference has been shown 
to be associated with a higher risk.170 As both overall and abdominal adiposity are strongly 
related to the development of type 2 diabetes mellitus, waist circumference should be 
measured in addition to BMI to assess the risk of type 2 diabetes mellitus in both males and 
females.171 A recent Belgian cross-sectional case-control study found that there is no 
significant association between obesity and COAD.172 
2.7.3.3 Low Physical Activity Levels 
A lack of physical activity has been associated with at least a 1.5-2.0 fold increased risk of 
CDL. A global estimate of physical inactivity accounting for 14% of type 2 diabetes mellitus 
and 22% of ischaemic cardiovascular disease is suggested by previous data, while in South 
Africa it could account for 20% of type 2 diabetes mellitus and 30% of ischaemic 
cardiovascular disease.123 Individuals who reportedly have never exercised have be shown 
to be twice as likely to develop type 2 diabetes mellitus.165 Research has shown that regular 
physical activity is important for the primary prevention of type 2 diabetes mellitus, with 
aerobic and resistance training shown to improve glucose homeostasis,173 by enhancing 
insulin sensitivity, decreasing abdominal adipose tissue, increasing muscle density, and 
improving inflammatory responses and immune system function.174 Literature suggests 
that 30 minutes of moderate intensity physical activity each day can decrease the incidence 
of type 2 diabetes mellitus and cardiovascular disease.174 
It has also been shown that in low-and middle-income countries, physical activity is 
associated with a decreased risk of hypertension.175 Despite this, the African INTERHEART 
study found that exercise was not related to the development of hypertension and risk of 
acute myocardial infarction in a predominantly African population (OR=0.88; 95% CI: 0.65-
1.20; p=0.15).148 Participants in the INTERHEART study were considered to be physically 
active if they were regularly involved in moderate or strenuous exercise for more than four 
hours per week.148 It must, however, be noted that the INTERHEART study primarily 
assessed for risk factors of acute myocardial infarction, where hypertension was 
considered a risk factor and not the primary outcome measure.148 A walking regimen as 
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physical activity has been shown to lower SBP by 3.84mmHg (95% CI: −5.19 to −1.97 
mmHg) and DBP by 1.54mmHg (95% CI: −2.83 to−0.26mmHg).176 Progressive resistance 
exercise has also been shown to lower SBP by between 3.0  and 4.6mmHg and DBP by 
between 3.0 to 3.8mmHg.177 
As shown in previous literature, exertional dyspnoea, which is one of the cardinal 
symptoms of COAD, may lead to limitations of physical activity in daily life, which may in 
turn influence the development of disability.178 In those with COAD, reduced physical 
activity and smoking were associated with the presence of comorbidities172 and it has been 
found that physical activity decreases over time independent of the severity of COAD.178 
The decline in physical activity is accompanied by a worsening of airflow obstruction and 
health status while sustained low levels of physical activity was found to be related to a 
continual decrease in exercise tolerance.178 
As previously stated, a lack of physical activity in individuals with MSD could lead to 
secondary complications such as obesity, hypertension, and type 2 diabetes mellitus.11 
Therefore, it is suggested that if the primary medical problem, MSD, is not managed 
effectively, a cycle of secondary complications such as CDL could occur. International 
guidelines recommend moderate-intensity physical activity of at least 150 minutes per 
week in order to achieve any form of health benefit.179 
2.7.3.4 Unhealthy Diet, Smoking & Alcohol Consumption 
The WHO has also identified unhealthy dietary habits as one of the four main behavioural 
risk factors for the causation of CDL.24 Excessive salt and saturated fat intake as well as low 
intake of fruits, vegetables, and whole grains are responsible for the increase in the burden 
of CDL.180 
Smoking is known for its hazardous effect and contribution towards cancer, cardiovascular 
disease, type 2 diabetes mellitus, and respiratory diseases, including tuberculosis (TB).180 Of 
over one billion global cigarette smokers the majority now live in low- and middle-income 
countries.180 Cigarette smoking is also a risk factor for cardiovascular disease and 
hypercholesterolaemia.147 Smoking has been found to contribute toward approximately 
85% of COAD cases, with at least 50% of smokers developing the disease in developed 
countries.163 Smokers have been found to have more abnormalities of lung function than 
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non-smokers.181 In South Africa, it has been shown that excessive consumption of alcohol 
significantly increases the risk for developing hypertension.166  
2.7.4 Intervention Strategies for Chronic Diseases of Lifestyle 
2.7.4.1 Hypertension, Hypercholesterolaemia, and Cardiovascular 
Disease  
The goal of management of hypertension is to decrease the blood pressure of 
uncomplicated patients to 140/90mmHg or below, and of high-risk patients to 
130/80mmHg or below.155 
In South Africa, guidelines for management of hypertension specify drug therapy and 
lifestyle modification education.155 Drug therapy should include a combination of a diuretic, 
an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), 
and a calcium-channel blocker (CCB).155,182 A beta blocker and blood thinning agent may 
also be used. The following medications are used in the South African public health care 
sector and are recommended by the WHO for use in the primary health care management 
of individuals with hypertension: 
 The thiazide diuretic Hydrochlorothiazide (HCTZ),183 also known as Ridaq in South 
Africa. Thiazide diuretics only effectively lower blood pressure in those with 
hypertension by reducing peripheral resistance.184 
 The calcium-channel blocker (CCB) Amlodipine.183 CCBs inhibit the flow of calcium 
through vascular cell walls which relaxes vascular smooth muscle.185 This then 
lowers blood pressure by dilating arteries, which has been shown to occur across 
all patient groups.185 Side effects of CCBs are headache, dizziness, drowsiness, 
nausea, constipation, rash, and oedema.185  Grapefruit juice should also be avoided 
when using CCBs as it increases the proportion of the drug that enters the 
circulation for absorption (bioavailability).185 Alternatives to Amlodipine are 
Verapimil and Nifedipine, also known as Adalat or Fedaloc in South Africa.182 
 The angiotensin-converting enzyme (ACE) inhibitor Enalapril,183 also known as 
Pharmapress in South Africa. These medications inhibit the renin system.183 Side 
effects of ACE inhibitors include persistent coughing.186 
 Angiotensin-receptor blockers (ARBs) such as Losartan.186 These medications also 
inhibit the renin system and are considered as new drugs and are not considered as 
41 
 
first line hypertension drugs in South Africa. ACE inhibitors and ARBs have been 
found to have similar long-term effects on blood pressure with ARBs having less 
side effects, of which the most notable for Losartan is dizziness.186 
 The beta blocker Atenolol.183 Beta blockers decrease heart rate, cardiac output, and 
peripheral vascular tone.167 These inhibitory mechanisms are reported to be 
incompletely understood.167 However, beta blockers are effective in the treatment 
of cardiac arrhythmias, cardiac failure, and coronary artery disease due to its heart 
rate lowering effects.167 
 The blood thinner Acetylsalicylic Acid (ASA), also known as Aspirin.183 It has been 
reported that, in those with hypertension, ASA can significantly decrease major 
cardiovascular events by 15% (p=0.03).187 
Lifestyle modifications aim to decrease blood pressure and total cardiovascular risk, and 
enhance drug efficiency.155 These modifications include education on weight reduction, 
regular physical activity, cessation of smoking, moderation of alcohol intake, reduction of 
salt and fat intake, and increasing intake of fresh fruits and vegetables.155 Exercise has also 
been shown to lower SBP by 4.16 mmHg which is clinically relevant as it is similar to the 
effects of blood pressure lowering therapy using a combination of an ACE inhibitor and 
thiazide diuretic.169 
In South Africa the treatment of hypercholesterolaemia includes lifestyle modification and 
pharmacotherapy.156 Lifestyle modifications should include a healthy diet, a reduction in 
alcohol consumption, smoking cessation and regular physical activity.147 The medication of 
choice, and the gold standard of treatment, are Statins, such as Simvastatin, which have 
very few side effects, are cost effective and act by prohibiting the synthesis of LDL 
cholesterol.156 It has been found that the effect of Statin therapy is best after one year and 
continues to improve thereafter.147 This effect is similar in all subgroups.147 High dose 
Simvastatin treatment may result in myopathy, therefore the presence of MSD in those on 
Simvastatin treatment should be monitored before and during treatment.147 
2.7.4.2 Diabetes Mellitus (Type II) 
As insulin resistance plays a fundamental role in the pathophysiology of type 2 diabetes 
mellitus, interventions have been identified to initially be aimed toward improving tissue 
insulin sensitivity.159 Insulin resistance in type 2 diabetes mellitus may improve with 
reduction of weight and/or pharmacological treatment of hyperglycaemia but is seldom 
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restored to normal.157 Structured lifestyle interventions combined with the oral use of 
Metformin remains the first treatment of choice.159 If oral dose adjustment of Metformin is 
not effective, early insulin therapy may be started.169 Metformin is the most commonly 
used medication for type 2 diabetes mellitus as it is a highly effective antihyperglycaemic 
agent which works independently of the pancreas and decreases hepatic glucose output.159 
Thiazolidinediones are medications which reduce glycaemia and enhance vascular function, 
and can be used in diabetics with reduced renal function.159 
Increasing physical activity has been found to reduce the incidence of type 2 diabetes 
mellitus in high risk individuals.188 Exercise therapy has been shown to improve glycaemic 
control in type 2 diabetes mellitus.169 When compared to control groups, exercise 
significantly improved glycaemic control, while no adverse effects or diabetic complications 
have been reported with exercise.189 A decrease in visceral and subcutaneous adipose 
tissue and plasma triglycerides, as well as an increase in insulin response, has also been 
shown with exercise.189 Recent literature has suggested that there are significant benefits 
related to physical activity after meals (ten minute walk within five minutes after each of 
the three main meals), particularly when the meals contain a substantial amount of 
carbohydrates, compared to walking 30 minutes a day at any time of the day.190 As 
previously mentioned, exercise decreases post exercise blood pressure and increases the 
bioavailability of nitric oxide.191 Most notably, the metabolic stress from exercise can 
increase the oxidation of carbohydrates during exercise and also maintains the post 
exercise consumption of oxygen, increasing the rate of fat oxidation after exercise, which 
improves glucose tolerance and insulin sensitivity and reduces hyperglycaemia for between 
two and 72 hours.191 Weight loss and improvement in fitness have also been shown to slow 
the decline in mobility in overweight adults with type 2 diabetes mellitus.192 
2.7.4.3 Chronic Obstructive Airway Disease 
The treatment for COAD is also pharmacological and non-pharmacological.161 It has been 
established that smoking cessation remains the cornerstone of treatment for COAD.160 
Pharmacological intervention for COAD is aimed at improving symptoms, exercise 
tolerance, and overall health status.193 Bronchodilators are most commonly prescribed and 
may be used in combination with anti-inflammatories such as corticosteroids.193  An 
increase in physical activity within a pulmonary rehabilitation context which includes 
education is also recommended.161  
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2.7.4.4 Mental Illness 
As previously mentioned, the best current practice of pharmacological intervention for 
major depressive and anxiety disorders are the antidepressant SSRIs as well as serotonin-
norepinephrine reuptake inhibitors (SNRIs).164 These are thought to improve the levels of 
serotonin and norepinephrine by affecting the neurotransmitter receptors to alter 
neurotransmission.164 Psychotherapy is also one of the first-line management strategies for 
major depressive and anxiety disorders and has been shown to be effective in doing so.194 
 
2.8 Associations between Musculoskeletal Disease, Chronic 
Diseases of Lifestyle, and Risk Factors 
In a South African study, common comorbidities such as hypertension (59,1%), type 2 
diabetes mellitus (24,8%), and cardiovascular problems (18,9%) were found in the sample 
of participants with MSD.12 These findings highlight a possible co-existence of MSD and CDL 
in patients attending disadvantaged CHCs in Cape Town.  
According to the Nord-Trondelag Health Study,195 the higher the blood pressure 
(specifically SBP) the lower the prevalence (10-60% decrease) of chronic MSD in subjects 20 
years and older.195 This could be due to hypertension-associated hypoalgesia, an effect of 
blood pressure on pain perception via the central nervous system.195 Hypertension-
associated hypoalgesia refers to an increase in the threshold to noxious stimuli and thus a 
decreased perception of pain associated with hypertension.196 These changes are thought 
to be related to the baroreflex system and changes in pathways within the central nervous 
system.196,197 It is thought that the hypoalgesia effect is related to the process that 
increases blood pressure and not the increased blood pressure itself, as even when blood 
pressure is reduced in those with hypertension the same hypoalgesic effects occur.196 This 
could be due to a stress response in which pain would be a distracting factor and thus a 
pain suppression system is activated.196 An internal component mediated by opioids has 
also been shown to be potentially related to hypertension-associated hypoalgesia in 
healthy individuals, particularly males.198 The Nord-Trondelag Health Study consisted of 
two surveys, with the second study, HUNT-2 (August 1995 to June 1997), measuring blood 
pressure with an automatic oscillometric method and including questions regarding 
musculoskeletal symptoms which were adopted from the Standardised Nordic 
Questionnaire.199,195 The Standardised Nordic Questionnaire has been found to be a valid 
44 
 
tool for estimating discomfort in the upper limb and spine, although information for the 
lower limb has not been validated.199 These studies were carried out in the Nord-Trondelag 
county in northern Norway,195 a high income country according to the World Bank.15 No 
information on MSD was investigated in the first of the two studies, HUNT-1, to provide a 
baseline. Most responders who responded to the MSD questions in HUNT-2 were younger, 
and likely to be female, with a higher socioeconomic status than the non-responders.200 
The effect of antihypertensive medication was also not evaluated.195 Although the study is 
a large-scale population-based study, the results were specific to the sample in its context 
and may not be generalizable and applicable in an under-resourced area of Cape Town 
especially in relation to musculoskeletal symptoms. It must also be noted that an 
association between chronic elevated blood pressure and the decreased perception of pain 
was not always found.196 In a cross-sectional study done in Brazil, a country similar in socio-
economic status to South Africa, it was found that the presence of MSD was positively 
associated with hypertension in both males (crude risk ratio=1.91; 95% CI: 1.40–2.59; 
p<0.001) and females (crude risk ratio=1.77; 95% CI: 1.46–2.15; p<0.001).139 However, 
when adjusting for other variables, this association in females was no longer significant.139 
Notably, males who were using antihypertensive medication were found to have the 
highest adjusted risk of MSD (adjusted risk ratio=1.78; 95% CI: 1.11–2.86) and no 
association between the prevalence of MSD and blood pressure was found.139 
A 2009 North West England population-based prospective cohort study found a moderate 
relationship between MSD and cardiovascular disease (mortality rate ratio=1.02; 95% CI 
0.99-1.1).201 A total of 4515 adult participants, in stratified gender and age groups (16-44, 
45-64, 65-74, 75+ years), returned a questionnaire that gathered demographic information 
and information on MSD.201 The study found that those with widespread pain were more 
likely to be female and older.201 The moderate relationship between an increased risk of 
cardiovascular disease mortality and widespread MSD was hypothesised to be associated 
with decreased physical activity levels.201 More recently, another English study also found 
that chronic MSD is associated with an increased risk of cardiovascular disease which 
increases with age, but physical activity levels were not found to contribute toward this 
relationship.202 This study is expanded upon in Table 3. 
Due to the long term metabolic changes (i.e. persistent hyperglycaemia) involved in type 2 
diabetes mellitus, numerous  complications may develop, including MSD.203 These 
complications are intensified by inconsistent or poor control of glycaemic levels and 
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improved by adequate pharmacotherapy, a healthy diet, and a monitored exercise 
regime.203 MSD has been found to be more prevalent in people with type 2 diabetes 
mellitus which may be associated with glycaemic control, gender and duration of 
diabetes.204 A 2005 study found that 60% of people with type 2 diabetes mellitus reported 
chronic pain.205 Those reporting chronic pain reported poorer overall self-diabetes 
management, which included an exercise and eating plan.205 The Nord-Trondelag Health 
study provided data on the association between diabetes mellitus and MSD, where 
individuals with diabetes mellitus were more likely to report chronic widespread MSD than 
those without.206 The study also found that the prevalence of chronic MSD increased with 
age, peaking in ages 60-64 years, increased with BMI, and were higher among females and 
in those who were physically inactive.206 
Owing to the broad, nonspecific literature on COAD and MSD, the links between risk factors 
such as smoking, reduced physical activity, systemic and local inflammation, oxidative 
stress, vitamin D deficiency, nutritional deficits, and age, have been identified as aspects for 
future research in the co-occurrence of these conditions.207 Some of these risk factors were 
identified in a 2014 study on preclinical COAD and smoking control subjects, where 
cardiovascular disease and MSD were reported to be the most prevalent comorbidities, and 
reduced physical activity and smoking were found to be independent risk factors for having 
two or more comorbidities.172 It has been shown that 32% of those with COAD have 
presented with skeletal muscle weakness and endurance.207 This weakness may contribute 
toward less physical activity, decreased active joint stability, and limitation of function.207 
Osteoporosis has also been found to be associated with COAD due to the obstruction of 
airflow, which may increase bone fracture risk.207 Thus, the decrease in exercise capacity 
associated with COAD may lead to or aggravate MSD. 
Research has shown that the prevalence of pain in those with depression (approximately 
65%) and the prevalence of depression in those with pain (5-85%) is higher than those that 
only experience one of the two conditions.208 Additionally, those who experience 
depression and anxiety may experience more pain and disability than those with either 
depression or anxiety.209 A global study, which included South Africa, found that 5% of the 
population experience chronic MSD, such as low back pain, neck pain and headaches, and 
joint pain, along with major depression and/or an anxiety disorder.41 This was then found 
to be higher in females than males.41 Of those with central processing dysfunction, such as 
fibromyalgia, 30% have also been diagnosed with major depression at the same time and 
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74% have been diagnosed with the condition in their lifetime.210 Additionally 60% of those 
with fibromyalgia have been diagnosed with an anxiety disorder in their lifetime.210 These 
prevalence rates are significantly higher than for those without central sensitisation. It can 
thus be deduced that MSD is commonly associated with depression and anxiety, with these 
conditions frequently coexisting, and hence the assessment and treatment of both is of 
great importance.208 
There is a lack of South African evidence regarding the inter-relationships between MSD, 
CDL, obesity and physical activity levels. Because of this, management is not targeted 
appropriately at risk factors and thus cannot reduce the high prevalence rates of MSD. 
Further literature on the association between MSD and CDL is summarised in Table 3 
below. 
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Table 3: Association between musculoskeletal disease and chronic diseases of lifestyle: review articles 
Author, 
Year of 
Publication 
CDL Study 
Design 
Location Study Sample Results Conclusions Level of 
Evidence102 
Hagen et 
al195, 2005 
Hypertension (HPT) Cross 
Sectional 
Survey 
Sweden: 
Nord-
Trondelag 
Study: 
 
HUNT-1: Jan 
1984-Feb 1986 
– no MSD 
outcomes 
HUNT-2: Aug 
1995-June 1997 
46901 adults 
completed 
HUNT 1 & 2 
 An SBP and DBP was associated with 
a 10% to 60% lower prevalence of 
chronic MSD. 
 There was a strong linear trend 
(p<0.001) of decreasing prevalence 
of chronic MSD with increasing BP 
values. 
 The prevalence of chronic MSD was 
highest among those with a low DBP  
 Individuals with an elevated SBP or 
DBP in HUNT-1 and/or HUNT-2 had a 
lower prevalence of chronic MSD 
compared with those with a normal 
BP in both surveys. 
 The lowest prevalence of chronic 
MSD was found among those with a 
high SBP or DBP in both studies. 
Individuals with a high 
BP had a lower 
prevalence of chronic 
MSD than individuals 
with a normal BP.  
 
 
II 
Ryan et 
al202, 2014  
Cardiovascular Disease 
(CVD) 
Secondary 
analysis of 
a 
population-
based 
survey 
(2008) 
England – 
private 
households 
3332 adults 
aged 45-64 
years & 2022 
adults older the 
66 years 
 Higher prevalence of cardiovascular 
disease in those with MSD for both 
the middle-aged (22.5% vs. 13.5%) 
and the older (46.8% vs. 28.2%) 
adults (p <0.001).  
 Older adults with cardiovascular 
disease were significantly more 
likely to have chronic MSD. 
MSD is associated with 
an increased risk of 
cardiovascular disease 
especially in older adults. 
Neither physical activity 
nor sedentary behaviour 
contributed to this 
relationship. 
II 
Klemp et 
al211, 1993 
Hypercholesterolaemia 
(HCL): Familial and 
juvenile 
Case 
Control 
Study 
Western 
Cape, South 
Africa: 
88 patients 
with 
hyperlipidaemia 
 65 (74%) patients had one or more 
MSD (p=0 026).  
 57 (65%) of the 88 patients had one 
Long term prospective 
studies relating serial 
lipid profiles to MSD 
III 
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Author, 
Year of 
Publication 
CDL Study 
Design 
Location Study Sample Results Conclusions Level of 
Evidence102 
hypercholesterolaemia 
and mixed 
hyperlipidaemia 
(increased cholesterol 
and triglycerides) 
and 88 age and 
gender 
matched 
controls 
or more of the MSD claimed to be 
associated with hyperlipidaemia 
(p<0.001). 
 MSD occurred in significantly more 
patients with adult familial 
hypercholesterolaemia and mixed 
hyperlipidaemia than controls. 
 MSD of some patients improved 
after lipid lowering treatment. 
should be carried out as 
the pathogenesis of the 
relation is not 
understood. 
 
Hoff et 
al206, 2008 
Type 2 Diabetes 
Mellitus 
Cross 
Sectional 
Survey 
Sweden: 
Nord-
Trondelag 
Study 
 
HUNT-2: Aug 
1995-June 1997 
65081 (70.0%) 
answered the 
first question 
about DM 
64785 (69.7%) 
responded to 
the first 
question about 
MSD 
 Adapted Standardized Nordic 
Questionnaire199 
 46.5% of 64785 reported chronic 
MSD  
 The prevalence of chronic MSD: 
- increased with age with a peak 
in the age group 60–64 years 
(59.7%),  
- higher for females in all age 
groups (overall 50.1% versus 
42.6%, p<0.001). 
- increased with BMI with a peak 
among obese with BMI ≥ 30 
kg/m2 (54.6%) 
- higher those with low physical 
activity (55.4% versus 44.9%, 
p<0.001). 
- higher among patients with DM 
than among individuals without 
(OR = 1.2, 95% CI 1.1–1.3) 
Those with type 2 
diabetes mellitus were 
more likely to report 
chronic widespread 
MSD. 
II 
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Author, 
Year of 
Publication 
CDL Study 
Design 
Location Study Sample Results Conclusions Level of 
Evidence102 
Abaraogu 
et al48, 
2016 
Type 2 Diabetes 
Mellitus 
Cross-
sectional 
Survey 
Nigeria 347 participants 
167 diabetics 
(48.1%) 
180 non-
diabetics 
(51.9%) 
 LBP most common MSD = 49.7% 
diabetics and 38.9% of non-
diabetics. 
 Chronic low back discomfort was 1.5 
times more likely among diabetics 
compared to non-diabetics. 
 Age, and NOT gender, was 
significantly associated with MSD 
(p=0.043). 
 Diabetics had 2.5 odds of MSD in at 
least one body part compared to 
non-diabetics. 
 Diabetics are more than 28 times at 
risk of MSD of the knee and are 
close to 29 times at risk of chronic 
upper back MSD compared to non-
diabetics. 
 
Individuals with type 2 
diabetes mellitus are at 
increased risk of 
developing chronic MSD. 
 
II 
Cielen et 
al207, 2014 
COAD Review Not 
Specified 
Not Specified  Skeletal muscle weakness and osteoporosis are two comorbidities 
of COAD. 
 Risk factors: smoking, low physical activity, systemic and local 
inflammation, oxidative stress, vitamin D deficiency, nutritional 
deficits, and age. 
V 
CDL=Chronic Disease of Lifestyle; HPT=hypertension; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; BP=Blood Pressure; MSD=Musculoskeletal disease; CVD=Cardiovascular 
disease; PA=Physical Activity; HCL=Hypercholesterolaemia ; DM=Diabetes Mellitus; LBP=Low Back Pain; COAD=Chronic Obstructive Airway Disease 
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2.9 Health-Related Quality of Life and Musculoskeletal Disease 
and Chronic Diseases of Lifestyle 
The European Quality of Life-5 Dimensions (EQ-5D) health index (see Appendix VIII) 
describes the health-related quality of life (HRQoL) of an individual. It uses five domains of 
function:  mobility, self-care, usual activities which includes study, work, housework, family 
or leisure, pain or discomfort and lastly depression or anxiety.212 The instrument also 
includes a visual analogue scale (VAS) on which participants can indicate their health 
status.212 The EQ-5D has been validated in a wide range of settings. Construct validity was 
explored by examining correlations between EQ-5D and Health Assessment Questionnaire 
(HAQ) and found moderate to high correlations with measures of impairment (Spearman 
r=0.61; p<0.05) and high correlations with disability measures (Spearman r=0.78;  
p<0.05).213 Reliability was analysed and found acceptable agreement between responses 
with intraclass correlation coefficient (ICC) of 0.70 (CI: 0.60-0.80) for EQ-5D VAS and ICC of 
0.73 (CI: 0.63-0.83) for EQ-5D utility.213 
 
2.10 Intervention Strategies for Musculoskeletal Disease  
The literature suggests that management of patients with MSD should include 
pharmacological treatment and management of pain, education and advice, and exercise 
treatment programmes focussing on maintaining and improving gross motor and whole 
body function.12 As chronic MSD often presents without specific findings, it has been noted 
that it is important to not only adhere to a biomedical approach to treatment but to follow 
a biopsychosocial model which gives a better understanding of the condition and 
appropriate management.5 Most current intervention therapies for MSD are focused on 
input mechanisms by treating peripheral elements such as muscles and joints, as well as 
output mechanisms which address motor control, while less attention is being paid to 
processing (central) mechanisms.75 In South Africa, 90% of patients with low back pain, 
including chronic pain, at primary health care level have been shown to receive only 
analgesia as a form of pain management, omitting any form of education and markedly 
limiting any referral for physiotherapy management.214 
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2.10.1 Pharmacological Intervention for Musculoskeletal Disease 
The pharmacological analgesic management of MSD follows three steps: Firstly, a non-
opioid analgesic such as Paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and 
ASA; secondly, weak opioids such as Codeine and Tramadol; and thirdly, strong opioids 
such as Morphine and Fentanyl.215  Other pharmacological agents used in the management 
of MSD are antidepressants, muscle relaxants and steroids,216 as well as antiepileptics and 
antiarrhythmics.217  
2.10.1.1 Non-Opioid Analgesia 
2.10.1.1.1 Paracetamol 
Paracetamol, or Acetaminophen, is commonly used as an antipyretic and analgesic for mild 
to moderate pain218 and has little to no anti-inflammatory effects.219 It is thought to inhibit 
descending pain pathways and has been shown to be as effective as NSAIDs.220 However, 
despite being safer than NSAIDs, Paracetamol seems to be underused for MSD as patients 
perceive it to be harmful or ineffective or dislike taking any form of medication.220 For MSD, 
Paracetamol is considered to be the first step in a step-wise method applied to guide the 
safety and efficacy of medications.221,222 As a result of its efficacy, good safety profile, lack 
of side effects, low cost, and ease of availability, Paracetamol should be the anchor of 
pharmacological management of MSD, especially when acute.218,221 The usual dose of 
Paracetamol ranges from 0.5 to 1 mg every four to six hours.221 There is insufficient 
evidence to determine the efficacy of Paracetamol in the treatment of non-specific low 
back pain223 or other non-specific chronic pain such as in conditions like fibromyalgia.224 
Recent literature has shown that Paracetamol is ineffective in decreasing pain intensity or 
improving quality of life in those with low back pain.225 For more specific chronic 
conditions, such as osteoarthritis, Paracetamol is also used as the first line of analgesic 
management226 but has been shown to be ineffective in reducing pain227 and stiffness.227  
2.10.1.1.2 Non-Steroidal Anti-Inflammatory Drugs  
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are anti-inflammatory, analgesic, 
antipyretic, and antithrombotic pharmacological agents that are widely used in acute and 
chronic MSD with mild to moderate pain, but has no effect on the disease process of 
chronic MSD.228 Commonly prescribed NSAIDs include Diclofenac Potassium (Cataflam, 
Voltaren), Ibuprofen, Indomethacin, Acetylsalicyclic Acid (ASA), and Celecoxib (Celebrex). 
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The primary mechanism of NSAIDs is to inhibit COX enzymes which are responsible for 
synthesising prostaglandins that are involved in the inflammatory process.68,229 NSAIDs 
have been shown to have increased morbidity, and to be the main cause of drug related 
morbidity,230 in those aged 65 years and older, due to associated gastric ulceration and 
haemorrhage and cardiovascular complications.34 Due to these gastrointestinal, 
cardiovascular, and renal complications and associated risk, the use of NSAIDs is limited in 
the management of chronic MSD.215 Selective COX-2 inhibitors may decrease these side 
effects compared to non-selective inhibitors.55 Low dose Ibuprofen appears to have a lower 
risk of gastrointestinal side effects or complications.221 NSAIDs have also been shown to be 
effective for short-term treatment of acute MSD but there is insufficient evidence of their 
efficacy in chronic MSD.231 In the management of MSD, Ibuprofen has been shown to be 
tolerated as well as Paracetamol, while both are better tolerated than ASA.232 NSAIDs are 
the most commonly used pharmacological intervention for osteoarthritis but should be 
considered only when Paracetamol does not provide effective pain relief, due to the side 
effects.226 Topical NSAIDs obtaining formulations of Diclofenac, Ibuprofen, Ketoprofen, 
Piroxicam, and Indomethacin have also been shown to be associated with good pain relief 
for acute MSD such as joint sprains, muscle strains, and overuse injuries, and are not 
associated with adverse local skin effects when compared with placebo.233 Thus, topical 
NSAIDs may be useful when treating acute MSD in those where oral NSAIDs are not 
tolerated well or are contraindicated.233 
2.10.1.2 Opioid Analgesia 
Opioids are the most potent acting analgesics234 and are used in the treatment of moderate 
to severe pain.219 The usual opioid treatment for MSD, including post-surgery, include 
Codeine, Oxycodone, Hydrocodone, or Morphine.219 Opioids frequently result in side 
effects such as sedation, dizziness, constipation, nausea, and vomiting26 and have a high 
affinity for addiction, abuse, and overdose.235 Opioids have been shown to be effective in 
pain management in the short-term but have not shown any long-term improvement in 
functional abilities or quality of life in those with chronic MSD,235 a finding that must be 
carefully considered with prescription and re-evaluated with long-term use.236 A risk-
benefit analysis is recommended before any prescription of opioids in chronic MSD.237 
Possible reasons for the long-term inefficacy of opioids include the development of 
pharmacologic opioid tolerance or increased sensitivity to pain.238 
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Tramadol, a synthetic form of Codeine,219 is a centrally acting weak opioid analgesic  
indicated for use in individuals who have NSAID intolerance (particularly gastrointestinal) or 
pain that is not aided by NSAIDs.215 Tramadol inhibits the reuptake of noradrenaline and 
serotonin.226 It has been shown to be a potent analgesic with less opioid-type side effects 
such as drowsiness, dry mouth, constipation, nausea, and vomiting, and can safely be used 
in combination with NSAIDs, antidepressants, and anticonvulsants.215 Tramadol has now 
become a first-line treatment  for MSD with clinicians being recommended to decrease the 
use of NSAIDs in favour of  weak opioids due to fewer side effects with long-term use.222 It 
has been shown to be effective in treating nociceptive and neuropathic pain and is now 
recommended in guidelines on the management of MSD,222 including osteoarthritis.226 
Recent literature has shown that weak opioids are as effective as NSAIDs in reducing pain in 
lower limb osteoarthritis patients.239 
The combination of oral Diclofenac and Paracetamol has been shown to produce a greater 
decrease in mean pain score than either NSAIDs or Paracetamol alone, but this benefit is 
small and not clinically significant, while the combination produces a higher a proportion of 
abdominal pain, nausea, or vomitting.228 Thus the use of Paracetamol, NSAIDs, and the 
Diclofenac-Paracetamol combination has been shown to be equally safe in managing pain 
in MSD.228 The combination of Ibuprofen-Paracetamol has been shown to produce modest 
short-term benefits for knee pain/osteoarthritis, with an increase in side effects and the 
combination appearing to be additive.240 The combination of Tramadol-Paracetamol has 
been found to be associated with a significant reduction in pain and increase in pain 
relief.231 
2.10.1.3 Skeletal Muscle Relaxants 
Skeletal muscle relaxants are pharmacological agents that decrease muscle tone and are 
thus thought to decrease musculoskeletal pain and muscle spasm.219 There are two major 
therapeutic classes of skeletal muscle relaxants – spasmolytics, or antispasmodics, and 
neuromuscular blockers. Spasmolytics are more applicable for MSD as they may act 
centrally, on the cortex of the brain, the brain stem, or the spinal cord, to reduce spasm 
and spasticity,219 whereas neuromuscular blockers do not act on the central nervous 
system. Neuromuscular blockers cause paralysis by interfering with neuromuscular end-
plate transmission and are thus only used during surgery, in intensive care units, and in 
emergency medicine. Examples of spasmolytics include Carisoprodol, Cyclobenzaprine 
Hydrochloride, and Metaxalone.241,242 Skeletal muscle relaxants have been found to be 
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more effective than placebo in relieving short-term pain in acute, and perhaps chronic, 
MSD such as in LBP,241,243 as they may reduce pain associated with muscle spasm.244 They 
improve range of movement and interrupt the spasm-pain-spasm cycle that may 
accompany acute musculoskeletal injury.245 It must, however, be noted that muscle 
relaxants bring about significant side effects such as drowsiness and dizziness,243 and ataxia 
and irritability.241 Muscle relaxants also have an increased risk of abuse241,243,245 and their 
use for MSD should be with caution,243 hence they are not recommended as first-line 
pharmacological treatment for MSD.  
2.10.1.4 Corticosteroids 
Intra-articular injection of corticosteroids have been found to be anti-inflammatory and 
useful for joint pain in the short term while found to be effective for between one and four 
weeks.226 However, long term benefits have not been proven, and repeated injection may 
lead to degeneration of cartilage, destruction of the joint, and atrophy of the surrounding 
tissue.226 Thus, corticosteroid injections may only be repeated after three months and their 
use is not recommended.226 Corticosteroid injections into facet joints of individuals with 
chronic low back pain have also proved to be ineffective and are thus of little value in the 
management strategy of chronic low back pain,246 however, subacromial injections of 
corticosteroids have been shown to improve rotator cuff tendonitis for up to nine 
months.247  
2.10.1.5 Antidepressants  
It is thought that the neurochemical pathways involved in mood disorders and in pain 
transmission and processing have similar neurotransmitters.64 Antidepressants, particularly 
serotonin-norepinephrine reuptake inhibitors (SNRIs) such as Venlafaxine, Duloxetine, and 
Desvenlafaxine, are preferentially prescribed for neuropathic and centralised pain states248 
and may be considered when a comorbid mood disorder is also present.64 Venlafaxine also 
inhibits the reuptake of dopamine and is less expensive than Duloxetine.64 Tricyclic 
antidepressants (TCAs) such as low dose Amitriptyline may also be used.249 Amitriptyline, 
more commonly known as Trepiline in South Africa, inhibits the reuptake of serotonin and 
noradrenaline64 and are thus prescribed for their specific analgesic effects rather than their 
mood altering effects, as serotonergic and noradrenergic activity has been shown to be 
important in the analgesic effect.217 These medications are more effective in treating 
neuropathic pain, generally require weeks to take effect, and should be used with caution 
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in the elderly.64 They also have a moderate effect on chronic pain processes such as 
fibromyalgia.250 Those with chronic MSD may also experience additional depression and 
anxiety, despite the use of optimised antidepressant therapy.209 
2.10.1.6 Gabapentinoids 
Gabapentanoids, such as gabapentin and pregabalin (also known by the trade name Lyrica) 
may also be used in the treatment of MSD. Gabapentin inhibits excitatory 
neurotransmitters along the pain pathway, while pregabalin is a precursor to gamma-
aminobutyric acid (GABA), a neutrotransmitter, both affecting calcium channels.251 They 
are antiepileptics, anticonvulsants, analgesics (mostly in neuropathic conditions),252 and 
anxiolytics251 and are thus used to treat epilepsy, neuropathic pain, fibromyalgia, and 
generalised anxiety disorder. 
2.10.1.7 Disease Modifying Anti Rheumatic Drugs  
Disease Modifying Anti Rheumatic Drugs (DMARDs), such as Methotrexate, are widely used 
for rheumatoid arthritis253 due to its unique anti-inflammatory effects.253,254 Other 
conditions where Methotrexate has been used include inflammatory bowel disease (IBD), 
cancer, and systemic lupus erythematosus (SLE).254 The standard dosage of Methotrexate 
for those with rheumatoid arthritis is 7.5-25mg once per week.253 It has recently been 
suggested that low dose (5-10mg) Methotrexate may be a helpful adjunct to other 
medication in those with severe fibromyalgia.254 This is based on the theory that all pain 
originates from inflammation and the inflammatory process and thus the broad spectrum 
anti-inflammatory action of Methotrexate helps to decrease pain.254 
2.10.2 Non-Pharmacological Intervention for Musculoskeletal 
Disease 
For acute MSD, physical management including the PRICE (protect, rest, ice, compression, 
elevation) principle is generally recommended.233 This may be done with the assistance of 
appropriate analgesia where necessary.233 The National Institute for Health and Clinical 
Excellence (NICE) in the United Kingdom, developed a clinical guideline recommending that 
health education, physical activity, and exercise should be used as the primary choice of 
non-pharmacological treatment for chronic MSD.255 This is due to modern pain 
neuroscience which lends itself toward treatment strategies that are aimed at desensitising 
the central nervous system.256 
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2.10.2.1 Manual Therapy 
Manual therapy includes massage and mobilisation of soft tissue and joints.257 These 
techniques are intended to modify the range and quality of movement of the targeted soft 
tissue and joint structures.258 Literature has shown that manual therapy in acute and 
chronic MSD is effective in reducing symptoms259,260 but has short-term effects on pain 
which do not persist, hence repeated use may lead to dependency on the therapist with 
little functional gain.257 
2.10.2.2 Pain Physiology and Health Education 
Patients with MSD often seek out an explanation and further information on their 
symptoms.6 Evidence suggests that personal sessions of pain neurophysiology education, 
along with written educational material, are effective for changing pain perceptions, 
disability, health status, catastrophisation, and physical performance in patients with 
various chronic MSD.74,261 Before the initiation of these sessions, two prerequisites should 
be present – evidence that the clinical presentation illustrates central sensitisation and that 
maladaptive pain cognitions such as fear avoidance and increased awareness of somatic 
symptoms are both present.74  
The first session should be educational and should explain the rationale of treatment. Here, 
patients should have an understanding of the mechanism of central sensitisation to 
improve their knowledge and perception about their pain state.74 After the first session, 
patients receive an information booklet about the neurophysiology of pain to be read 
carefully at home.74 This written information should reinforce the verbal educational 
information given and serve as revision.74 The second session should also be educational 
with insight given into “somatic, psychosocial and behavioural factors associated with pain” 
(p.416).74 The application of this knowledge to everyday situations should also be discussed 
to promote better pain coping strategies, self-management programs, and graded activity 
or exercise.74 Examples of this are stopping rumination and worrying about their pain 
disorder, reducing stress, increasing physical activity levels, and promoting relaxation.74 
This education on pain physiology should be a continuous process throughout active 
therapy and rehabilitation.74 
57 
 
2.10.2.3 Exercise Therapy 
The amygdala is a part of the brain involved in the pain neuromatrix which is likely to be 
overactive when central sensitisation has occurred.80 The amygdala is also the fear-memory 
centre of the brain and, due to the key role is plays in negative emotions and pain-related 
memory, it may facilitate the association of fear between movement and pain.256 
Manual therapy has been shown to provide a similar benefit to exercise therapy when 
combined with usual care in hip and knee osteoarthritis.258 However, exercise therapy is 
then required to desensitise the abovementioned process by being cognition-targeted and 
also by setting SMART (Specific, Measurable, Attainable, Realistic, Timed) goals for 
treatment, followed by repeated exposure to movement to “generate a new memory of 
safety, replacing or bypassing the old and maladaptive movement-related pain memories” 
(p.219).256 Exercise, such as walking, has been shown to have significant improvements in 
pain outcomes in those with chronic MSD.262 Interestingly, no difference has been shown in 
the pain relieving effects for MSD between exercise on land or in water, as in during 
hydrotherapy, although both are more effective than no exercise.263,264 
In a South African context, an intervention of education, exercise, and relaxation has been 
shown to have significant effects on pain severity and pain interference, as measured by 
the BPI, compared to usual care in individuals with osteoarthritis, awaiting arthroplasty.265  
Exercise does play an important role in managing symptoms in those with hip and knee 
osteoarthritis. The prescription thereof should be based on the assessment of individual 
impairments, preference, comorbidities, and accessibility, while maximising adherence 
which may be enhanced by the use of supervised exercise sessions possibly in a class 
format.266 
 
2.11 Summary of the Literature Review 
As one of the aims of the study was to determine the prevalence of both MSD and CDL, the 
literature review explored papers which reported on both the impact and prevalence of 
these conditions. NCDs, which include both MSD and CDL, were found to be a major cause 
of both mortality and morbidity and to contribute significantly to the global burden of 
disease, particularly in low-income countries. The reported community prevalence of MSD 
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has a very high range: from 20-50% of adults globally, and from 16-59% in Africa. In South 
Africa most information available is based on samples of those attending CHCs, also mostly 
women, and these consistently report a prevalence rate of between 40 and 45%. Even 
though some studies on the prevalence of MSD were conducted in South Africa, there 
seems to be a lack of evidence regarding the onset of MSD according to age and the 
prevalence of comorbidities associated with the presence of MSD. It is hoped that this 
study will assist in filling this gap. 
Pain is used to define the presence of MSD in the COPCORD screening tool. In addition, the 
review revealed that there is a clear relationship between chronic MSD and CDL. For these 
reasons, both the nature of pain and the measurement of pain was discussed in detail.  
Based on an evaluation of the different pain measurement methods available, the review 
concluded that the COPCORD approach to screening and BPI for pain measurement were 
the most feasible instruments to use within the context of this study. As a further aim was 
to determine the association between risk factors and MSD and CDL, literature related to 
MSD was sourced. The prevalence of different risk factors was discussed with emphasis on 
obesity and decreased levels of physical activity, as both contributing to and resulting from 
MSD. The IPAQ was identified as a suitable measure of physical activity within this study 
context. Literature on the prevalence and pathophysiology of the most common CDL were 
presented to further explain the relationship between MSD and CDL. These conditions 
were defined, and methods of screening and measurement were presented. An 
examination of the identified risk factors for CDL revealed considerable overlap with those 
of MSD, including obesity and low levels of physical activity. Finally, the different 
management strategies for chronic MSD were discussed. There was no documentation 
found on the current management at CHCs, which hinders the development of appropriate 
methods of holistic management of MSD and CDL. 
It is concluded that both MSD and CDL have a high prevalence and a major functional 
impact. There are interactions between these health conditions, and they share common 
risk factors. A study of these health conditions, within a specific under-resourced context, 
could inform the development of a holistic management strategy for Mitchells Plain CHC, 
targeting the common risk factors and the interaction between these conditions. 
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3 METHODOLOGY 
3.1 Introduction 
Chapter 3 herewith describes the methodology of this study. The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting on 
observational studies267 were used to inform the design, planning, implementation, 
analysis, and presentation of the this study (see Table 29). The research design and 
sampling procedure are described first, followed by the selected instruments for data 
collection. The study procedure is then described, followed by the process and rationale of 
data management and analysis. The chapter is concluded by expanding upon the ethical 
considerations of this study. 
 
3.2 Research Design 
A descriptive, cross-sectional, analytical study design was used. This study design was 
chosen to describe the existing prevalence of, and association between, musculoskeletal 
disease (MSD), chronic diseases of lifestyle (CDL), and risk factors within the sample. 
 
3.3 Participants 
All males and females, aged 18 years and older, attending any medical services at the 
Mitchells Plain Community Health Centre (CHC) in Cape Town, South Africa, were eligible to 
participate in this study. This CHC was purposefully selected as it is situated in an under-
resourced area and, as described in section 1.5, it is one of the busiest clinics in the Cape 
Metropole with approximately 46000 patients attending per month.  
The study was not limited to any ethnic group, i.e. people who met the inclusion criteria 
attending the CHC were eligible to participate in the study, irrespective of ethnicity, on the 
days when data were scheduled to be collected. There was no randomization as all people 
who agreed to participate and who met the inclusion criteria were included in this study. 
Participants who were pregnant120,268 or who were unable to complete either the English, 
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Afrikaans, or isiXhosa versions of the questionnaires were excluded. The eligibility criteria 
are summarised in Table 4 below. 
Table 4: Inclusion and exclusion criteria for participation in this study 
 
3.3.1 Sample Size Determination 
A 2010 South African study in a similar context, albeit with only female participants, found 
the overall prevalence of MSD to be 36%.12 The prevalence of MSD per age category was: 
18-29 years: 7.9% (n=201); 30-39 years: 10.7% (n=177); 40-49 years: 20% (n=192); 50-59 
years: 40% (n=209); 60-69 years: 47% (n=134); and 70 years and older: 45.8% (n=85).12 
Using the lowest expected prevalence of 7.9% in a population of N=1000, a minimum 
sample size of 149 subjects per age category was required to estimate the true prevalence 
(TP) with a margin of error of 4% (precision) with a 95% confidence level (Open Epi™ 
Version 7.2013) (see Table 5). In other words, if the true prevalence was 7.9%, the sample 
prevalence would fall between 3.9 and 11.9% in 95 of 100 samples drawn. 
 
 
 
Inclusion Criteria Exclusion Criteria 
 Males and females older than 18 
years of age.  
 Willing to participate in the study 
and able to give informed consent. 
 Able to understand, read and write 
either in English, Afrikaans or 
isiXhosa. 
 Attending CHC for medical 
treatment on day of recruitment. 
 Inability to complete either the 
English, Afrikaans, or isiXhosa 
versions of the questionnaires. 
 Pregnancy.  
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Table 5: Sample size calculation 
Population size (N) 1000 
Expected Frequency 7.9% 
Margin of Error 4% 
Design Effect 1.0 
Sample for Each Age Group  149 
 
Stratified sampling was used to ensure that there were an equal number of respondents in 
each age group. The first person in the waiting area was approached, informed about the 
study, and asked to disclose their age if they agreed to participate. Recruitment continued 
until the quota per age group, as aforementioned, was reached. 
 
3.4 Instrumentation and Outcome Measures 
As discussed in the literature review, a suite of instruments and outcome measures was 
identified to screen for MSD, CDL, and risk factors. These instruments and outcome 
measures measure pain, monitor body weight and levels of physical activity, and explore 
the health-related quality of life (HRQoL) of the participants. 
3.4.1 Community Orientated Program for Control of Rheumatic 
Diseases 
The screening questions used in phases one and two of the Community Orientated 
Program for Control of Rheumatic Diseases (COPCORD) questionnaire were used to identify 
those with MSD and CDL. The questions used to identify those with acute and chronic MSD 
were “during the last 7 days have you experienced pain, aching, swelling, stiffness 
(tightness) in or around your joints or back which is not related to an injury/accident?” and 
“during the last 3 months have you experienced pain, aching, swelling, stiffness (tightness) 
in or around your joints or back which is not related to an injury/accident?”. Thus, pain 
related to specific trauma was excluded. In addition, the COPCORD questions were used to 
gather data on demographic characteristics, risk factors, comorbidities and management of 
MSD and CDL. The COPCORD was previously adapted and validated by Hendricks (2019) 
(see Appendix VI).10 The adapted questionnaire was then translated into Afrikaans and 
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isiXhosa languages. The translated versions of the adapted COPCORD were also assessed 
for criterion validity by Hendricks (2019).10 The COPCORD has been shown to be a valid and 
reliable tool when used in other South African languages.133 The English, Afrikaans, and 
isiXhosa versions of this questionnaire were used in this study.  
3.4.2 The Brief Pain Inventory 
Pain was assessed using the Brief Pain Inventory (BPI) (see Appendix VII). This is a self-, or 
interviewer-administered questionnaire which measures the severity of pain by asking the 
participant to rate their pain according to: “worst”, “least”, “average” and “present” pain 
on a numeric scale of 0–10.92 The four pain severity scores ranging from 0-10 are averaged 
to generate a pain severity score (PSS).92 When exploring the reliability of the BPI, in terms 
of internal consistency, high Cronbach alphas of 0.89 (study 1) and 0.82 (study 2), and an 
intraclass correlation coefficient (ICC) of 0.81 (95% CI: 0.68-0.90) for test-retest reliability 
was found.94 Construct validity was explored between the BPI and Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC). A high degree of correlation was 
found between the BPI interference scale (r=0.62; p<0.01) and BPI sleep item (r=0.29; 
p<0.0001) and the WOMAC.94 The BPI interference scale and the sleep item both 
demonstrated strong responsiveness.94 The BPI has been validated for use in South African 
languages to measure the prevalence of pain, as well as pain severity and interference.97 
The BPI has thus been shown to be a valid and reliable tool for MSD research.94,95 
Additionally, an isiXhosa version of the BPI has been shown to be a valid tool to measure 
pain prevalence, severity, and interference with the Cape Town context.97 The English, 
Afrikaans, and isiXhosa versions of the BPI were used in this study. 
3.4.3 Body Mass Index and Waist-Hip Ratio 
Anthropometric measurements were taken to calculate body mass index (BMI) and waist-
hip ratio (WHR). Body weight was measured using the MDW 300L health and fitness 
electronic digital scale, manufactured in Johannesburg, South Africa, calibrated and 
accurate to 0.05kg. The height of each participant was recorded to the nearest 0.1cm using 
a measuring tape which was placed securely against a flat wall and a flat headboard at a 
right angle to the wall.269 Participants stood with their backs, buttock and heels as close to 
the wall as possible. The measurement was taken without shoes.269 BMI, in kg/m², was 
calculated using the above measurements for each participant.  
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The waist and hip circumferences were measured in order to determine the waist-hip ratio. 
The participant was asked to stand erect, arms at their side, feet positioned closely 
together, and their body weight equally distributed.120 Measurements were taken over the 
participants’ undergarments. Waist circumference was measured across the smallest 
portion of the waist, usually found at the midpoint between the top of the iliac crest and 
the lower margin of the last palpable rib in the mid axillary line. This was measured at the 
end of normal expiration and parallel to the floor.120 Hip circumference was measured over 
the widest portion of the buttocks, also parallel to the floor.120 
3.4.4 International Physical Activity Questionnaire  
The short version of the International Physical Activity Questionnaire (IPAQ) was used to 
monitor physical activity (see Appendix IX). It is an acceptable measurement of physical 
activity for use in adults in many settings and in different languages. Participants respond 
to questions relating to time spent being physically active in the last seven days during 
activities at work, house chores, outside of the house, to get from place to place, and in 
their spare time for recreation, exercise or sport.131 The IPAQ has been shown to be a valid 
and reliable tool for surveillance of physical activity in adults.132 Test-retest reliability 
showed that the IPAQ produced repeatable data.132 Comparable data was found from both 
the long form (Spearman’s correlation coefficients clustered around 0.8 [95% CI: 0.79–
0.82]) and the short form (Spearman’s correlation coefficients was 0.76 [CI: 0.73–0.77]) 
indicating good repeatability.132 Concurrent validity tests showed that the short and long 
forms showed reasonable agreement.132 The pooled coefficients for comparison between 
the short and long form were 0.67 (CI: 0.64–0.70) and for comparisons of different short 
instruments was 0.58 (CI: 0.51–0.64).132 The criterion validity of the IPAQ data against 
Computer Science and Applications, Inc. (CSA) accelerometers was assessed on total 
reported physical activity for both the long and short forms. There was fair to moderate 
agreement between the two measures, with pooled coefficients of 0.33 (CI: 0.26–0.39) for 
the long forms against the CSA and 0.30 (CI: 0.23–0.36) for the short forms and CSA.132 The 
IPAQ has been shown to be a valid and reliable tool when used in other South African 
languages.133 The English, Afrikaans, and isiXhosa version of the IPAQ short-version was 
used for this study.  
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3.4.5 EQ-5D Health Related Quality of Life measure 
The South African version of the European Quality of Life-5 Dimensions (EQ-5D) 
questionnaire was used to explore self-reported health-related quality of life (HRQoL). It 
uses five domains of function: mobility, self-care, usual activities which includes study, 
work, housework, family or leisure, pain or discomfort and lastly depression or anxiety.212 
The EQ-5D health index score is scored across these five dimensions by combining different 
levels (no problems [1], moderate problems [2], severe problems [3]) from each 
dimension.212,270 Thus, a full health index set of “11111” would be equal to 1, a single score 
representing heath status.270 The instrument also includes a visual analogue scale (VAS) on 
which participants can indicate their health status.212 The EQ-5D has been validated in a 
wide range of settings. Construct validity was explored by examining correlations between 
the EQ-5D and the Health Assessment Questionnaire (HAQ) and found moderate to high 
correlations with measures of impairment (Spearman r=0.61; p<0.05) and high correlations 
with disability measures (Spearman r=0.78; p<0.05).213 Reliability was analysed and found 
acceptable agreement between responses with ICC of 0.70 (95% CI: 0.60-0.80) for EQ-5D 
VAS and ICC of 0.73 (CI: 0.63-0.83) for EQ-5D utility.213 
 
3.5 Procedure 
3.5.1 Ethical Approval 
Ethical approval was obtained from the Human Research Ethics Committee of the 
University of Cape Town (HREC REF: 856/2014) (see Appendix I). Following ethical approval, 
permission for commencement of this study was obtained from the Western Cape 
Department of Health (WCDoH) Research Committee (see Appendix II) as well as the facility 
manager of the Mitchells Plain community health centre (see Appendix III).  
3.5.2 Training of Investigators 
All research assistants were familiarised with each questionnaire and each question and 
outcome measure was explained. As data were collected using mobile tablets, each 
research assistant was also trained to use the device and mobile data collection 
application. A total of 14 investigators were trained to conduct interviews, with between 
two and five investigators present on each day of data collection. At least one research 
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assistant was proficient in English and IsiXhosa, and at least two were proficient in English 
and Afrikaans. Measurements of data for calculation of BMI and WHR were demonstrated 
and all research assistants had to practice these under supervision prior to data collection. 
3.5.3 Pilot Study 
A pilot study to assess the feasibility of this study, as well as participant comprehension of 
questionnaires, time to complete the discussed standardised outcome measures, and 
reproducibility of clinical measures, was conducted at a community health centre in the 
Cape Town Metropole area. The pilot study followed a similar procedure as described in 
this study but did not make use of mobile data collection technology and took place over 
one week (five hours per day). Feasibility criteria included: 
 At least 83% (n=63) of participants responded to being able to participate per week 
(main study needed to recruit a minimum of 75 participants per week to recruit 900 
participants in 12 weeks). 
 At least 90% of participants (n=81) were able to complete all outcome measures 
and clinical tests. 
 Participants were able to complete all outcome measures and clinical tests within 
45 minutes (main study required an average of 45 minutes for each participant in 
order to gather data of 900 participants over a 12 week period). 
Ninety-three (93) out of 105 eligible individuals that were approached consented to 
participate in the pilot study, making for a response rate of 88.6%.  Seventy-five (75) 
(81%) were female and 17 (18%) were male, with 52% of females (n=39) and 59% of 
males (n=10) reporting having both MSD and CDL. Seventy-six participants in total (81%) 
completed all outcome measures, doing so in an average time of 27 minutes. 
The results of the pilot study showed that two out of three criteria of the feasibility 
outcomes had been achieved. The primary feasibility outcome was the response rate of 
participants (89%). Thus, this study was feasible to conduct at the Mitchells Plain CHC. As 
data for the pilot study was collected at an alternative facility, results from the pilot study 
were not included in the final sample. 
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3.5.4 Data Management and Data Collection 
Electronic versions of the outcome questionnaires and instruments were developed on the 
mobile data collection application Magpi by the DataDyne Group, LLC as a mobile form for 
use on tablets and mobile devices. On the days of data collection, researchers approached 
adult males and females waiting in queues and waiting areas at the pharmacy and outside 
various consulting rooms at the CHC, explained the purpose of the research study and 
obtained informed written consent. A target of 150 participants in each of the six identified 
age groups was required, therefore research assistants approached potential participants 
to fill these quotas. Once consent and agreement to participation was given, the participant 
was ensured that their place in the waiting queue at the CHC would not be forfeited as a 
research assistant would wait in the place of the participant until all the testing procedures 
had been completed. The same researcher administered and assisted with the self-
reported questionnaires. Participants were then escorted to a separate room where 
weight, height, waist and hip circumference were measured by a different researcher.  WiFi 
and 3G enabled tablets were used to gather, record, and send data to a central database 
and the data were exported to Microsoft Office Excel spreadsheets for data analysis. The 
data files were password protected and stored on a server and backed up by an external 
hard drive. Both were firewall protected. 
 
3.6 Data Analysis 
In order to discuss the outcomes of this study, an analysis of the statistics was required. 
Statistics encompass the methods of collecting, summarising, presenting, analysing and 
drawing conclusions from observations on variables of interest.271 These variables are 
either categorical (each individual belongs to one of a number of distinct categories) or 
numerical (the values are continuous).271 Biostatistics refers to the application of statistics 
to a wide range of topics within the health sciences. Statistica [Dell Inc. (2015). Dell 
Statistica (data analysis software system), version 13. software.dell.com] and the Centres 
for Disease Control and Prevention’s (CDC) Epi Info 7.1.5.2™ statistical software was used 
for statistical analysis.  
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3.6.1 Descriptive Statistics 
Descriptive statistics were used to summarize and describe the characteristics of the 
sample, the prevalence and management of MSD and CDL, risk factors, and HRQoL across 
six age categories (i.e. 18 -29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 
70 years and older) within the sample. This description includes reports on frequency 
distribution and proportion for categorical nominal and ordinal data as well as summary 
statistics for numerical data. The 95% CIs for proportions were calculated using Vassar 
Stats.272 Summary statistics for numerical data include: median (“the observation which 
falls in the middle of the set of observations when they are arranged in increasing order of 
magnitude” [p.1125])271 and range (“difference between the largest and smallest 
observations in the dataset” [p.1126])271 for non-parametric (non-normally distributed) 
numerical data , and mean (the sum of all the observations divided by the number in the 
dataset)271 and standard deviation (SD) for parametric (normally distributed) numerical 
data. SD can be calculated by obtaining the square root of the variance. Variance can be 
described as a measure of the degree of deviation from the mean. The lower the variance, 
the more likely it is that the sample is representative of the wider population.273 
3.6.2 Interferential Statistics 
Statistical testing of a hypothesis is an inferential process where the sample data is used to 
draw conclusions about one or more parameters of interest in the population.271 Statistical 
inference is a mechanism that allows us to evaluate an observed finding relative to 
differences that may have occurred by chance alone, as there is observed variability in 
measurements.273 This inference allows us to make statements about an entire population 
without having to study every member of that population.273 The statistical tests determine 
the probability of a difference being a true difference instead of being observed under the 
null hypothesis (N0) of no true underlying difference. “When this probability is small, it may 
be concluded that there is a real difference between the two populations that the samples 
represent” (p.1454).273 This is the meaning of the term significant.273 A p-value of less than 
0.05 signifies that there is a true difference between two sample groups  and allows us to 
reject a N0 with more than 95% certainty.271,273 When a result has a p-value of less than 
0.05 it is said to be statistically significant. Thus, the statistical level of significance (α) of 
p<0.05 and a 95% CI was accepted for this study. 
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To  test for normality, the one sample Kolmorogov-Smirnov test,274 Lillefors274 probabilities, 
and the Shapiro Wilk W test275 was used. It is noted that the Shapiro Wilk test has been 
shown to be the more powerful test for normality.276 If the d or W statistic was found to be 
significant, the hypothesis that the respective distribution is normal was rejected. 
Relationships and associations were estimated between gender and age categories and 
variables such as MSD and CDL, risk factors such as obesity and physical activity, and 
HRQoL. Gender was described using frequency distribution and proportions. Differences 
between genders for various outcome measures were estimated using the Chi-Squared 
test. Differences between the MSD group and no MSD group were also calculated using the 
Chi-Squared test for nominal and ordinal categorical data (Figure 2). Tests in the shaded 
boxes require relevant assumptions to be satisfied.271 
(Tests in the shaded boxes require relevant assumptions to be satisfied). 
Petrie A. Statistics in orthopedic papers. The Journal of Bone & Joint Surgery (Br) 2006; 9:1121-1136.271 
 
(Tests in the shaded boxes require relevant assumptions to be satisfied). 
Petrie A. Statistics in orthopedic papers. The Journal of Bone & Joint Surgery (Br) 2006; 9:1121-1136.271 
Figure 2: Flowchart indicating choice of test for binary/categorical data 
 
Differences between groups of numerical data were calculated using independent t-tests 
by variables or by groups (Figure 3). For these continuous numerical variable histograms 
are used to illustrate the frequency distribution.  
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(Tests in the shaded boxes require relevant assumptions to be satisfied) (ANOVA=analysis of variance). 
Petrie A. Statistics in orthopedic papers. The Journal of Bone & Joint Surgery (Br) 2006; 9:1121-1136.271 
Figure 3: Flowchart indicating choice of test for numerical data 
 
However, due to the large sample size (i.e. N=1 115), the central limit theorem277 was used 
for all analysis. The central limit theorem states that when a sample is very large, the 
means will follow the normal distribution even if the respective variable is not normally 
distributed in the population.277 Thus, parametric methods of data analysis, was 
appropriate for this large sample. 
Selected relationships between two variables, where at least one variable is numerical, are 
also described using scatter plots. If the variables are not related, the points on the scatter 
plot form an irregular “cloud”. Linear relationships were assessed using the Pearson’s 
Correlation Coefficient (r), which ranges from -1 to 1. If r is a positive number the slope of 
the line will be upwards, while if r is a negative number the slope of the line will be 
downward. If r = 0, there is no linear relationship. Relationships between ordinal or non-
parametric variables were calculated using the Spearman’s Correlation Coefficient which 
also ranges from -1 to 1.271 Correlations were interpreted as weak (-0.29 to -0.1 and 0.1-
0.29), moderate (-0.49 to -0.3 and 0.3 to 0.49), and strong (-1.0 to -0.5 and 0.5 to 1.0).278 
The Chi-Squared statistic was calculated to test the association between categorical 
variables. CHAID (Chi-Squared IBM® SPSS® Automatic Interaction Detector) is a statistical, 
multi-way tree algorithm that presents data quickly and efficiently while building segments 
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and profiles of the desired outcome.279 The CHAID algorithm builds non-binary trees,  
where more than two branches can attach to a single root or node, which is well-suited for 
the analysis of larger datasets.279 CHAID was used to identify which factors were associated 
with MSD and the results are presented in a classification tree with percentages and 
graphs. Four models were developed: the first included MSD and CDL; the second included 
MSD, CDL and age category as it was clear that age would confound any association as 
most conditions increased with age; the third included MSD and risk factors; and the final 
model included MSD, risk factors and age category. 
A summary of the statistical analysis and tests used to address each objective of this study 
are shown in Table 6 below. 
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Table 6: Summary of research questions and statistical tests for this study 
Objective Outcome Measure Type of Data Obtained Descriptive Measures Significance Tests used for Data Analysis 
Were the demographic characteristics and 
outcome measures normally distributed? 
All Various  Kolmogorov-Smirnov one sample test 
Lillifors Probability 
Shapiro Wilk Test 
What are the proportions of people with 
MSD and CDL across different age 
categories occurring in the sample? 
COPCORD 
BPI 
Categorical 
(Nominal & Ordinal) 
Numerical Non-
Parametric 
Numerical Parametric 
Frequency 
Proportions (%) 
Median (Range) 
Mean ± SD 
Chi-Squared 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
What is the association between risk 
factors, such as age, gender, obesity, 
occupations, and social habits such as 
smoking, MSD and CDL occurring in the 
sample? 
COPCORD 
Anthropometric 
Measurements 
 
 
Categorical/Nominal 
Ordinal 
Numerical 
Frequency 
Proportions (%) 
Median (Range) 
Mean ± SD 
Chi-Squared 
CHAID 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
What is the physiotherapy and medical 
management and treatment of MSD at a 
CHC in Cape Town, South Africa? 
COPCORD Categorical/Nominal 
Ordinal 
Frequency 
Proportions (%) 
Median (Range) 
Chi-squared 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
What are the HRQoL and health index 
scores of people with and without MSD and 
CDL in the sample? 
 
EQ-5D Categorical/Nominal 
Ordinal 
Numerical 
Frequency 
Proportions (%) 
Median (Range) 
Mean ± SD 
Chi-squared 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
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Objective Outcome Measure Type of Data Obtained Descriptive Measures Significance Tests used for Data Analysis 
What is the association between the 
HRQoL and health index scores and MSD 
and CDL across the different age categories 
in the sample? 
COPCORD 
EQ-5D 
Categorical/Nominal 
Ordinal 
Numerical 
Frequency 
Proportions (%) 
Median (Range) 
Mean ± SD 
Chi-squared 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
What is the self-reported level of physical 
activity in the population with MSD? 
IPAQ Categorical/Nominal 
Numerical 
Frequency 
Proportions (%) 
Mean ± SD 
Chi-squared 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
Are self-reported physical activity levels 
associated with MSD and CDL in a 
population at a CHC in Cape Town, South 
Africa? 
 
COPCORD 
IPAQ 
Anthropometric 
measurements 
Categorical/Nominal 
Ordinal 
Numerical 
Frequency 
Proportions (%) 
Median (Range) 
Mean ± SD 
Chi-squared 
CHAID 
Fishers exact 
Spearman’s Correlation 
t-test 
Kaplan-Meier estimator 
MSD=Musculoskeletal disease; CDL=Chronic Diseases of lifestyle; SD=Standard Deviation; CHC=Community Health Centre; HRQoL=Health Related Quality of Life; COPCORD=Community 
Orientated Program for Control of Rheumatic Disease; EQ-5D=European Quality of Life–5 Dimensions; IPAQ=International Physical Activity Questionnaire; CHAID=Chi-Squared IBM® SPSS® 
Automatic Interaction Detector 
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3.7 Ethical Considerations 
The study conformed to the principles of the Declaration of Helsinki280 throughout its 
duration, following the principles of justice, autonomy, beneficence, and non-
maleficence.281 
3.7.1 Risk to Participants 
As participants responded to questionnaires and had clinical measurements done to 
determine BMI and waist-hip ratio, there was minimal to no risk to the participants, 
ensuring non-maleficence. Those who decided not to participate in the study were 
reassured that their decision would not affect their future treatment or access to care, 
ensuring autonomy. 
3.7.2 Benefit to Participants 
There were no direct benefits for participating in this study. Participants were advised and 
encouraged to contact the researcher and the CHC should they be interested to see the 
results of this study, thus gaining knowledge into MSD and CDL, ensuring beneficence. 
Participants were also made aware that the results of the study might be published in an 
accredited health care journal to create an awareness of the profile of the disadvantaged 
population with MSD and CDL and will potentially also have positive impacts on 
management strategies, service delivery and policy. Participants with severe pain were 
reported to the resident physiotherapist for further management and referral.  
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4 RESULTS 
4.1 Introduction 
Chapter 4 presents the results of this study. The sample will first be described by 
presentation of the descriptive data. Data obtained pertaining to musculoskeletal disease 
(MSD) and chronic diseases of lifestyle (CDL) will then be presented, followed by the 
estimated associations between these conditions, and possible risk factors. A description of 
the self-reported health-related quality of life (HRQoL) of the sample is also presented. 
 
4.2 Response Rate and Sampling Process 
One thousand two hundred and forty-two (1242) patients that attended the Mitchells Plain 
Community Health Centre (CHC) were approached to participate in this study. One hundred 
and twenty-two (122) patients did not consent to participate; therefore 1120 participants 
were recruited for this study resulting in a response rate of 90.2%. Five (5) participants did 
not meet the inclusion criteria as one was pregnant and four were under the age of 
eighteen years. Thus, a final sample of 1115 participants was eligible to continue with the 
study. A summary of the sampling process is shown in Figure 4 below. 
 
Figure 4: The sampling process 
The anthropometric measurements, were taken from 992 (89.0%) to calculate body mass 
index (BMI), while 1004 (90.0%) completed measurements needed to calculate waist-hip 
1242 CHC attendees 
approsteoarthritisched 
to participate in study
122 attendees refused 
to participate
1120 participants 
recruited
5 participants excludedFinal Sample: 1115 participants  
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ratio (WHR). All participants did not complete these measurements as some were called 
into their scheduled appointments or did not want to leave the client queues. 
 
4.3 Demographic, Socio-economic, and Clinical Characteristics 
4.3.1 Demographic Characteristics 
The age distribution of the sample is shown graphically in Figure 5 below. The mean age 
was 48.7 years with a standard deviation (SD) of 16.8 years (Range: 18-89 years). As 
stratified sampling was used, a minimum of 150 respondents in each of the six identified 
age groups were recruited.   
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N=1115 
Figure 5: Histogram of participant age 
 
Table 7 illustrates the number of participants recruited across gender and six age 
categories. Over 70% of the participants recruited were female, and the highest proportion 
(20%) of respondents were between the ages of 50 and 59.   
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Table 7: Frequency of specific age groups and gender of study sample 
Age 
Category 
Frequency of 
total sample (N) 
% of total 
sample 
Frequency 
Female (N) 
% 
Female 
Frequency 
Male (N) 
% 
Male 
18-29  190 17.0 138 17.2 52 16.7 
30-39 184 16.5 132 16.4 52 16.7 
40-49 179 16.1 126 15.7 53 17.0 
50-59 223 20.0 171 21.3 52 16.7 
60-69 188 16.9 137 17.1 51 16.3 
70+ 151 13.5 99 12.3 52 16.7 
Total 1115 100 803 100.0 312 100.0 
 
The demographic characteristics of the sample can be seen in Table 8. The majority of 
participants spoke Afrikaans (38.4%) as their first language, followed by isiXhosa and 
English. Almost half of the participants were married with the majority having four children 
or less. More than one quarter of the participants did not surpass the primary level of 
schooling (i.e. grade 7) and 16.0% completed grade 12 (not shown) while 2.5% obtained a 
post-school qualification.  
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Table 8: Demographic characteristics of study sample 
Demographic Characteristic Frequency 
of total 
sample 
% 
of total 
sample 
Mean SD Median Range 
Age 48.7 16.8 50  18-89 
Home Language 
   Afrikaans 428 38.4     
   isiXhosa 366 32.8     
   English 301 27.0     
   Other 18 1.6     
   Undisclosed 2 0.2     
Marital Status 
   Married 485 43.5     
   Single 420 37.7     
   Widowed 133 11.9     
   Separated/Divorced 73 6.5     
   Partner 4 0.4     
Number of Children 2.7 1.9 3 0-12 
   0 143 12.8     
   1 184 16.5     
   2 226 20.3     
   3 227 20.3     
   4 145 13.0     
   5 or more 189 16.9     
   Undisclosed 1 0.1     
Highest Level of Education (Number of years in school)  8.7 2.9 9  0-13 
   No formal schooling 15 1.35     
   Attended Primary School  278 24.8     
   Attended Secondary School 647 58     
   Post-school qualification 28 2.5     
   Undisclosed 147 13.2     
SD=Standard Deviation 
N=1115 
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Table 9 shows a summary of the reasons for visitation to the CHC by the study sample 
within the data collection period. Most of the participants (31%) attended the CHC awaiting 
a consultation with a medical practitioner (including nursing staff), whereas 28.3% were 
attending to collect prescribed medication for CDL and other medical conditions. Four 
percent (4%) were attending physiotherapy services. 
Table 9: Reasons for CHC visits of study sample 
Reason for visit to CHC Frequency of total sample % of total sample 
Medical Practitioner 346 31.0 
   Initial CDL Assessment 123 11.0 
   Other Problems 223 20.0 
Pharmacy 315 28.3 
   CDL Medication 147 13.2 
   Medication - Other Problems 168 15.1 
Other 107 9.6 
Chronic Disease Clubs 59 5.3 
Physiotherapy 42  3.7 
   Initial Assessment 8 0.7 
   Osteoarthritis Group 6  0.5 
   Other Problems 28 2.5 
Undisclosed 246 22.1 
CHC=Community Health Centre; CDL=Chronic Disease of Lifestyle 
N=1115 
 
4.3.2 Socio-Economic Characteristics 
Over one third of the sample reported being unemployed (Table 10). Of those that were 
unemployed, 52% were not looking for current employment. The highest percentage of 
unemployed participants had completed grade twelve (16.3%), grade ten (16.1%), and 
grade nine (13.5%) and 2.1% did not have any type of formal schooling. Of those 
unemployed or retired, 215 (35.0%) had stopped work due to injury or illness. 
More than one quarter reported some form of paid employment or other source of 
income, while 16.4% were retired from working. More than half of the sample reported to 
be the primary breadwinner for the household, with 48% earning a monthly income of 
R1001-2000 (R=South African rand). 
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Table 10: Socio-economic characteristics of study sample 
Socio-economic Characteristic Frequency 
of total 
sample 
% of 
total 
sample 
Frequency 
Female 
% 
Female 
Frequency 
Male 
% 
Male 
Current Employment 
   Unemployed 431 36.6 291 36.3 140 45.0 
   Housewife 199 19.7 199 24.8 0 0.0 
   Retired 183 16.4 119 14.8 64 20.6 
   Manual Work 103 9.2 62 7.7 41 13.2 
   Small Business/ Retail 74 6.7 43 5.4 31 10.0 
   Other 70 6.3 46 5.7 24 7.7 
   Administration 33 3 23 2.9 10 3.2 
   Education 10 0.9 10 1.2 0 0.0 
   Healthcare 7 0.6 7 0.9 0 0.0 
   Police and Military 3 0.3 2 0.2 1 0.3 
   Undisclosed 2 0.2 1 0.1 1 0.3 
   Total 1115 100 803 100 312 100 
Household Breadwinner 
   Yes 567 50.8 355 44.3 212 68.2 
   No 546 49 447 55.7 99 31.8 
   Undisclosed 2 0.2 1 0.1 1 0.1 
Monthly Income (in South African Rands) 
   0-1000 334 29.9 249 31.0 85 27.3 
   1001-2000 536 48.1 376 46.9 160 51.4 
   2001-3000 106 9.5 77 9.6 29 9.3 
   3001-5000 56 5 40 5.0 16 5.1 
   5001-7000 26 2.3 16 2.0 10 3.2 
   >7000 18 1.6 11 1.4 7 2.3 
   Undisclosed 39 3.5 34 4.0 5 1.6 
State-Issued Special Grants 
   Government Pension 276 24.8 184 22.9 92 29.6 
   Child Care Grant 174 15.6 174 21.7 0 0.0 
   Permanent Disability Grant 148 13.3 111 13.8 37 11.9 
   Temporary Disability Grant 82 7.3 67 8.4 15 4.8 
   Foster Care Grant 2 0.2 2 0.2 0 0.0 
   Other Grant 9 0.8 5 0.6 4 1.3 
   Total Grants 691 62 543 67.7 148 47.6 
N=1115 
 
4.4 Musculoskeletal Disease   
This section describes current and previous occurrences of musculoskeletal pain or injuries 
of both the acute and chronic nature within the sample. This includes sites of pain as well 
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as management strategies used within the primary health care system for treatment of 
musculoskeletal pain.  
4.4.1 Prevalence 
The primary outcome measure to determine the prevalence of MSD were the COPCORD 
questions relating to pain. Those who reported having pain for seven days or less were 
categorised as having acute MSD, whereas those reporting pain for three months or more 
were categorised as having chronic MSD. Information relating to the nature of the MSD 
was missing for both acute and chronic pain in 11 cases and thus the denominator for 
calculating the prevalence rate was reduced to 1104. The prevalence of acute MSD was 371 
(33.6%; 95% CI: 30.1-36.5%) and that of chronic MSD was 478 (43.3%; CI: 40.4-46.3%). The 
number with both acute and chronic MSD was 344 (31.2%; CI: 28.5-34.0%) and the overall 
prevalence of both combined was 478 (all yes) and 27 (yes for acute) = 505 (45.7%; CI: 42.8-
48.7) (see Table 11).  
Table 11: Prevalence of acute and chronic MSD 
  Acute 
MSD 
Chronic MSD 
Yes 
Chronic MSD 
No 
Missing 
Data 
Total 
Frequency Yes 344 27 0 371 
% of total sample    31.2  
 
2.4 0.0 33.6 
Frequency No 123 572 1 696 
% of total sample   11.1 51.8 0.1 63.0 
Frequency Missing 11 26 * 37 
% of total sample   1.00 2.36 * 3.35 
Frequency All Groups 478 625 0.1 1104 
Total %   43.3  56.1 
 
  
MSD=Musculoskeletal Disease 
n=1104, *11 missing from both acute and chronic and excluded 
 
Gender was associated with both chronic MSD (45.8% of females and 36.9% of males [Chi-
Square=7.26; p=0.007]) and acute MSD (43.4% of females and 13.6% of males [Chi-
Square=86.0; p<0.001]). 
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4.4.2 History of Previous Injuries 
Previous musculoskeletal injuries, including the type and mechanism of these injuries and 
the result thereof at the time of questioning, are shown in Table 12 below. Almost one 
quarter (23.6%) of the sample reported previous injuries. A history of previous injury was 
found to be significantly associated with chronic MSD (p<0.001). 
Table 12: Reported previous injuries, injury mechanisms, and injury results in participants 
with chronic MSD 
Variable Frequency 
Previous Injuries 
Previous 
Injuries % of 
total sample 
(n=1104) 
Previous 
Injuries 
Frequency 
chronic MSD 
Previous 
Injuries % 
chronic 
MSD 
Previous Injuries 263  23.6 186  70.7 
   Lower limb fracture 18 6.8 12 66.7 
   Lower limb joint/ligament 30 11.4 12 40.0 
   Lower limb muscle/tendon 20  7.6 13  65.0 
   Spinal joint 19 7.2 11 57.9 
   Spinal muscle 7 2.7 6  85.7 
   Spinal fracture 5 1.9 3 60.0 
   Upper limb joint/ligament 24 9.1 13  54.2 
   Upper limb muscle/tendon 10 3.8 7 70.0 
   Upper limb fracture 12 4.6 8 66.7 
   Unspecified 118 44.9 101 85.6 
Previous Injury Mechanism 263  186 70.7 
   Fall 55 20.9 48 87.3 
   Industrial 2 0.8 2 100.0 
   Vehicle 21 8.0 17 81.0 
   Violence 2  0.8 1 50.0 
   Other 23  8.8 21 91.3 
   Unspecified 160  60.8 97  60.6 
Previous Injury Result 265  187 7.6 
   Chronic pain 87 32.8 74 85.1 
   Cured 102 38.5 61 59.8 
   Deformity 3 1.1 2 66.7 
   Disabled 20 7.5 16  80.0 
   Joint stiffness 34 12.8 23 67.7 
    Other 16 6.0 9 56.3 
    Unspecified 3  1.1 2 66.7 
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4.5 Chronic Diseases of Lifestyle  
Approximately three quarters of the sample (75.3% of the female and 77.2% of the male 
participants) reported being diagnosed with at least one of the CDL listed in Table 13. 
Hypertension  was the most prevalent condition (47.8%; CI: 44.8-50.7%), followed by type 2 
diabetes mellitus (21.4%; CI: 19.1-23.9%) and hypercholesterolaemia (20.2%; CI: 17.9-
22.6%). A high proportion (30%) of “other” CDL was reported as well. Unfortunately, no 
further investigation was done to determine what “other” CDL could have been. This is a 
limitation of this study. Furthermore, it is noted that higher proportions of these common 
CDL were reported by females. Significant associations were found between gender and 
hypertension (p<0.001), type 2 diabetes mellitus (p=0.024), and hypercholesterolaemia 
(p=0.005). 
Significant associations were also found between chronic MSD and hypertension (p<0.001), 
cardiovascular disease (p<0.001), type 2 diabetes mellitus (p=0.002), 
hypercholesterolaemia (p<0.001) and chronic obstructive airway disease (COAD) (p<0.001), 
as seen in Table 14 below. 
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Table 13: Self-reported chronic diseases of lifestyle by gender 
Chronic Disease of Lifestyle Frequency % of total 
sample 
(N=1115) 
Frequency 
Females with 
condition (n) 
 
*Females with 
condition 
% 
Frequency 
Males with 
condition (n) 
**Males with 
condition 
% 
Chi-Square p 
Hypertension 533 47.8 422 52.6 111 35.6 25.951 <0.001 
Cardiovascular disease 74 6.6 55 6.9 19 6.1 0.209 0.647 
Hypercholesterolaemia 225 20.2 179 22.3 46 14.7 7.947 0.005 
Type 2 diabetes mellitus 239 21.4 186 23.2 53 17.0 5.089 0.024 
COAD 122 10.9 97 12.1 25 8.0 3.814 0.05 
Mental Illness  28 2.5 18 2.2 10 3.2 0.852 0.356 
Other CDL 335 30.0 243 30.3 92 29.5 0.064 0.8 
COAD=Chronic Obstructive Airway Disease; CDL=Chronic Disease of Lifestyle 
*Females with condition out of total female sample (803) 
**Males with condition out of total female sample (312) 
df=1 
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Table 14: Self-reported chronic diseases of lifestyle with and without chronic MSD 
Chronic Disease of Lifestyle Frequency % of total 
sample 
(1115) 
Frequency 
Comorbid MSD 
(n) 
 
*Comorbid 
MSD 
% 
Frequency 
No MSD 
(n) 
**No MSD 
% 
Chi-Square p 
Hypertension 533 47.8 296 55.9 233 44.1 65.912 <0.001 
Cardiovascular disease 74 6.6 48 65.7 25 34.3 15.998 <0.001 
Hypercholesterolaemia 225 20.2 148  66.4 75 33.6 60.378 <0.001 
Type 2 diabetes mellitus 239 21.4 123 52.1 113 47.9 9.43 0.002 
COAD 122  10.9 78  65.0 42 35.0 25.734 <0.001 
Mental disorders  28 2.5 14 50.0 14 50.0 0.519 0.471 
Other CDL 335  30.0 136  41.0 196 59.0 1.089 0.297 
MSD=Musculoskeletal Disease; COAD=Chronic Obstructive Airway Disease; CDL=Chronic Disease of Lifestyle  
*Comorbid MSD out of total MSD sample n=478 
**No comorbid MSD out of no MSD sample n=625 
df=1 
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4.6 Changes in Musculoskeletal Disease and Chronic Diseases of 
Lifestyle over the Adult Lifespan 
This section illustrates, by six age categories, the frequency and proportion of participants 
with MSD and CDL. The change in proportion of these conditions across the adult lifespan is 
also shown.  
Figure 6 below displays the proportion of both acute and chronic MSD and CDL within six 
age categories. All chronic diseases except COAD continually increased with age, while 
COAD and both acute and chronic MSD peaked around the 50-59 year old age category and 
then decreased with age. Acute and chronic MSD were the most prevalent conditions in 
the youngest age group (16-18%). The prevalence of hypertension increased linearly and 
tracked the MSD prevalence until it diverged in the 50-59 age group. 
 
 
N=1115; 20=20-29 yrs; 30=30-39 yrs; 40=40-49 yrs;, 50=50-59 yrs; 60=60-69 yrs; 70=70 yrs and older 
Figure 6: Proportion of respondents reporting presence of chronic diseases in each age 
category  
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Similar proportional changes in MSD and CDL were illustrated in females where all chronic 
diseases, except COAD, continually increased with age, while COAD and both acute and 
chronic MSD peaked around the 50-59 year old age category and then decreased with age 
(Figure 7). 
 
In males, the proportion of participants with MSD and CDL continually increased with age, 
but, COAD, acute MSD, and chronic MSD dropped at the 60-69 age group and then 
increased once more (Figure 8). 
  
20 30 40 50 60 70
HPT 0,05 0,19 0,45 0,74 0,87 0,89
 CVD 0,00 0,03 0,02 0,12 0,12 0,13
DM II 0,03 0,08 0,14 0,32 0,42 0,42
 Cholesterol 0,01 0,08 0,18 0,35 0,39 0,31
COAD 0,08 0,07 0,17 0,18 0,10 0,11
Acute MSD 0,18 0,25 0,53 0,72 0,52 0,33
Chronic MSD 0,18 0,25 0,50 0,76 0,57 0,39
-0,10
0,10
0,30
0,50
0,70
0,90
1,10
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Proportional changes in CDL and MSD  across the adult lifespan in females
n=803; 20=20-29 yrs; 30=30-39 yrs; 40=40-49 yrs; 50=50-59 yrs; 60=60-69 yrs; 7 =70 yrs and older 
Figure 7:  Proportion of female respondents reporting health conditions in each age 
category 
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n=312; 20=20-29 yrs; 30=30-39 yrs; 40=40-49 yrs; 50=50-59 yrs; 60=60-69 yrs; 70=70 yrs and older. 
Figure 8: Proportion of male respondents reporting presence of chronic diseases in each 
age category 
 
4.7 Lifestyle Risk Factors for Musculoskeletal Disease 
Data on relevant risk factors, as deduced from previous literature, for MSD and CDL are 
presented here. 
4.7.1 Obesity 
This section presents data collected as determinants for the classification of obesity. 
Constituents of BMI, i.e. weight and height, and waist-hip ratio, i.e. waist and hip 
circumference, are presented, followed by relationships shown between these factors and 
chronic diseases of lifestyle and musculoskeletal disease. 
Figure 9 presents BMI measurements of participants, categorized by gender. The mean BMI 
of the total sample was 29.2kg/m2 (SD=7.6kg/m2). 
20 30 40 50 60 70
HPT 0,10 0,19 0,32 0,37 0,53 0,63
 CVD 0,02 0,06 0,06 0,04 0,10 0,10
DM II 0 0,10 0,11 0,12 0,31 0,38
 Cholesterol 0,06 0,06 0,02 0,13 0,27 0,35
COAD 0,08 0,02 0,09 0,13 0,06 0,10
Pain 7 Days 0,10 0,12 0,08 0,22 0,08 0,23
 Pain 3 Months 0,16 0,25 0,40 0,45 0,42 0,54
-0,10
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
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op
or
tio
n
Proportional changes in CDL and MSD across the adult lifespan in males
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Histogram of BMI Measurement; categorized by Gender
BMI Measurement
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Females n=693; Males n=300; Missing n=23 
Figure 9: Histogram of BMI categorised by gender 
 
Classification of participants’ BMI is shown below in  
Table 15. Most participants ranged within the ‘normal’ (29.1%) and ‘overweight’ (26%) 
categories, with the highest proportion of females (50%) being “obese” and of males being 
“normal” (45.7%).  
Table 15: Body mass index categories of participants 
BMI 
Category 
Frequency 
of sample 
% 
of sample 
Frequency 
Female (n) 
 
% Female 
(n=693) 
Frequency 
Male (n) 
% Male 
(n=300) 
Underweight 36 3.6 7 1.0 29 9.7 
Normal 289 29.1 152 21.9 137 45.7 
Overweight 258 26.0 182 26.3 76 25.3 
Obese 1 209 21.0 175 25.3 34 11.3 
Obese 2 113 11.4 99 14.3 14 4.7 
Obese 3 87 0.1 78 11.3 9 3.0 
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Females n=693, Males n=300, Missing n=22 
A scatter plot correlating age and BMI is shown in Figure 10, with r=0.19.  This displays a 
positive, weak (0.1-0.3) linear correlation between age and BMI.  
 
Age v s Body  Mass Index
BMI      = 24.930 + .08804 * Age
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0,95 Conf.Int.  
n=993; Missing=22 
Figure 10: Scatter plot of linear correlation between age and BMI 
  
Figure 11 below illustrates the proportional changes in BMI category of the study sample. 
”Obese 1”, “obese 2”, and “obese 3” were classified under “obese” for this illustration. The 
“obese” category is the only category to increase with age until the 60-69 year mark is 
reached. The “overweight” category shows a steady increase from age 40. 
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n=993; Missing n=22; 20=20-29 yrs; 30=30-39 yrs; 40=40-49 yrs; 50=50-59 yrs; 60=60-69 yrs; 70=70 yrs and 
older. “Obese 1”, “obese 2”, and “obese 3” were classified under “obese”. 
Figure 11:Proportional changes in BMI over the adult lifespan 
 
BMI category was associated with MSD (p<0.001) with 73% of those with MSD being 
overweight or obese and 27% of the sample being extremely obese (see Table 16). There 
were significant differences in BMI between those with and without hypertension 
(p<0.001), hypercholesterolaemia (p<0.001), and type 2 diabetes mellitus (p<0.001) (see 
Table 17). 
 
 
  
20 30 40 50 60 70
Underweight 0,04 0,04 0,04 0,06 0,01 0,02
Normal 0,46 0,33 0,36 0,20 0,19 0,21
Overweight 0,28 0,31 0,15 0,23 0,27 0,35
Obese 0,22 0,32 0,45 0,52 0,53 0,43
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Table 16: BMI categories in those with and without chronic MSD 
MSD=Musculoskeletal Disease 
Chi-Square=28.8; df=5; p<0.001 
  
Chronic 
MSD 
Frequency 
of total 
sample 
Underweight 
Frequency 
Underweight 
% 
Normal 
Frequency 
Normal 
% 
Overweight 
Frequency 
Overweight 
% 
Obese 1 
Frequency 
Obese 
1 
% 
Obese 2 
Frequency 
Obese 
2 
% 
Obese 3 
Frequency 
Obese 
3  
% 
Yes 425 15  3.5 96 22.6 106 24.9 95 22.4 60 14.1 53 12.5 
No  564 20 3.5 192 34.0 152 27.0 114 20.2 53 9.4 33 5.9 
Total 989 35 3.5 288 29.1 258 26.1 209 21.1 113 11.4 86 8.7 
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Table 17: BMI categories in those with and without CDL 
CVD=Cardiovascular Disease; HCL=Hypercholesterolaemia; DM=Diabetes Mellitus; COAD=Chronic Obstructive Airway Disease 
*df=5; p<0.001 
Variable Frequency 
of total 
sample 
Underweight 
Frequency 
Underweight 
% 
Normal 
Frequency 
Normal 
% 
Overweight 
Frequency 
Overweight 
% 
Obese 1 
Frequency 
Obese 
1 
% 
Obese 2 
Frequency 
Obese 
2 
% 
Obese 3 
Frequency 
Obese 
3  
% 
Hypertension*  462 6 1.3 79 17.1 119 25.7 122 26.4 77 16.7 59 12.8 
No Hypertension 530 30 5.7 210 39.6 139 26.2 87 16.4 36 6.8 28 5.3 
CVD 69 1 1.4 16 23.2 14 20.3 19 27.5 12 17.4 7 10.1 
No CVD 923 35 3.8 273 29.6 244 26.4 190 20.6 101 10.9 80 8.7 
HCL* 200 0 0 28 14.0 59 29.5 53 26.5 35 17.5 25 12.5 
No HCL 792 36 4.5 261 32.9 199 25.1 156 19.7 78 9.8 62 7.8 
Type 2 DM* 201 1 0.5 28 14.0 48 24.0 72 36.0 30 15.0 22 11.0 
No Type 2 DM 791 35 4.4 261 33.7 210 26.5 137 17.3 83 10.5 65 8.2 
COAD 107 5 4.7 26 24.3 28 26.2 18 16.8 14 13.1 16 14.9 
No COAD 885 31 3.5 263 29.7 230 26.0 191 21.6 99 11.2 71 8.0 
Mental Illness 25 1 4.0 11 44.0 2 8.0 7 28.0 2 8.0 2 8.0 
No Mental Illness 967 35 3.6 278 28.7 256 26.5 202 20.9 111 11.5 85 8.8 
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4.7.2 Physical Activity Levels 
This section presents data collected as determinants for classification of physical activity 
(PA) level via the International Physical Activity Questionnaire (IPAQ) short version. The 
proportional changes in physical activity levels across the adult lifespan are illustrated. 
Physical activity levels in participants with MSD and CDL are also described. The mean total 
MET-minutes was 2805.1 (SD=2905.8) (Figure 12).  
Histogram of IPAQ MET Total; categorized by Gender
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n=1092, Missing n=23, Female n=780, Male n=312 
Figure 12: Histogram of Total MET-minutes categorised by gender 
 
Classification of participants reported physical activity level is shown below in Table 18. 
Most females reported to be highly physically active (46.0%) while males reported mostly 
low physical activity levels (47.8%). An association between gender and physical activity 
level was shown (Chi-Square=109.389; df=2; p<0.001). 
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Table 18: Physical activity level categories of participants 
Level of Physical 
Activity 
Frequency of 
total sample 
% of total 
sample 
Frequency 
Female 
% 
Female 
Frequency 
Male 
% Male 
Low  324 29.7 175 22.4 149 47.8 
Moderate 362  33.2 245 31.4 117 37.5 
High 405 37.1 359 46.0 46 14.7 
n=1091 
Figure 13 illustrates the proportional changes in physical activity level over the adult 
lifespan of the study sample. Around the 50-59 year old age group the proportion of 
participants with a ‘high’ physical activity level decreases while that of participants with a 
‘low’ physical activity level increases at the same age group. 
n=1091; Females n=780; Males n=312; Missing n=22; 20=20-29 yrs; 30=30-39 yrs; 40=40-49 yrs; 50=50-59 yrs; 
60=60-69 yrs; 70=70 yrs and older 
 
In participants reporting acute MSD, most had ‘moderate’ (33.2%) or ‘high’ (33.2%) levels 
of physical activity, whereas 34.1% of those reporting chronic MSD had a ‘low’ level of 
physical activity. A significant association (Chi-Square=13.833; df=2; p=0.001) was found 
between chronic MSD and physical activity levels. No significant association was found 
between acute MSD and physical activity levels (Chi-Square=2.007; df=2; p=0.37). A higher 
Figure 13: Change in percentage of activity levels across age categories 
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proportion of those without MSD reported high levels of physical activity (41% compared 
to 32%) (Table 19). 
Table 19: Physical activity levels in participants with and without chronic MSD 
Chronic 
MSD 
Frequency 
Low PA Level 
Frequency 
% 
Low PA 
Level 
Frequency 
Moderate 
PA Level 
 
% 
Moderate 
PA Level 
Frequency 
High PA Level 
%  
High PA 
Level 
Yes 
 
163 35.0 154 33.1 149 32.0 
No 
 
159 25.6 208 33.4 255 41.0 
Total 
 
322 29.6 362 33.3 404 37.1 
MSD=Musculoskeletal Disease; PA=Physical Activity 
n=1088; Chi-Square=13.8; df=2; p=0.001 
 
A higher proportion of those with CDL reported high levels of physical activity (43.8% 
compared to 35%) (Table 20). 
Table 20: Physical activity levels in those with and without CDL 
CDL Frequency 
Low PA 
Level 
 
% 
Low PA 
Level 
 
Frequency 
Moderate 
PA Level 
 
% 
Moderate 
PA Level 
Frequency 
High PA 
Level 
 
% 
High PA 
Level 
 
Yes 
 
67 25.1 83 31.1 117 43.8 
No 
 
257 32.1 279 33.9 288 35.0 
Total 
 
324 29.7 362 33.2 405 37.1 
CDL=Chronic Disease of Lifestyle; PA=Physical Activity 
n=1091; =Pearson Chi-square 7.2; df=2; p=0.026 
 
No correlation was found between total MET-minutes and BMI (r=0.044; p=0.171) (Table 
21). 
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Table 21: Comparison of total MET between those with and without chronic conditions 
Variable Frequency 
Yes 
Mean 
Yes 
 
SD 
Yes 
 
Frequency 
No 
Mean 
No 
SD 
No 
 
t separate 
variances 
df p 
Chronic MSD 467 2318.0 2347 622 3176.0 3218 -5.09 1086 <.001 
Hypertension 522 2547.3 2567 570 3041.0 3168.1 -2.841 1074.3 0.0046 
Hypercholesterolaemia 218 2289.0 2314 874 2934.0 3023 -3.45 422.0 0.001 
Cardiovascular disease 73 1773.0 1929 1019 2879.0 2950 -4.53 97.96 <.001 
Type 2 DM 234 2177.0 2105 858 2976.0 3067 -4.62 532.4 <.001 
COAD 119 2650.0 2581 973 2824.0 2944 0.617* 1090 0.537 
Mental Illness 26 1828.0 2856 1066 2829.0 2904 -1.74* 1090 0.083 
SD=Standard Deviation; MSD=Musculoskeletal disease; hypertension=Hypertension; DM II=Diabetes Mellitus Type II; COAD=Chronic Obstructive Airway Disease 
*Not tested with separate variances 
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4.7.3 Other Lifestyle Risk Factors 
Participants reported on the history of smoking and consuming alcoholic beverages (Table 
22). Over a quarter (29.9%) of the participants reported to be currently smoking and 15% 
reported that they were consuming alcohol at the time of data collection.  A lower 
proportion of females reported current smoking (22%) and consuming alcohol (13%) 
compared to males (49% and 20% respectively). 
Table 22: Current and past smoking and alcohol use of participants 
Variable Frequency 
of total 
sample 
% of 
total 
sample 
Frequency 
Female 
% 
Female 
Frequency 
Male 
% 
Male 
Smoking 
Never smoked 670  60.1 531 66.2 139  44.7 
Previously smoked 116 10.4 95  11.8 21 6.8 
Current Smoker 327 29.9 176  21.9 151 48.6 
Undisclosed 2  0.2 1 0.08 1 0.3 
Total 1115  802  311  
Alcohol Use 
Never consumed alcohol 813 72.9 598  74.6 215 69.1 
Previously consumed alcohol 133 11.9 100 12.5 33 10.6 
Currently consume alcohol 167 15.0 104  13.0 63 20.3 
Undisclosed 2  0.2 1 0.08 1 0.3 
Total 1115  802  311  
N=1115 
 
The percentage of previous smokers was highest in the respondents with COAD (32%) and 
hypercholesterolaemia (22.7%) (Table 23).  The percentage of current smokers ranged from 
24-38% in all those with chronic conditions and in those without conditions. The one 
exception was those with COAD (19%). 
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Table 23: Smoking in participants with MSD and/or CDL 
MSD/CDL 
 
Frequency of 
total sample 
Frequency 
Never Smoked 
% Never 
Smoked 
Frequency 
Previously 
Smoked 
% Previously 
Smoked 
Frequency  
Current Smoker 
% Current 
Smoker 
Chi-
square 
df p 
Acute MSD 371 192 51.8 51  13.7 128  34.5 23.969 2 <0.001 
Chronic MSD 478 247 51.7 69 14.4 162 33.9 27.711 2 <0.00 
Hypertension 533 316 59.3 74  13.9 143  26.9 14.164 2 0.001 
Cardiovascular disease 74 33 44.6 17 23.0 24 32.4 15.438 2 <0.001 
Type 2 DM 239 147 61.5 35 14.6 57 23.8 8.461 2 0.015 
Hypercholesterolaemia 225 102  45.3 51 22.7 72 32.0 51.577 2 <0.001 
COAD 122 60 49.2 39 32.0 23  18.8 12.418 2 0.002 
Mental Illness 28 17  60.7 1 3.6 10 35.7 1.687 2 0.430 
Other CDL 335 210  62.7 25 7.5 100 29.9 4.557 2 0.102 
No CDL 269 175  65.1 11  4.1 83 30.9 15.305 2 <0.001 
MSD=Musculoskeletal Disease; CDL=Chronic Diseases of Lifestyle; DM= Diabetes Mellitus; COAD=Chronic Obstructive Airway Disease
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4.8 Risk Factors and their association with Chronic 
Musculoskeletal Disease and Chronic Diseases of Lifestyle 
The proportion of respondents in each age category reporting these risk factors were 
plotted across the adult life span (Figure 14).  There was a trend of increasing obesity, high 
waist-hip ratio and low levels of physical activity with age. However, no risk factor seemed 
to track the plot of MSD.  
 
MSD=Musculoskeletal Disease; WHR=Waist-Hip Ratio; PA=Physical Activity 
Figure 14: Proportional changes in chronic MSD and risk factors over the adult lifespan 
 
20 30 40 50 60 70+
Chronic MSD 0,18 0,25 0,47 0,69 0,53 0,44
Breadwinner 0,25 0,60 0,57 0,61 0,50 0,50
Female 0,73 0,72 0,67 0,77 0,73 0,66
High WHR 0,05 0,06 0,10 0,11 0,19 0,16
Obesity 0,22 0,32 0,45 0,52 0,53 0,43
Low PA Level 0,27 0,22 0,26 0,26 0,35 0,46
Smoking 0,30 0,27 0,28 0,39 0,28 0,21
0,00
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4.9 Association between Presence of Musculoskeletal Disease, 
Chronic Diseases of Lifestyle, and Risk Factors 
Chi-Square Automatic Interaction Detector (CHAID) was used to analyze the association of 
CDL and risk factors with the outcome variable of the presence or absence of chronic MSD 
(pain 3 months) (Figure 15). The outcome was the presence (blue bar) or absence (red bar) 
of chronic MSD and the variables entered into the first CHAID analysis were all the CDL, 
hypertension, hypercholesterolaemia (cholesterol), cardiovascular disease, type 2 diabetes 
mellitus, COAD and mental illness.  
Pain 3 Months=Chronic Musculoskeletal Disease; HPT=Hypertension; COAD=Chronic Obstructive Airway Disease; 
Cholesterol=Hypercholesterolaemia 
n=1103 with MSD; 12 missing  
Figure 15: CHAID analysis of relationship between MSD and CDL 
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In this analysis, hypertension emerged as the being the most associated with MSD (Chi-
Square=65.9; p<0.001) with 56.0% of those with hypertension also reporting chronic MSD, 
compared to 31.7% without hypertension reporting chronic MSD (blue bars). In those with 
hypertension, hypercholesterolaemia was most associated with MSD (67.6% of those with 
hypertension and hypercholesterolaemia had chronic MSD, compared to 50.3% of those 
who had hypertension but no hypercholesterolaemia). In those who did not have 
hypertension, COAD was most associated with 52.8% of those with COAD reporting chronic 
MSD, compared to 29.6% of those without COAD. The other CDL were not significantly 
associated with chronic MSD, in the presence of those included above. 
As there was an almost linear increase in the proportion of CDL across the age categories, it 
was clear that age was an important factor and the second CHAID analysis included all the 
CDL as listed above, plus the age categories (Figure 16). 
Pain 3 Months=Chronic Musculoskeletal Disease; Cholesterol=Hypercholesterolaemia 
n=1103 with MSD; 12 missing; 20=20-29 yrs; 30=30-39 yrs; 40=40-49 yrs; 50=50-59 yrs; 60=60-69 yrs; 70=70 yrs 
and older 
Figure 16: CHAID analysis of relationship between MSD and CDL with age included 
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Once age was included in the analysis (Figure 16), the relationship with most of the CDL fell 
away and it was apparent that age was most associated with MSD (Chi-Square=136.6; 
p<0.001), with the greatest percentage of those with chronic MSD in the 40-49 years of age 
category (68.9% of those in the category). As was seen when the proportion of MSD was 
plotted against age, those who were older than 50 years of age had a lower percentage of 
chronic MSD (49.0% of those in the category) which was similar to the 30-39 year old 
category. In those between 40-49 years of age, gender was associated with chronic MSD 
(Chi-Square=17.7; p<0.001) with 76.2% of females in this age group reporting chronic MSD, 
compared to 45.1% of males.  
In the third CHAID analysis (Figure 17), the following risk factors were included: levels of 
physical activity, obesity categories, smoking, and alcohol use. Gender was also included as 
it appeared that gender might be associated with the different risk factors. BMI category 
emerged as being the most strongly associated with chronic MSD (Chi-Square=26.4; 
p<0.001), with 56.8% reporting chronic MSD in the “obese 2” and “obese 3” categories, 
compared to 33.3% in the normal weight category. physical activity was associated with 
chronic MSD in the normal BMI category, with a higher proportion of those with a low level 
of physical activity reporting MSD 53.8%, compared to 40.1% of non-smokers. In non-
smokers there were more reporting MSD in the low physical activity category (51.2%) 
compared to the high category (35.8%). In smokers, gender was associated with chronic 
MSD, with 64.4% of women smokers reporting MSD compared to 40.0% of the males. 
 
103 
 
  
Pain 3 Months=Chronic Musculoskeletal Disease; IPAQ=International Physical Activity Questionnaire; PA=Physical Activity 
n=1103 with MSD; 12 missing 
 
Figure 17: CHAID analysis of relationship between MSD and risk factors 
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The final analysis, which included age categories, yielded different results as age emerged 
as having the highest association (Chi-Square=136.6; p<0.001) as reported in Figure 18. In 
the younger age group, smoking emerged as being a risk factor (30.8% of smokers had 
chronic MSD compared to 17.5% of non-smokers). In the smokers, being in an age category 
higher 20-29 was associated with an increased risk (42% compared to 21.1%). In the 30-39 
and 40-49 age groups, low levels of physical activity were associated with chronic MSD 
(70.6% compared to 37.5% of those with high levels). Gender emerged as a  factor in the 
40-59 categories with 76.2% of females in this age category reporting chronic MSD 
compared to 45.1% of the males. 
Pain 3 Months=Chronic Musculoskeletal Disease; IPAQ=International Physical Activity Questionnaire; 
PA=Physical Activity 
n=1103 with MSD; 12 missing  
Figure 18: CHAID analysis of relationship between MSD and risk factors including age 
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4.10 Impact of MSD and CDL on Impairments and Health-
Related Quality of Life 
This section explores the impact on impairments associated with MSD, such as pain and 
stiffness, and on the HRQoL via the European Quality of Life-5 Dimensions (EQ-5D). 
Associations between gender, age and HRQoL will be presented, followed by analysis of the 
relationships between acute and chronic MSD and health index and health status scores as 
rated on the visual analogue scale (VAS). 
4.10.1 Impairments of Function - Pain 
As noted previously, prevalence of MSD was reported using the Community Orientated 
Program for Control of Rheumatic Diseases (COPCORD) questionnaire. The Brief Pain 
Inventory (BPI) was used to report on pain severity, using the pain severity score (PSS), and 
pain interference, using the pain interference score (PIS). Results obtained using the BPI for 
those reporting MSD is shown in Table 24. The mean PSS was 5.4 (SD=1.4) and the mean 
PIS was 5 (SD 2.2). The greatest interference was with sleep (5.8; SD=3.2). 
Table 24: Pain severity and pain interference scores reported by participants with MSD 
(Brief Pain Inventory) 
Variable Frequency Mean SD 
BPI Worst 257 8.0 1.7 
BPI Least 256 3.5 2.1 
BPI Average 257 5.5 1.9 
BPI Now 257 4.5 3.1 
BPI Pain Severity Score 257 5.4 1.4 
BPI General Activity 256 5.8 2.7 
BPI Mood 256 5.4 3.3 
BPI Walking Ability 256 5.4 3.2 
BPI Normal Work 256 5.7 3.0 
BPI People 254 2.7 3.0 
BPI Sleep 255 5.8 3.4 
BPI Life Enjoyment 255 3.9 3.2 
BPI Pain Interference Score 256 5.0 2.2 
BPI=Brief Pain Inventory; SD=Standard Deviation 
Scale of 0 – 10; 0 = no pain/does not interfere and 10 = pain as bad as you can imagine/completely interferes 
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Common anatomical sites of MSD are shown in Figure 19 below. The most common sites of 
MSD amongst the study sample were the knees (35.6%; 95% CI: 31.5-39.9%), low 
back/pelvis (33.8%; CI: 29.8-38.0%), shoulders (26.8%; CI: 23.1-30.9%), and hands/fingers 
(21.9%; CI: 18.5-25.7%). 
 
n=503 respondents; multiple sites 
Figure 19: Most common painful anatomical sites reported in participants with MSD 
  
Table 25 expands on the sites of MSD as reported by the study sample, as well as the time 
of onset of pain, the average duration of pain, and a description of the 24 hour behaviour 
of pain. Participants reported multiple sites of pain. In females, the most prevalent areas of 
reported pain were the knees, shoulders, and low back, while males reported a higher 
prevalence of MSD in the hips, wrists, and head/neck.  
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Table 25: Self-reported sites and description of MSD 
Pain Characteristic Frequency % of total 
sample 
(N=1115) 
% of those 
reporting any 
MSD (n=503) 
Site (Multiple responses) Lower limb  
   Knees 179 16.1 35.6 
   Hips 84 7.5 16.9 
   Ankles 72 6.5 14.3 
   Feet/Toes 69 6.2 13.7 
Spinal 
   Low back 170 15.3 33.8 
   Head/Neck 67 6.0 13.3 
   Mid back 54 4.8 10.7 
Upper limb  
   Shoulders 135 12.1 26.8 
   Hand/Fingers 110 9.9 21.9 
   Wrists 72 6.5 14.3 
 
   Elbows 66 5.9 13.1 
Pain Onset  
 (n=429, 76 missing data) 
Last 7 days 29 2.6 6.8 
Last 3 months 62 5.6 14.5 
3-12 months ago 47 4.2 11 
>12 months ago 244 21.9 57 
Undisclosed 46 4.1 10.75 
Pain Duration 
(n=429, 76 missing data) 
Few hours 223 20.0 52 
Few days 106 9.5 24.7 
4-6 weeks 16 0.1 3.7 
6-12 weeks 2 0.2 0.5 
> 3 months 40 4.6 9.3 
Undisclosed 42 3.8 9.8 
24 hour behaviour of pain  
(n=429, 76 missing data) 
Morning 110 9.9 25.7 
During activity 82 7.4 19.2 
Night 172 0.2 40.2 
Stays the same 24 2.2 5.6 
Undisclosed 40 3.6 9.35 
MSD=Musculoskeletal Disease  
N=1115; Females n=803; Males n=312 
 
MSD management strategies reported by the study sample are shown in Table 26 below.  
The most common management strategy was the use of analgesia, both prescribed (52%) 
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and used over-the-counter (25.7%). Dosages were not recorded. The most commonly used 
non-pharmacological management strategy reported was exercise (19.7%). 
Table 26: Self-reported MSD management strategies 
Pain Management Strategy Frequency 
 
% 
with MSD (n=505) 
% 
of total sample 
(N=1115) 
Medication (n=401) 
   Prescribed oral analgesia 209 52.1          18.7 
   OTC analgesia 103 25.7 9.2 
   No medication 72 18.0 6.5 
   Prescribed oral NSAIDs 69  17.2 6.2 
   Natural remedies 20 5.0 1.8 
   Other medication 16 4.0 1.4 
   OTC NSAIDs 14 3.5 1.3 
   Injection 10 2.5 0.9 
   Undisclosed 11 2.7 1.0 
Effect of Medication (n=332) 
   Helped 272 81.9 24.4 
   Did not help 49 14.8 4.4 
   Undisclosed 11 3.3 1.0 
Other Treatments (n=401) 
   Only Medication 274 68.3 24.6 
   Exercise 79  19.7 7.1 
   Massage 31 7.7 2.8 
   Education 25  6.2 2.2 
   Joint mobilisation 19 4.7 1.7 
   Other treatment 15 3.7 1.35 
   Herbal/Natural Strategies 12 3.0 1.1 
   Electrotherapy 9 2.2 0.8 
   Acupuncture/Dry needling 7 1.75 0.6 
   Strapping /Bracing 3 0.75 0.3 
   Undisclosed 11  2.7 1.0 
MSD=Musculoskeletal Disease; OTC= Over-the-counter; NSAIDs=Non-Steroidal Anti-Inflammatory Drugs  
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Participants further described which management strategy was most effective in reducing 
their MSD symptoms. A single response was required, and 191 participants responded to 
this question. As seen in Figure 20, 68 participants (35.6% of those responding) reported 
that exercise was the best management strategy for MSD, while 61 (32.0%) reported that 
oral medication provided the most relief. No participants reported strapping or bracing to 
be the best management strategy for their pain. 
 
 n=191 
Figure 20: Self-reported best management strategy for MSD 
 
4.10.2 Impairments of Function - Stiffness 
A summary of characteristics of self-reported joint stiffness can be seen in Table 27. These 
characteristics include the site(s) of stiffness, morning stiffness, and whether movement 
relieves stiffness and any previous diagnosis of rheumatism recalled by the study sample. 
All participants were as asked about stiffness. 
Exercise
35%
Medication
32%
Massage
9%
Education
7%
Joint Mobilisation
4%
Electrotherapy
2%
Acupuncture/Dry 
Needling
1%
Natural/Herbal
2%
Injection
2%
Undisclosed
6%
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The most common sites of stiffness were the knees (47%; 95% CI: 41.6-52.8%), low back 
(40%; CI: 34.7-45.8%), and shoulders (32.7%; CI: 27.7-38.3%). Of the 23.5% of the sample 
reporting joint stiffness (n=299), 84.6% reported that stiffness decreased with movement.  
Table 27: Characteristics of self-reported joint stiffness 
Joint Stiffness Characteristic Frequency 
of sample 
% of sample 
Morning stiffness 299  27.8 
Site of stiffness 
         Neck 43  14.3 
         Mid back 29  9.7 
         Low back 120  40.0 
         Shoulder(s) 98  32.7 
         Elbow(s) 38  12.7 
         Wrist(s) 49  16.3 
         Hand(s)/Finger(s) 77  25.7 
         Hip(s) 70  23.3 
         Knees(s) 141  47.0 
         Ankle(s) 56 18.7 
         Feet/Toe(s) 27  9.0 
Movement relieves stiffness 253  84.6 
n=1076 
4.10.3 Health-Related Quality of Life 
A description of the five domains of the EQ-5D across gender is seen in Figure 21. 
 
n=109; Female n=785; Male n=31; Missing n=19; Sev.=Severe 
Figure 21: EQ-5D dimensions by gender 
No Some Sev. No Some Sev. No Some Sev. No Some Sev. No Some Sev.
Mobility Self-care Usual activities Pain/Discomfort Anxiety/Depression
All 62,8 36,4 0,8 85,0 13,5 1,6 65,8 31,7 2,6 56,1 38,9 4,7 65,0 31,8 3,1
Females 61,8 37,8 0,4 85,0 14,9 0,4 64,2 34,4 1,4 52,1 43,2 4,2 66,6 30,8 2,4
Males 65,3 32,8 1,9 85,2 10,0 4,8 69,8 24,8 5,5 66,2 28,0 5,8 60,8 34,4 4,8
0,0
10,0
20,0
30,0
40,0
50,0
60,0
70,0
80,0
90,0
%
EQ-5D dimensions by gender
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The dimension with the least problems overall was self-care (85% no problems) and the 
most problems were reported in the pain dimension (65% no problems). Females reported 
more problems in each dimension apart from anxiety/depression and there was a 
significant difference between females and males in the pain/discomfort (z=3.71; p<0.001) 
and anxiety/depression (z=-2.05; p=0.041) dimensions. 
The mean EQ-5D health index score for females was 0.78 (SD=0.25), and for males was 0.76 
(SD=0.31). No significant difference was found between gender and the health index score 
(t=1.166; df=1088; p=0.244). The mean health status VAS score for females was 69.9 
(SD=21.9) and for males was 71.0 (SD=22.0). Again, no significant difference was found 
between gender and the health status VAS score (t=-0.750; df=1094; p=0.453). 
4.10.3.1 Age and Health-Related Quality of Life 
The EQ-5D health index and VAS scores of the sample are further described by age category 
in Figure 22 and Figure 23. The mean health index score ranges from 0.70 to 0.88 and 
display an almost linear trend, with the highest mean of 0.88 being found in the 18-29 age 
group and the lowest was in the 50-59 and over 70 age groups.  
 
Figure 22: Mean EQ5D health index score by age group 
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The health index, which represents a preference based composite score of the dimensions, 
shows a linear downward trend until 60 years of age at which it appears to stabilise at 
around 0.7-0.73 (Figure 22). 
The VAS, a measure of perceived global health, shows a similar linear downward trend until 
60 years of age when it stabilises at 71% (Figure 23). 
 
Figure 23: Mean EQ5D health VAS score by age group 
4.10.3.2 MSD, CDL and Health-Related Quality of Life 
A description of the five domains of the EQ-5D of those with and without chronic MSD is 
seen in Figure 24. 
 
Figure 24: Percentage responses to the EQ-5D dimensions for chronic MSD 
18-29 30-39 40-49 50-59 60-69 70+
Health VAS 78,22 73,44 65,90 63,16 70,63 70,88
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No Some Sev. No Some Sev. No Some Sev. No Some Sev. No Some Sev.
Mobiity Self-care Usual activities Pain/discomfort Anxiety/depression
No MSD 76,6 23,3 0,2 92,3 6,3 11,4 77,2 21 1,8 73,9 24,6 1,5 72,5 25,7 1,8
MSD 44,4 53,9 1,7 75,2 22,9 1,9 50,5 45,9 3,6 32,8 58,2 9 54,9 40,2 4,9
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Those with chronic MSD reported having the most problems in the pain/discomfort and the 
mobility dimensions (33% and 44% reporting no problems respectively).  In the usual 
activities and anxiety/depression dimensions, 50% and 55% reported no problems 
respectively. The least number of problems (75.2% no problems) was experienced in the 
self-care dimension. 
As can be seen in Table 28, the poorest self-perceived health was in those with mental 
illness (VAS=56% and Health Index=0.6).  Hypertension seemed to have the least impact on 
HRQoL (VAS =67% and Health Index=0.72). In every condition, the VAS and Health Index 
scores were significantly less in those reporting the health condition and the differences in 
scores was greatest for those with mental illness (VAS=15 % and Health Index=0.18) and 
chronic MSD (VAS=12% and Health Index=0.20). 
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Table 28: Comparison of the EQ-5D Index and VAS scores between those with and without chronic health conditions. 
Condition 
 
Yes n Yes Mean Yes SD No n No Mean No SD t-value df p Dif 
Chronic MSD 
 
VAS 470 63.5 21.5 623 75.2 20.7 9.1 1091 <0.001 11.70 
Index 469 0.66 0.3 619 0.86 0.21 12.48* 813.5 <0.001 0.20 
Hypertension VAS 525 67.4 20.0 571 72.7 23.2 4.02 1089 <0.001 5.30 
Index 523 0.72 0.3 567 0.82 0.27 6.38 1059 <0.001 0.10 
Cardiovascular disease VAS 73 64.1 21.2 1023 70.6 21.9 2.5 1094 0.014 6.50 
Index 73 0.69 0.21 1017 0.80 0.27 2.8 1088 0.005 0.11 
Hypercholesterolaemia VAS 221 63.5 21.5 875 71.8 21.7 5.1 1094 <0.001 8.30 
Index 219 0.66 0.3 871 0.80 0.25 6.42* 296.8 <0.001 0.14 
COAD VAS 119 61.3 21.6 977 71.2 21.7 4.7 1094 <0.001 9.90 
Index 120 0.70 0.3 970 0.78 0.27 2.69* 141.7 0.008 0.08 
Mental illness 
 
VAS 26 55.6 28.8 1070 70.5 21.6 2.62* 25.69 0.010 14.90 
Index 27 0.60 0.4 1063 0.78 0.37 2.46* 26.69 0.020 0.18 
MSD=Musculoskeletal Disease; COAD=Chronic Obstructive Airway Disease 
*tested with separate variances. 
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4.11 Summary of Results 
This section summarises the main results and emphasises those that are related to the 
objectives of the study as outlined in the Introduction. 
There were 1115 participants who were interviewed, with a mean age of 48.7 (SD=16.8) 
years. Pain persisting for longer than the last three months (chronic MSD) was reported in 
43.3% (95% CI: 40.4-46.3) of participants. A significant association was found between 
gender and chronic MSD, with a higher proportion of females reporting pain. 
More than three quarters of the sample reported at least one CDL. hypertension was the 
most prevalent condition (47.8%; CI: 44.8–50.7%), followed by type 2 diabetes mellitus 
(21.4%; CI: 19.1-23.9%), and hypercholesterolaemia (20.2%; CI: 17.9-22.6%). Higher 
proportions of these common CDLs were reported by females. The prevalence of all chronic 
diseases except COAD increased with age. However, both acute and chronic MSD peaked 
around the 50-59 year old age category and then decreased thereafter. 
 
Female gender was associated with a higher prevalence of hypertension, 
hypercholesterolaemia, and type 2 diabetes mellitus. In bivariate analysis, significant 
associations were found between chronic MSD and hypertension (p<0.001), cardiovascular 
disease (p<0.000), type 2 diabetes mellitus (p=0.002), and hypercholesterolaemia 
(p<0.001). A significant association (Chi-Square=13.833; df=2; p=0.001) was found between 
chronic MSD and physical activity levels, with a higher proportion of those reporting no 
pain having higher levels of physical activity. Similarly, bivariate analysis detected 
significant associations between smoking and both acute and chronic MSD, and all CDL’s 
except mental illness and other CDL. No significant association was found between alcohol 
use and MSD. 
 
However, multivariate analysis with CHAID revealed that the associations with MSD were 
more complex and that age was the primary factor influencing MSD, with the lowest 
prevalence of MSD in those under 30 and the highest prevalence in those between 40-59 
years of age. Once age was included, an association remained only with gender (females 
had a higher prevalence of MSD) in the 40-59 years age groups and presence of 
hypercholesterolaemia in the older respondents. With regard to association between MSD 
and risk factors, the inclusion of age similarly altered the relationships and the risk factors 
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varied considerably between age groups, with smoking emerging in those younger than 30, 
low levels of physical activity in the 30-49 age groups and gender in the 40-59 age groups 
(as in the analysis of MSD and CDL).  
 
With regard to the impact of MSD on impairments of function, lower limb and spinal pain 
were reported by at least 34% of respondents. Upper limb pain was less prevalent but still 
reported by at least 27%. Treatment for MSD included medication in 80% of those with 
MSD while 20% had been given exercise, 8% massage and 5% joint mobilization. Exercise 
and medication were reported to be the most effective interventions. The BPI mean scores 
were approximately midway between no pain/no interference and worst imaginable pain/ 
complete interference. 
 
With the exception of self-care, 50% or more of those with MSD reported having some or 
severe problems in the dimensions of the EQ-5D. HRQoL showed a linear downward trend 
with age in the health index with the lowest point at 50-59 years. The VAS also decreased 
until 50-59 years but then showed an increase of about 7% and stabilized as that value. In 
every case those with a health condition reported significantly worse HRQoL in both the 
health index and the VAS, the greatest difference being between those with mental illness 
followed by chronic MSD. 
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5 DISCUSSION 
The aims and objectives of this study were successfully addressed by the research and the 
results presented in the previous chapter will be discussed in this chapter. 
The current study shows that among patients attending a community health centre (CHC), 
there was a high prevalence of chronic diseases of lifestyle (CDL), particularly hypertension 
(HPT). The prevalence of musculoskeletal disease (MSD) was also high (43.3%; CI: 40.4-
46.3%), with a higher prevalence among females. The association between MSD and CDL, 
as well as MSD and risk factors, proved to be complex. The general linear increase in 
prevalence with increasing age gave rise to bivariate associations which then diminished 
once age was included in analysis.  
Interestingly, the results showed that the trends in increasing prevalence reversed after 60 
years of age with regard to chronic MSD, obesity and high levels of physical activity (PA). In 
addition, health-related quality of life (HRQoL) appeared to increase after 60 years of age. A 
further finding of interest is that there was no correlation between metabolic equivalent of 
a task minutes (MET-minutes) and body mass index (BMI) and that a large proportion of 
the respondents, despite the high prevalence of obesity (over 50% in females), reported 
high levels of physical activity (46%). Both the levels of obesity and physical activity were 
considerably lower in males. 
 
5.1 Participant Characteristics 
The characteristics of the participants in this study will be discussed below. The sample and 
response rate is firstly elaborated upon, followed by relevant descriptive, socio-economic 
and clinical characteristics of the sample. 
5.1.1 Recruitment and Sample 
A response rate of 90.2% was achieved for this study. Approximately 89% of the 
participants recruited completed the required anthropometric measurements. This is in 
keeping with previous studies also conducted in this study setting, as it is quite usual for 
the total number of respondents to not complete clinical tests required for some studies133. 
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This occurs especially if clinical testing is done in a different room or building to where 
questionnaires or interviews are completed133 as occurred in this study.  
Over 70% of the participants recruited were female, with the highest proportion (20%) of 
respondents  between the ages of 50 and 59 years. Previous literature has shown that 
females are generally more concerned about their health and will seek medical assistance 
more often than males.49,282,283 In addition to this, in the Mitchells Plain area there is a high 
percentage of unemployment amongst females due to not finding suitable employment, 
being housewives, or being retired. Therefore for socio-economic reasons, these females 
are forced to seek medical assistance at the state provided primary health care centres.284 
Over one third of the sample reported being unemployed. This is supported by data 
supplied by Statistics South Africa in the 2011 census where 68% of the work force in the 
Mitchells Plain health district were reported to be employed.22 According to the 
International Labour Organisation (ILO), the 2017 rate of employment in global developing 
countries is 93.8%, while in Sub-Saharan Africa and South Africa the employment rate is 
92.8% and 74% respectively.285 A monthly income of R1001-R2000 was reported by almost 
half of the sample of this study. This is also supported by the 2011 census where 61% of 
households  reported to have a monthly income of R3200 or less.22 The 2011 census also 
found that 32% of those aged 20 years and older have completed Grade 12 or higher.22  
This was found to be higher than the results in this study where more than one quarter of 
the participants did not surpass the primary level of schooling (i.e. grade 7), and 15.9% 
completed grade 12 and 2.5%  completed tertiary studies.  
Socioeconomic status (SES) is described in three categories (high SES, middle SES, and low 
SES).286 This describes how the families or individuals are categorised.286 When selecting 
the appropriate category income, education, and occupation are assessed.286 Based on the 
results of this study, Mitchells Plain would be deemed to have a low SES, which is in 
keeping with previous statistics.287 Earlier research has found that there is a weak 
correlation (r=0.22) between SES and academic achievement.288 The low socioeconomic 
status of the sample could also be attributed to the fact that services at the CHC are free of 
charge and specifically cater for the low-income population.23 
A large proportion of the participants were attending the CHC for management of a chronic 
condition, which is in keeping with research and estimates for Mitchells Plain CHC.23 In 
South Africa, 84% of the population is dependent on public health services,289 which at 
119 
 
primary healthcare level are nurse-led, and up to 86% of consultations are by nurses.289 
Thus, the number of patients awaiting a medical practitioner consultation at Mitchells Plain 
CHC could be high, although they could have been referred by nursing staff.   
 
5.2 Musculoskeletal Disease 
In the following section results regarding MSD found in this study are discussed. This 
includes both acute and chronic MSD and joint stiffness. Possible risk factors and their 
associations with MSD are also discussed here. 
5.2.1 Prevalence and Risk Factors of Musculoskeletal Disease 
A prevalence of 43.3% (95% CI: 40.4-46.3%) of chronic MSD was found in the sample which 
corresponds with an earlier prevalence study done in rural South Africa where 42.9% (95% 
CI: 37.4%-47.1%) of 392 adult participants reported chronic musculoskeletal pain.43 Data 
were collected during face-to-face interviews using undisclosed structured questionnaires, 
while a smaller sample size of 394 participants was used.43 This quantitative cross-sectional 
study was carried out in the rural village of Baziya in the Transkei region of the Eastern 
Cape province of South Africa.43 Baziya has a small estimated population of 6 000 at the 
time of study, with most residents aged 50 years or older.43  
The prevalence of chronic MSD found in this study is also similar to other previous South 
African literature where a prevalence rate of chronic MSD of 45.8%42 and 41%44 was found. 
A 2013 quantitative cross-sectional study was conducted at the Manguang University of the 
Free State Community Partnership Program Community Health Centre in Bloemfontein in 
the Free State province of South Africa to determine the prevalence and functional impact 
of MSD.42 This CHC services between 19000 and 22000 patients per month,42 
approximately half of those seen at the Mitchells Plain CHC. Three hundred and twenty-six 
(326) participants were included in this study, where the COPCORD and Stanford Health 
Assessment Questionnaires (HAQ) were completed.42 Similarly, another 2013 quantitative 
cross-sectional study conducted in the city of Tshwane (formerly known as Pretoria) in the 
Gauteng province of South Africa inspected the prevalence of chronic MSD.44 A strength of 
this study is that it was conducted at four healthcare institutions (two CHCs and two 
hospitals) and 1066 adult participants were interviewed using the Brief Pain Inventory.44 
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A lower prevalence of chronic MSD was found in Brazil, also classified as an upper middle 
income country as South Africa is, where the prevalence varied between 9.4% and 39.6%.39 
However, it must be noted that this research was conducted on an elderly population 
where the most prevalent sites of chronic MSD were the spine and lower limb. The 
aforementioned South Africa studies also found that the back and knees were the most 
commonly reported sites of MSD.42,44 The current study found that the most prevalent sites 
of chronic MSD were the knees (35.6%; 95% CI: 31.5-39.9%), low back/pelvis (33.8%; CI: 
29.8-38.0%) and shoulders (26.8%; CI: 23.1-30.9%). This suggests that intervention 
strategies for chronic MSD should target the spine and lower limbs as these are the most 
common areas of pain. Compared to the global prevalence of chronic MSD of around 
34.5%,38 as well as of that in countries of similar socioeconomic status, the prevalence of 
chronic MSD within the context of this CHC is higher. 
As previously stated, the suburb of Mitchells Plain has a low socioeconomic status. 
Literature has suggested that socioeconomic differences between countries affect MSD 
with a higher prevalence where there is more poverty.290–294 Individuals classified into the 
low socioeconomic status have been shown to experience an almost threefold increase in 
the risk of chronic MSD.293 This could be attributed to health behaviours such as smoking, 
physical inactivity, poor diet, and substance abuse which are closely linked to both 
socioeconomic status and health outcomes.286 Higher risks have also been shown for those 
with lower levels of education.295 In the current study, 78% of the participants earned less 
than R2000 per month which is well below the South African minimum wage of R20 per 
hour or R3500 per month as of January 2019.296 This supports the low socioeconomic status 
of the Mitchells Plain community and, together with the high prevalence of chronic MSD, 
highlights the link between low socioeconomic status and risk of chronic MSD in this 
sample. 
The findings of this study supports previous evidence that the prevalence of MSD is higher 
among females and increasing with age.33,2,46 Furthermore, in previous literature, after 
controlling for CDL, age and socioeconomic status have been found to be statistically 
significant and positively associated with obesity among females, while higher education 
was associated with obesity in males.41,113 For both genders, those who were single and 
never married were found to be less likely to be obese than those who were married.113  
A recent six-country study found an MSD prevalence of 38.5% (95% CI: 34.9-42.2%) in those 
older than 50 years of age in South Africa.27 This study, however only looked at pain 
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reported in the 30 days prior to questioning. The study also found that females (34.9%; 
95% CI: 33.0-36.9%), and those living in rural areas (31.5%; CI:29.2-33.8%) had a higher 
prevalence of pain.27 Females may be more pain sensitive and have a less efficient internal 
pain inhibitory capacity compared to males.104 Other factors such as expectancies, 
conditioning, and ovarian hormones, which can change the neurophysiology of pain, could 
also attribute to the difference in the reporting of pain between males and females.50 In 
older females, factors such as BMI, systolic blood pressure (SBP), and depressive symptoms 
have also been found to be associated with MSD.297 Also, pertinent to the context of South 
Africa, a socially and culturally diverse country, are the findings that socio-cultural beliefs 
about femininity and masculinity have also been determined to have an effect on different 
gender pain responses. This is because it is generally more socially acceptable among 
females to express pain than among males.107 This may lead to biased reporting of pain.107 
5.2.2 Management of Musculoskeletal Disease 
The most common treatment for MSD-related pain at the CHC was oral analgesia, of which 
almost three quarters of those using medication reported that it did not reduce their pain. 
Interesting, only 191 participants provided an answer to the best management of their 
MSD. This could be due to participants using alternative methods of pain relief that were 
not listed as possible management strategies. Strategies such as traditional medicine were 
not listed in the questionnaires as they were considered out of the scope of this 
dissertation. This could be a possible limitation of the current study. Another possible 
reason could be attributed to the interpretation that none of the listed management 
strategies improved the MSD. However, over 37% of participants with MSD reported that 
exercise was more helpful than oral medication in managing their pain. Exercise had been 
shown to increase pain thresholds and tolerance.298,299 This could be attributed to the 
endogenous opioid system as well as an increase in mood post exercise due to the release 
of mood enhancing neurotransmitters. 
This study found that various forms of Paracetamol were being used by 8% of the sample, 
making it the most prescribed analgesic. Despite the findings that a large proportion of 
respondents reported exercise to be more beneficial than oral medication, pharmacological 
intervention of MSD has still been found to be first line of management within the primary 
health care sector of South Africa.300  
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5.3 Chronic Diseases of Lifestyle 
This section addresses the objective to determine the proportion of people with CDL 
occurring in an adult population attending medical services at a CHC in Cape Town, South 
Africa.  
This study found that more than three quarters of the sample reported being diagnosed 
with at least one of the CDL. Hypertension was the most prevalent condition in both 
genders, followed by type 2 diabetes mellitus and hypercholesterolaemia. This has been 
found in South African literature where hypertension (13.1%301-63%13) is the most common 
CDL encountered at primary healthcare level. This is followed by type 2 diabetes mellitus 
(3.9%),301 and COAD (0.6%).301 Hypertension has also been found to most commonly occur 
in conjunction with type 2 diabetes mellitus.301 In South Africa, it has been shown that the 
risk of developing hypertension is twofold in those that are obese.166 As over half of the 
participants in this study were overweight or obese, this could be a possible contributing 
factor to the high prevalence of hypertension. 
The prevalence of mental illness found in this study was less than the global prevalence.29 
However, it has been shown that the prevalence of mental disorders is less in developing 
than developed countries.302 This could be attributed to the increased stigma and various 
cultural views around mental disorders in developing countries.41 A high proportion (30%) 
of other CDL was reported as well. Unfortunately, no further investigation was done to 
determine what “other” CDL could have been. Within the South African context, it may be 
presumed that a large portion of the “other” CDL may be attributed to HIV/AIDS (Human 
Immunodeficiency Virus/Acquired Immunodeficiency Virus). Currently, in South Africa, the 
estimated total number of people living with HIV has increased from 4,25 million in 2002 to 
7,52 million in 2018 and therefore, for 2018, it is estimated that 13,1% of the population is 
HIV positive.303  
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5.4 Changes and Associations between Musculoskeletal Disease, 
Chronic Diseases of Lifestyle, and Risk Factors over the 
Adult Lifespan 
The proportional changes in CDL and MSD across six age categories within the study sample 
is discussed here. All chronic diseases except chronic obstructive airway disease (COAD) 
continually increased with age, while COAD and both acute and chronic MSD peaked 
around the 50-59 year old age category and then decreased with age. The proportional 
increase in chronic MSD with age has been widely shown in previous research.41 This trend 
was found in both developed and developing countries,41 which leads to the deduction that 
socioeconomics, demographics, and culture may not play a big role in the development of 
chronic MSD and confirms that chronic MSD is quite prevalent in the global general 
population.  
Similar proportional changes in MSD and CDL were illustrated in females where all chronic 
diseases except COAD continually increased with age, while COAD and both acute and 
chronic MSD peaked around the 50-59 year old age category and then decreased with age. 
In males, the proportion of participants with MSD and CDL, continually increased with age. 
Again, the findings on prevalence and gender distribution of MSD in this study is quite 
consistent with that of previous literature.41   
Multivariate analysis using Chi-Square Automatic Interaction Detector (CHAID) indicated 
that the association between chronic MSD and CDL fell away once age categories were 
entered into the analysis. Thus, the primary association was with age. However, although 
not associated once age is factored in, all the CDLs were present and increased with age. 
Whilst the highest initial prevalence rate of chronic MSD was found in the 50-59 group 
(69%), with multivariate analysis, the 40-49 age group displayed the highest prevalence of 
chronic MSD (69%). As a further gender association was shown in this age group, it can be 
deduced that, within this study context, females aged between 40 and 59 years have a 
higher prevalence of chronic MSD. This finding should inform the development of culturally 
appropriate intervention strategies for the management of chronic MSD.  
The prevalence of chronic MSD decreased after the age of 60. This correlates with a 
decrease in obesity and breadwinner status, also after the age of 60, as well as a decrease 
in physical activity level. Most employed participants partook in vocations that were not 
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sedentary. Also, within a low socioeconomic status community, the population is more 
likely to utilise public transport, where walking to various terminals is common. Where 
public transport cannot be afforded, walking long distances to places of employment is also 
common. Thus, the decrease in the level of physical activity after age 60 could be 
attributed to employment being ceased as retirement age was reached, as well as a 
reduced prevalence of chronic MSD. 
In those with a normal BMI and those in the 30-49 age group, a higher proportion of those 
with a low level of physical activity reported  MSD (53.8% and 42% respectively).  A recent 
2017 study, in a similar population, found no significant difference between the self-
reported physical activity levels of those with chronic MSD compared to matched 
controls.126 This was most likely due to the small sample size (24 participants) in 
comparison to the current study. Significant differences were however found in objective 
physical activity measures, with the chronic MSD group scoring lower than the matched 
controls on the repeated sit-to-stand test (RSST) (17.9sec [11.83–105] vs 7.85sec [5.5–
11.5]; U=0; p<0.01), the 6 minute walk test (6MWT) (335m [30–430] vs 680m [430–795]; 
U=0.5; p<0.01), mean daily pedometry readings (2985.1 [32.8–13785.4] vs 6409.4 [4207.1–
15313.6]; U=35; p<0.03), and total pedometry readings (20896 [229–96526] vs 44865.5 
[29450–107195]; U=35; p<0.03).126 Although found more objectively, this supports the 
findings of the current study where participants with chronic MSD had significantly lower 
physical activity levels than those without chronic MSD. This result was expected and is in 
keeping with other previous literature.304,305 Those with chronic MSD have been found to 
take 29% fewer steps than those without chronic MSD.304 Also, the manner in which these 
steps were accumulated was found to be different,304 with less intense movement,306 and 
more time spent lying down (47.0 [10.2]% vs 34.3 [5.6]%; p=0.000)306 compared to those 
without chronic MSD. These suggest changes in pain behaviour. A possible reason for not 
engaging in physical activities, outside of normal work duties, could be fear-avoidance of 
physical activity.101 The fear-avoidance model hypothesises that those with chronic pain 
believe that physical activity will increase their pain and therefore physical activity is 
avoided.307 Fear and anxiety lead to physiological, behavioural, and cognitive responses 
such as increased muscle reactivity, avoidance behaviour and hypervigilance, and 
catastrophizing thoughts.307 Those with  pain may thus develop fear of pain, moving, re-
injury, or work-related activities.307 Thus, altered patterns of movements126 may be 
adopted to avoid these fears or anxieties, but could restrict the normal use of injured tissue 
and allow for further deterioration of the condition/injury. 
125 
 
In this study, more than 70% of those with chronic MSD were overweight or obese. In 
South Africa obesity has been found to be more prominent in females, ranging from 28% to 
41%, whilst among males, obesity steadily increases with socioeconomic status from 6% to 
18%.113  Increased physical activity has been found to be associated with low obesity in 
women.113 Smoking has been found to negatively correlate with obesity in males as well as 
females, although among males, smoking has been fore to be more an attribute of the 
poor.113 Conversely, physical exercise and smoking have been found to be positively 
correlates in females.113 This would imply that these activities occur more among wealthy 
females. Other notable contributors toward obesity inequalities among males have been 
shown to be age (8.5%) and employment (6.6%), while living in a rural area (20.3%), 
physical activity (−28.6%) and smoking (−11.4%) contributed significantly to the obesity 
inequality among females.113 However, no correlation was found between obesity and age, 
or between obesity and MET-minutes/level of physical activity. Thus, diet may be the 
behavioural determinant of obesity308 within this study context, instead of level of physical 
activity. It has been shown that in the low socioeconomic context of Cape Town, unhealthy 
foods outnumber healthy ones by a ratio of 2:1, with a high content of sugar and refined 
foods.309 
Smoking was found to be associated with chronic MSD in younger participants. However, 
the numbers of those who smoked and had MSD was small. No significant difference was 
found in the alcohol use of those reporting MSD and those without MSD. This could be due 
to the analgesic effects of alcohol as it results in a small increase in pain threshold.310 
However, the greater the use of alcohol the greater the analgesic effect, which could 
provide potential addiction and dependence in those with pain.310 
The bivariate association between chronic MSD and hypertension displayed in this sample 
is in keeping with similar research where a higher prevalence of MSD was reported in those 
with hypertension,311 although this was limited to males with uncontrolled hypertension.311 
The association between MSD and type 2 diabetes mellitus has also been well documented. 
In participants with type 2 diabetes mellitus, ‘low’ and ‘moderate’ physical activity levels 
were both reported as the most common (35.1%) categories. Significant differences were 
found between physical activity levels and type 2 diabetes mellitus (p=0.004), and 
cardiovascular disease (p=0.004). This link to low levels of physical activity could attribute 
for the associations between these conditions and MSD. 
126 
 
It was hypothesised that there is a cycle in which chronic MSD may result in reduced 
physical activity and this, in turn, would increase BMI and the increased BMI would result in 
increased MSD. However, there was no evidence of any of the factors preceding or trailing 
each other. From the results of this study, as well as from previous literature, it is has been 
shown that, in order to decrease the burden of disease of chronic MSD, it is of importance 
to include a focus on promoting physical activity,126 as well as to target the barriers to 
physical activity312 in the management of chronic MSD. Intervention components that 
address fear avoidance and self-efficacy may thus be more effective in reducing long-term 
disability.312 
 
5.5 Health-Related Quality of Life 
In this study, a mean European Quality of Life-5 Dimensions (EQ-5D) health index score for 
the total sample of 0.8 ± 0.3 was found, with no significant difference found between 
gender and the health index score and scores on the visual analogue scale (VAS). This is 
supported by previous literature, in the culturally and socially diverse South African 
context, which found that gender had no influence on self-reported quality of life.313  
The mean health index score decreased with age, with the lowest score in the 50-59 and 
over 70 age categories. Age has been found to be a major determinant of self-reported 
HRQoL in South Africa313 while in China, also an upper middle-income country, health 
status was found to decline with advancing age.314 This included a decrease in mean VAS 
score as well as an increase in problems in each EQ-5D dimension.314 This could be 
attributed to the rise in chronic MSD and CDL with age and is in keeping with global HRQoL 
trends. 
Research has suggested that there is a positive relationship between chronic pain, disability 
and low quality of life, especially in the case of non-specific pain.315 The relationship 
between intensity of pain and quality of life, however, has not been as well researched.315 
In this study, participants reporting acute MSD and chronic MSD reported a lower health 
index and VAS scores than those with no MSD. This is supported by literature stating that 
individuals in Brazil with chronic MSD, such as in osteoarthritis, were more likely to have 
lower VAS scores, while those with hypertension and COAD were not.316  
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It has been found that the worst HRQoL patterns were found for in those with 
osteoarthritis of the hip, osteoporosis, rheumatoid arthritis (RA), and fibromyalgia, while 
those with multiple sites of chronic MSD were found to have the poorest HRQoL.317 
Globally, individuals with chronic MSD have also reported lower quality of life.315 The 
results in this study therefore follow the global trend, as well as that for upper middle-
income countries for chronic MSD and HRQoL. The effect of chronic MSD on HRQoL could 
be attributed to the reduced physical ability or function reported with disease,317 as well as 
pain interfering with everyday interactions and activities of daily living.315 Thus, 
interventions for chronic MSD that address disability and HRQoL, including educational 
programmes, may be more effective in the management of chronic MSD  than 
conventional pharmacological management alone.318 
Another factor affecting HRQoL in this study may be the low socioeconomic status and the 
stress that accompanies it. It has been found that stress in populations of low economic 
status may adversely affect health.319 This is supported by the findings of a negative 
relationship between socioeconomic status and the prevalence of health problems316 and 
the association between socioeconomic status and HRQoL.314 This may be suggestive of 
health inequality that favours the wealthy,316 but this was not explored in this study. 
 
5.6 Limitations and Recommendations 
There are several limitations to this study.  
As the sample was limited to adults attending a CHC, the results of this study may not be 
generalisable to adults in the community who do not attend the CHC. The prevalence of 
MSD and CDL is likely to be higher in this study than in the general population. However, as 
these are the adults who are likely to access intervention for MSD, the choice of sample is 
defensible. 
As this is a cross-sectional study, no conclusions may be drawn on causal relationships of 
MSD or CDL. Therefore, it is unclear which conditions influence MSD and, conversely, which 
conditions are influenced by MSD. These causal relationships are recommended to be 
expanded upon in further research which would need to be longitudinal to better examine 
the development of the different conditions over the adult life span. 
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No further investigation was done to determine what “other” CDL could have been. With 
the South African context, a large contribution could be attributed to HIV/AIDS due to its 
high prevalence in sub-Saharan Africa. 
The results of this study suggest that more holistic, self-management driven interventions, 
for both MSD and CDL, should be implemented within the primary health care sector of 
South Africa. This should focus on preventing and managing risk factors identified in this 
study. Good quality intervention studies need to be implemented to pilot such 
management strategies to determine its effectiveness and feasibility before implementing 
it across primary health care centres in South Africa. 
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines267 were used as a benchmark for evaluating study limitations. The guideline 
criteria are presented below in Table 29, indicating how these were addressed in the study. 
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Table 29: Evaluation of this study in relation to STROBE guidelines for cross-sectional studies 
Item Item No Recommendation Section where this is addressed 
Title and abstract 1 Indicate the study’s design with a commonly used term in the title or the abstract 
Provide in the abstract an informative and balanced summary of what was done and 
what was found 
Abstract 
  
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Section 1.1 
Objectives 3 State specific objectives, including any prespecified objectives Section 1.3.2 
Methods  
Study Design 4 Present key elements of study design early in the paper Section 3.2 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Study setting is described in Section 1.5 
Periods of recruitment and data 
collection are described in Sections 3.5 
and 3.6 
Participants 6 Give the eligibility criteria, and the sources and methods of selection of participants Section 3.3 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Section 3.6 
Data 
sources/measurements 
8* For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
Section 3.6 
Bias 9 Describe any efforts to address potential sources of bias N/A 
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Item Item No Recommendation Section where this is addressed 
Study size 10 Explain how the study size was arrived at Section 3.3.1 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
Section 3.6 
Statistical methods 12 Describe all statistical methods including those used to control for confounding Section 3.6 
  Describe any methods used to examine subgroups and interactions Section 3.6 
  Explain how missing data were addressed N/A 
  If applicable, describe analytical methods taking account of sampling strategy N/A 
  Describe any sensitivity analyses N/A 
Results 
Participants 13* Report numbers of individuals at each stage of study – e.g. numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in study, completing follow-up, and 
analysed 
Section 4.2 
  Give reasons for non-participation at each stage Section 4.2 
  Consider use of a flow diagram Section 4.2 
Descriptive data 14* Give characteristics of study participants (e.g. demographic, clinical, social) and 
information on exposures and potential confounders 
Section 4.3 
  Indicate number of participants with missing data for each variable of interest Section 4 
Outcome data 15* Report numbers of outcome events or summary measures Section 4 
Main results 16 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for 
Section 4 
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Item Item No Recommendation Section where this is addressed 
and why they were included 
  Reported category boundaries when continuous variables were categorized Section 4 
  If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
N/A 
Other analyses 17 Report other analyses done – eg analyses of subgroups and interactions, and sensitivity 
analyses 
Section 4 
Discussion 
Key results 18 Summarise key results with reference to study objectives Section 4.11 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias. 
Section 5.6 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from the similar studies, and other relevant evidence 
Section 5 
Generalisability 21 Discuss the generalisability (external validity) of the study results Section 5 and 6 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based. 
Abstract 
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6 CONCLUSIONS AND RECOMMEDATIONS 
6.1 Brief Description of the Study and the Most Important 
Results 
There is inadequate South African evidence regarding the inter-relationships between 
musculoskeletal disease (MSD), chronic diseases of lifestyle (CDL), obesity and physical 
activity levels. This highlights a gap in research as management may not be targeted 
appropriately at risk factors and thus may not reduce the high prevalence rates of MSD. 
The main aim of this study was thus to determine the patterns of onset of MSD, CDL and 
risk factors across gender and six age categories (i.e. 18-29 years, 30-39 years, 40-49 years, 
50-59 years, 60-69 years, and 70 years and older), in patients receiving medical services at 
a community health centre (CHC) in Mitchells Plain, South Africa. 
A descriptive, cross-sectional, analytical study design was used at primary health care level 
at a CHC in Cape Town, South Africa. All males and females, aged 18 years and older, 
except those who were pregnant or unable to answer the English, Afrikaans, or isiXhosa 
versions of questionnaires, were eligible to participate. The outcome measures were the 
Community Orientated Program for Control of Rheumatic Diseases (COPCORD) 
questionnaire, the Brief Pain Inventory (BPI), the European Quality of Life-5 Dimensions 
(EQ-5D) questionnaire, the International Physical Activity Questionnaire (IPAQ), and 
anthropometric measures of weight, height, and waist and hip circumference. Data were 
collected via interview and responses were captured by online questionnaires on mobile 
devices using mobile data collection application Magpi by DataDyne Group, LLC. 
Anthropometric measurements were taken as well. Data were exported to Microsoft Office 
Excel spreadsheets for descriptive and inferential statistical analysis. Ethical permission was 
obtained from the University of Cape Town. 
This study recruited 1115 participants, with a mean age of 48.7 ± 16.8 years. A prevalence 
rate of 33.3% for acute MSD and 42.9% for chronic MSD was found, with a significant 
association found between gender and MSD (p<0.01). The most common sites of chronic 
MSD were knees (35.6%), low back/pelvis (33.8%), shoulders (26.8%), and hands/fingers 
(21.9%). Of those with MSD, exercise was reported as the best management strategy for 
MSD (37.4%). Hypertension was the most prevalent CDL in both genders, followed by type 
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2 diabetes mellitus and hypercholesterolaemia. All chronic diseases except chronic 
obstructive airway disease (COAD) continually increased with age, while COAD and both 
acute and chronic MSD peaked around the 50-59 year old age category and then decreased 
with age. Significant differences (p<0.01) were found between anthropometric 
measurements of those with MSD and those without.  
Multivariate analysis using Chi-Square Automatic Interaction Detector (CHAID) indicated 
that the association between MSD and other CDL fell away once age categories were 
entered in to the analysis. In fact, the primary association was with age. In other words, the 
comorbidity appears to be due almost entirely to the aging process, rather than the mutual 
influence that MSD and other CDL (such as type 2 diabetes mellitus or hypertension) might 
have. The reason that bivariate associations were detected is because they all become 
more prevalent with age. Thus, given the cross-sectional nature of this study we were not 
able to infer causation and it is clear that “correlation does not imply causation” in this 
study. 
With regard to risk factors, it was hypothesised that there was a cycle in which MSD might 
result in reduced physical activity and this, in turn, would increase BMI and the increased 
BMI would result in increased MSD. However, there was no evidence of any of the factors 
preceding or trailing each other or even displaying an association with MSD (apart from 
hypercholesterolaemia). With regard to risk factors, smoking was associated with MSD in 
the younger participants. However, the numbers who smoked and had MSD were small. Of 
interest, physical activity was only associated with MSD among those in the 30-49 years of 
age categories and low levels of physical activity were associated with MSD. This is the 
group that has a prevalence of 41%, compared to the prevalence of 69% in the 40-59 age 
bracket. There might thus be a window of opportunity and increasing physical activity 
levels in this group might result in a decrease in the rate of MSD in the older age group. 
However, although it is not possible to determine if this was due to reduced activity due to 
pain, it is important to increase activity in this group as there is evidence that increased 
activity can reduce pain in chronic MSD.  
The only factor that emerged as being predictive in the group with the highest prevalence, 
the 40-59 categories was gender. Although gender is clearly not modifiable, this finding 
should inform the development of culturally appropriate intervention strategies.  
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6.2 Recommendations 
6.2.1 Management 
Although it was not possible to detect any evidence supporting causation, the co-existence 
of chronic MSD, comorbid CDL and risk factors, such as high BMI and low physical activity, 
does highlight the need for holistic care to address the multiple problems that the adults, 
and specifically older patients, who attend community health centres experience. The 
impact of chronic MSD is large, both in terms of prevalence and impact on health-related 
quality of life (HRQoL).  
The small number reporting non-pharmaceutical intervention indicates that there is a need 
to provide multi-disciplinary care, including physiotherapists and dietitians. It would appear 
that physiotherapists have a pivotal role in the management of MSD and CDL. 
The primary target groups with chronic MSD at community health centres are females, 
between the ages of 40-59 years and, to a lesser extent, males above the age of 40 years. 
About one third will have low physical activity levels, while three quarters will be 
overweight or obese and nearly a quarter extremely obese. They are likely to have 
comorbid hypertension, type 2 diabetes mellitus, hypercholesterolaemia, and, to a lesser 
extent COAD. They have moderate levels of pain and the chronic MSD is reducing their 
HRQoL considerably. 
Interventions that are tailored to meet the profile of those with chronic MSD should be 
designed. The patients are likely to be drawn from reduced socio-economic backgrounds 
and the cost of travel to and from the clinic and the opportunity cost of attending multiple 
clinics needs to be considered. The management of chronic MSD should thus focus on the 
most effective and affordable intervention strategies and healthcare systems and coherent 
policies for dealing with chronic MSD should be developed. This management should not 
only be based on a pharmacological model but on biopsychosocial integration emphasising 
self-management. A programme developed within a community health centre in the Free 
State320 which consisted of a weekly educational programme utilising a workbook, 
discussion group and exercise class could serve as a model. 
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6.2.2 Research 
There were several limitations to the current study, including the recruitment of 
participants who had already accessed the health system through the community health 
centre. Another shortcoming was that the study was cross-sectional and not longitudinal 
which limits the conclusions that can be drawn from the data. As MSD and CDL are 
contributing increasingly to the burden of disease, both in terms of prevalence and impact 
on HRQoL, large scale epidemiological research is warranted to further understand the 
complex relationships between the comorbidities and the risk factors. It is thus 
recommended that future research should use a longitudinal design which would help to 
unravel the issue of causality and correlation. In addition, the research should be 
community-based rather than facility-based to obtain a true estimate of the prevalence of 
these conditions within the wider community. 
The decrease in prevalence and decrease in decline of HRQoL after the age of 60 also needs 
to be investigated. This study was not able to identify the reasons for the improvement at 
this age and it might be useful to investigate this further. 
Although there has been at least one culturally appropriate intervention study trialled in 
South Africa, the sample size was small.13,320 Although a positive effect was reported on 
HRQoL, the study was underpowered to detect other changes that might have taken place.  
Further research into appropriate models of holistic care need to be undertaken within 
CHCs to establish which intervention strategies are cost-effective. 
6.2.3 Policy 
The implications of these findings at a policy level include the need to consider chronic 
MSD as a CDL and that the management of CDL and MSD should be offered as part of a 
horizontal rather than vertical programme which encompasses more than simply the 
prescription of medication. CDL clinics should be structured to provide integrated holistic 
care, which includes management of the symptoms, such as pain and reduced mobility, as 
well as pharmacological treatment.  
There is need to employ more physiotherapists and other disciplines, such as dietitians, at 
the community health centre level so that culturally appropriate and effective programmes 
can be developed and implemented. 
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6.3 Conclusion 
This study highlights the effect of the aging process on the development of MSD and CDL. 
The prevalence of chronic MSD is high, especially in females between the ages of 40 and 59 
years. The co-existence of chronic MSD, comorbid CDL, and risk factors highlight the need 
for holistic care to address the multiple problems that the adults, and specifically older 
patients, who attend community health centres experience. The management of chronic 
MSD should focus on the most effective and affordable intervention strategies and 
healthcare systems, and coherent policies for dealing with chronic MSD should be 
developed. This management should not only be based on a pharmacological model but on 
biopsychosocial integration emphasising self-management. 
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8.2 Appendix II: Letter to WCDOH Research Committee 
Western Cape Department of Health 
Western Cape Health Research Committee 
To whom it may concern: 
RE: Requesting permission to conduct a research study 
I, Carmen Britz, am currently doing my MSc in Physiotherapy at the Department of Health 
and Rehabilitation Sciences at the University of Cape Town. I would like to inform you 
about the research study that I wish to conduct in people with musculoskeletal disease 
(MSD) and chronic diseases of lifestyle (CDL) attending community health centres (CHCs) in 
Cape Town.   
Background:  
Musculoskeletal disease is the most common cause of severe chronic pain, functional 
limitations and physical disability, affecting 20-50% of adults and is becoming even more 
prevalent over time. Literature highlighted that subjects with MSD have been diagnosed 
with chronic diseases of lifestyle (CDL) such as diabetes mellitus (type 2), hypertension and 
heart disease (Parker and Jelsma, 2010). Even though the interactions between MSD and 
CDL are not well understood in a South African context, it is currently a huge health 
problem for health professionals and the government, highlighting the need for further 
investigation.  
Thus, the title of my study is: 
“A cross-sectional investigation into the risk factors of musculoskeletal diseases and the 
association between chronic diseases of lifestyle in an under-resourced area of the Cape 
Town Metropole” 
The research questions are therefore:   
• What is the prevalence and types of MSD in adult males and females across six age 
categories (i.e. 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 
70 years and older) attending a CHC in Cape Town? 
• What comorbidities and risk factors occur in the population? 
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• At which age is the onset of MSD and CDL? 
• Are these comorbidities associated with MSD? 
• What are the management and treatment strategies for MSD and CDL? 
• What is the health-related quality of life in population with MSD and/or CDL? 
• What is the impact and association of MSD and CDL on health-related quality of life 
across various age categories? 
• What is the self-reported level of physical activity in the population with MSD? 
• Is the self-reported level of activity associated with MSD and/or identified 
comorbidities? 
• What is the self-reported level of physical activity in the population with MSD? 
• Is the self-reported level of activity associated with MSD and/or identified 
comorbidities? 
The aim for this project is to determine the patterns of onset of musculoskeletal diseases, 
chronic diseases of lifestyle and risk factors across six age categories (i.e. 18-29 years, 30-39 
years, 40-49 years, 50-59 years, 60-69 years, and 70 years and older), in patients attending 
medical services at a community health centre in Cape Town, South Africa. 
The specific objectives of the study are: 
• To determine proportions of people with musculoskeletal diseases and chronic 
diseases of lifestyle across different age categories ranging from 18 years and older 
at a community health centre in Cape Town, South Africa, to establish how these 
change over the adult lifespan. 
• To determine the proportion of people with musculoskeletal diseases and pain 
related to chronic diseases of lifestyle in men and women aged 18 years and older, 
attending medical services at a community health centre in Cape Town, South 
Africa, using the Brief Pain Inventory (BPI) and an adapted version of the COPCORD 
questionnaire. 
• To determine the proportion of people with chronic diseases of lifestyle such as 
hypertension, diabetes mellitus type II and cardiovascular disease occurring in a 
population attending medical services at a community health centre in Cape Town, 
South Africa.  
• To determine the association between risk factors, such as age, gender, obesity, 
occupations, and social habits such as smoking, musculoskeletal diseases and 
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chronic diseases of lifestyle occurring in a population attending a community health 
centre in Cape Town, South Africa. 
• To determine the physiotherapy and medical management and treatment of MSD 
and CDL in a population with musculoskeletal diseases and chronic diseases of 
lifestyle at a community health centre in Cape Town, South Africa. 
• To determine the health-related quality of life and health index score, using the 
EQ5D, of people with and without MSD and CDL in a population attending a 
community health centre in Cape Town, South Africa. 
• To determine the association between the health-related quality of life and health 
index score and MSD and CDL across the different age categories in a population 
attending a community health centre in Cape Town, South Africa. 
• To determine whether self-reported physical activity levels are associated with 
MSD and chronic diseases of lifestyle through investigating the level of self-
reported physical activity, using the IPAQ (International Physical Activity 
Questionnaire), in a population at a community health centre in Cape Town, South 
Africa. 
• To explore the relationships between musculoskeletal diseases, chronic diseases of 
lifestyle and identified risk factors by establishing whether there are clusters of 
chronic diseases in a population at a community health centre in Cape Town, South 
Africa. 
Stratified age sampling will be used to recruit males and females, aged 18 years and older, 
attending the medical services at the selected CHC’s. The first person in waiting area will be 
approached, informed about the study, and asked to disclose their age. This will continue 
until the quota per age group, as aforementioned, has been reached. They will be required 
to give informed consent and understand English, Afrikaans or isiXhosa to participate in the 
study. Participants who are pregnant or who are unable to complete either the English, 
Afrikaans, or isiXhosa versions of the questionnaires will be excluded. 
Assessments: 
The following outcome measures will be used when collecting data: 
• Brief Pain Inventory (BPI) and adapted COPCORD questionnaires to screen for MSD 
and CDL. 
• EQ-5D as a self-report of health-related quality of life. 
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• International Physical Activity Questionnaire (IPAQ) as a self-report of physical 
activity. 
• Anthropometric measures of weight (in kilograms) and height (in metres) for 
calculation of body mass index (BMI); waist and hip circumference, relevant for 
classification of obesity, a possible risk factor. 
Ethical Considerations 
The study will conform to the principles of the Declaration of Helsinki (Fortaleza, Brazil, 
2013). Ethical approval has been obtained from the Faculty of Health Sciences, University 
of Cape Town. All information obtained from the primary health care facilities and 
participants will be kept confidential and their identity will be anonymous and will only be 
used for statistical analysis and writing of results. All stakeholders will be acknowledged 
with all publications and conference proceedings. The findings of the study will be 
disseminated to you and respective departments. 
 
I would like to request permission to access the community health centres in the Cape 
Town Metropole region from May 2014 up until December 2015. This is only an estimated 
timeframe for data collection, but should my study be completed before hand, a 
notification will for forwarded to your department. Annual reports on the progress of my 
study will be forwarded to all stakeholders involved. I also would like to request permission 
to obtain medical information from the folders of the participants involved in the study to 
confirm the self -reported information about the medical history and treatment received at 
the CHC. Lastly, I would like to request permission to make use of the resources 
(examination rooms to do baseline testing) available at the CHC to conduct my study. 
Please be advised that the intention of my study is not to affect service delivery negatively 
but to assist in establishing the burden of chronic diseases in order to develop a 
comprehensive rehabilitation model of care for MSD and CDL. As principle investigator, I 
will ensure the smooth running of services provided at the facility by managing all 
researchers and data collection processes. I have attached a copy of my research proposal 
if you require any additional information regarding my study. 
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I look forward to hearing from you and your assistance is greatly appreciated.   
Sincerely  
Ms Carmen Britz (MSc candidate)   
 
Email: carmenbritzphysio@gmail.com 
 
Supervisors: 
Ms Candice Hendricks: candice.hendricks@uct.ac.za 
Prof J Jelsma: jennifer.jelsma@uct.ac.za 
 
Prof. M Blockman (Human Research Ethics Committee, Faculty of Health Sciences,) 
marc.blockman@uct.ac.za 
Tel: 021-406-6626  
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8.3 Appendix III: Letter to Facility Manager at CHC 
Community Health Centre X 
Facility Manager  
To whom it may concern: 
RE: Requesting permission to conduct a research study 
I, Carmen Britz, am currently doing my MSc in Physiotherapy at the Department of Health 
and Rehabilitation Sciences at the University of Cape Town. I would like to inform you 
about the research study that I wish to conduct in people with musculoskeletal disease 
(MSD) and chronic diseases of lifestyle (CDL) attending community health centres (CHCs) in 
Cape Town.   
Background:  
Musculoskeletal disease is the most common cause of severe chronic pain, functional 
limitations and physical disability, affecting 20-50% of adults and is becoming even more 
prevalent over time. Literature highlighted that subjects with MSD have been diagnosed 
with chronic diseases of lifestyle (CDL) such as diabetes mellitus (type 2), hypertension and 
heart disease (Parker and Jelsma, 2010). Even though the interactions between MSD and 
CDL are not well understood in a South African context, it is currently a huge health 
problem for health professionals and the government, highlighting the need for further 
investigation.  
Thus, the title of my study is: 
“A cross-sectional investigation into the risk factors of musculoskeletal diseases and the 
association between chronic diseases of lifestyle in an under-resourced area of the Cape 
Town Metropole” 
The research questions are therefore:   
• What is the prevalence and types of MSD in adult males and females across six age 
categories (i.e. 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 
70 years and older) attending a CHC in Cape Town? 
• What comorbidities and risk factors occur in the population? 
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• At which age is the onset of MSD and CDL? 
• Are these comorbidities associated with MSD? 
• What are the management and treatment strategies for MSD and CDL? 
• What is the health-related quality of life in population with MSD and/or CDL? 
• What is the impact and association of MSD and CDL on health-related quality of life 
across various age categories? 
• What is the self-reported level of physical activity in the population with MSD? 
• Is the self-reported level of activity associated with MSD and/or identified 
comorbidities? 
• What is the self-reported level of physical activity in the population with MSD? 
• Is the self-reported level of activity associated with MSD and/or identified 
comorbidities? 
The aim for this project is to determine the patterns of onset of musculoskeletal diseases, 
chronic diseases of lifestyle and risk factors across six age categories (i.e. 18-29 years, 30-39 
years, 40-49 years, 50-59 years, 60-69 years, and 70 years and older), in patients attending 
medical services at a community health centre in Cape Town, South Africa. 
The specific objectives of the study are: 
• To determine proportions of people with musculoskeletal diseases and chronic 
diseases of lifestyle across different age categories ranging from 18 years and older 
at a community health centre in Cape Town, South Africa, to establish how these 
change over the adult lifespan. 
• To determine the proportion of people with musculoskeletal diseases and pain 
related to chronic diseases of lifestyle in men and women aged 18 years and older, 
attending medical services at a community health centre in Cape Town, South 
Africa, using the Brief Pain Inventory (BPI) and an adapted version of the COPCORD 
questionnaire. 
• To determine the proportion of people with chronic diseases of lifestyle such as 
hypertension, diabetes mellitus type II and cardiovascular disease occurring in a 
population attending medical services at a community health centre in Cape Town, 
South Africa.  
• To determine the association between risk factors, such as age, gender, obesity, 
occupations, and social habits such as smoking, musculoskeletal diseases and 
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chronic diseases of lifestyle occurring in a population attending a community health 
centre in Cape Town, South Africa. 
• To determine the physiotherapy and medical management and treatment of MSD 
and CDL in a population with musculoskeletal diseases and chronic diseases of 
lifestyle at a community health centre in Cape Town, South Africa. 
• To determine the health-related quality of life and health index score, using the 
EQ5D, of people with and without MSD and CDL in a population attending a 
community health centre in Cape Town, South Africa. 
• To determine the association between the health-related quality of life and health 
index score and MSD and CDL across the different age categories in a population 
attending a community health centre in Cape Town, South Africa. 
• To determine whether self-reported physical activity levels are associated with 
MSD and chronic diseases of lifestyle through investigating the level of self-
reported physical activity, using the IPAQ (International Physical Activity 
Questionnaire), in a population at a community health centre in Cape Town, South 
Africa. 
• To explore the relationships between musculoskeletal diseases, chronic diseases of 
lifestyle and identified risk factors by establishing whether there are clusters of 
chronic diseases in a population at a community health centre in Cape Town, South 
Africa. 
Stratified age sampling will be used to recruit males and females, aged 18 years and older, 
attending the medical services at the selected CHC’s. The first person in waiting area will be 
approached, informed about the study, and asked to disclose their age. This will continue 
until the quota per age group, as aforementioned, has been reached. They will be required 
to give informed consent and understand English, Afrikaans or isiXhosa to participate in the 
study. Participants who are pregnant or who are unable to complete either the English, 
Afrikaans, or isiXhosa versions of the questionnaires will be excluded. 
Assessments: 
The following outcome measures will be used when collecting data: 
• Brief Pain Inventory (BPI) and adapted COPCORD questionnaires to screen for MSD 
and CDL. 
• EQ-5D as a self-report of health-related quality of life. 
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• International Physical Activity Questionnaire (IPAQ) as a self-report of physical 
activity. 
• Anthropometric measures of weight (in kilograms) and height (in metres) for 
calculation of body mass index (BMI); waist and hip circumference, relevant for 
classification of obesity, a possible risk factor. 
Ethical Considerations 
The study will conform to the principles of the Declaration of Helsinki (Fortaleza, Brazil, 
2013). Ethical approval has been obtained from the Faculty of Health Sciences, University 
of Cape Town. All information obtained from the primary health care facilities and 
participants will be kept confidential and their identity will be anonymous and will only be 
used for statistical analysis and writing of results. All stakeholders will be acknowledged 
with all publications and conference proceedings. The findings of the study will be 
disseminated to you and respective departments. 
 
I would like to request permission to access the community health centres in the Cape 
Town Metropole region from May 2014 up until December 2015. This is only an estimated 
timeframe for data collection, but should my study be completed before hand, a 
notification will for forwarded to your department. Annual reports on the progress of my 
study will be forwarded to all stakeholders involved. I also would like to request permission 
to obtain medical information from the folders of the participants involved in the study to 
confirm the self -reported information about the medical history and treatment received at 
the CHC. Lastly, I would like to request permission to make use of the resources 
(examination rooms to do baseline testing) available at the CHC to conduct my study. 
Please be advised that the intention of my study is not to affect service delivery negatively 
but to assist in establishing the burden of chronic diseases in order to develop a 
comprehensive rehabilitation model of care for MSD and CDL. As principle investigator, I 
will ensure the smooth running of services provided at the facility by managing all 
researchers and data collection processes. I have attached a copy of my research proposal 
if you require any additional information regarding my study. 
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I look forward to hearing from you and your assistance is greatly appreciated.   
Sincerely  
 
Ms Carmen Britz (MSc candidate)   
 
Email: carmenbritzphysio@gmail.com 
 
Supervisors: 
Ms Candice Hendricks: candice.hendricks@uct.ac.za 
Prof J Jelsma: jennifer.jelsma@uct.ac.za 
 
 
Prof. M Blockman (Human Research Ethics Committee, Faculty of Health Sciences,) 
marc.blockman@uct.ac.za 
Tel: 021-406-6626  
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8.4 Appendix IV: Information Sheet for Participants 
 
 
  
 
 
 
University of Cape Town 
Division of Physiotherapy  
Department of Health and Rehabilitation Sciences 
  
Dear Participant: 
 
I am a physiotherapist, doing postgraduate studies at the Department of Health and 
Rehabilitation Sciences at the University of Cape Town. I am interested in finding out if you 
suffer from joint or muscle pain, and/or other chronic health problems (high blood 
pressure, sugar). People who have pain or stiffness may find it difficult to move around the 
house or at work. Sometimes these conditions can be the cause of gaining weight and can 
stop you from doing physical activities such as walking or participating in sport.  I want to 
find out how these conditions are related, and at what age these conditions start to 
develop and impact your life. This information will help me and future researchers to 
understand the relationships between joint and/or muscle pain and some chronic health 
problems. 
 
 
INFORMATION LEAFLET 
ABOUT THE STUDY 
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The topic of my study is: 
“A cross-sectional investigation into the risk factors of musculoskeletal diseases and the 
association between chronic diseases of lifestyle in an under-resourced area of the Cape 
Town Metropole” 
 
This study is being done on people older than 18 years who are attending the Mitchells 
Plain community health centre. The Mitchells Plain health district serves around 13.6 % of 
the Cape Town population and has been identified as an under-resourced area of the City. 
The community health centre attends to around 9230 patients per week, making it one of 
the busiest community health centres in the city. This is why I have decided to do this study 
here. 
 
On the days when data are scheduled to be collected, the first person in waiting area will 
be approached, informed about the study, and asked their age. This will carry on until the 
total number of participants has been reached. Taking part is completely voluntary, so you 
do not have to take part if you don’t want to. 
 
If you volunteer to participate, you will be asked to complete three questionnaires which 
will determine if you have musculoskeletal and chronic diseases, the kind of physical 
activities you do during your week and questions about the pain you feel because of your 
chronic diseases. A researcher will help you with the questionnaires which you can answer 
in English, Afrikaans, or isiXhosa. The questionnaires are electronic and must be answered 
on tablets because they are on the internet in an application called Magpi. This application 
will help me to keep all information organised and will be very well protected. Only I will 
have access to the application. Once I have finished collecting all the information needed, I 
will transfer it to Microsoft Excel and it will then no longer be on the internet. This should 
take about 3-6 months. 
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After answering the questionnaires, a researcher will escort you to a room to measure your 
height, weight, waist and hip measures. These measurements must be done over your 
underwear or one layer of clothing, so you might have to undress. Someone will be sitting 
in your place to avoid losing your place in the queue. Your medical folder will only be 
checked to confirm any medical diagnosis. This study does require some time (30-45 
minutes) from all participants. 
 
There is no direct benefit to you for taking part in this study. I may be able to offer some 
physiotherapy advice on how to manage your health condition and improve function and 
refer you to the most applicable health professional if necessary. 
 
There are no potential risks involved. All tests are safe and valid. Measurements and 
instruments are reliable.  You will receive no money to take part in the survey and 
measurements. 
Please feel free to ask any questions about the study. You have the right to withdraw at any 
time during the interview with no penalties (that means it will not negatively influence any 
current or future health care at the community health centre). Please remember that 
participation is voluntary.  
Confidentiality and privacy of participants will be ensured. All your personal information 
will be coded with only general information such as gender, age and your health conditions 
being available to other researchers. I understand the importance of confidentiality and 
respect your privacy.  
  
What if something goes wrong? 
The University of Cape Town (UCT) has insurance cover for the event that research-related 
injury or harm results from your participation in the trial. The insurer will pay all reasonable 
medical expenses in accordance with the South African Good Clinical Practice Guidelines 
(DoH 2006), based on the Association of the British Pharmaceutical Industry Guidelines 
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(ABPI) in the event of an injury or side effect resulting directly from your participation in 
the trial. You will not be required to prove fault on the part of the University. 
 By agreeing to participate in this study, you do not give up your right to claim 
compensation for injury where you can prove negligence, in separate litigation. In 
particular, your right to pursue such a claim in a South African court in terms of South 
African law must be ensured. Note, however, that you will usually be requested to accept 
that payment made by the University under the SA GCP guideline 4.11 is in full settlement 
of the claim relating to the medical expenses.  
An injury is considered trial-related if, and to the extent that, it is caused by study activities. 
You must notify the study doctor immediately of any side effects and/or injuries during the 
trial, whether they are research-related or other related complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your injury 
came about because you chose not to follow the instructions that you were given while you 
were taking part in the study. Your right in law to claim compensation for injury where you 
prove negligence is not affected. Copies of these guidelines are available on request. 
 
If you want to ask me anything before we start with the questions, or later on, please 
phone or text me, Ms Carmen Britz, at 081 336 1233, or my supervisors, who are also 
involved in the study. 
Supervisors:   
Ms Candice Hendricks: 021 406 6382 
Professor Jennifer Jelsma: 021 406 6595 
 
If you have any problems or want to know more about the study or want to report anything 
that you feel unhappy about, please contact:  
Professor Marc Blockman, the chairperson of the Human Research Ethics Committee, 
Faculty of Health Sciences, University of Cape Town (contact number: 021 406 6411).   
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8.5 Appendix V: Informed Consent 
 
 
  
 
University of Cape Town 
Division of Physiotherapy  
Department of Health and Rehabilitation Sciences 
 
Topic of study: 
“A cross-sectional investigation into the risk factors of musculoskeletal diseases and the 
association between chronic diseases of lifestyle in an under-resourced area of the Cape 
Town Metropole” 
 
I __________________________________________ have been approached to take part in 
a research study. 
 
 
I have been informed regarding the study by the researchers from the Division of 
Physiotherapy of the University of the Cape Town. 
 
 
I may contact any of the following researchers if I have any queries/questions regarding the 
study: 
Ms Carmen Britz – 081 336 1233   
Supervisor: Ms Candice Hendricks – 084 751 6692 
CONSENT TO PARTICIPATE IN STUDY  
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I may contact Prof Blockman at the Human Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (contact number: 021 – 406 6411) if I have any queries 
regarding my rights as research participant.  
 
Taking part in the study is purely voluntary and I will not be punished or lose benefits at the 
community health centre if I refuse to take part or decide to stop taking part. 
 
If I agree to take part, I will be given a signed copy of consent to take part in the study, as 
well as the participant information sheet, which is a written summary of the research. 
 
I hereby grant permission to take part in the study and for my height, weight, waist and hip 
measures to be taken by the researcher.  I hereby grant permission for the researchers to 
view my personal records in my medical folder as well. 
 
The research study, including the above information has been verbally described to me.  
I understand what my involvement in the study means and I voluntarily agree to 
participate. 
 
____________________     ______________________ 
Signature of Participant                       Date 
 
 
____________________     ______________________ 
Signature of Witness (if necessary)                     Date 
 
____________________     ______________________ 
Signature of Researcher                       Date 
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8.6 Appendix VI: Musculoskeletal Conditions and Chronic 
Disease Questionnaire (adapted from COPCORD) 
 
This questionnaire is for anyone attending Community Health Centres. 
 
This questionnaire is about chronic joint pain, obesity, hypertension and type 2 diabetes 
mellitus. 
 
This questionnaire is completely voluntary. You may choose not to participate or not to 
answer any specific question.  
               
This questionnaire is completely anonymous.   
 
The data will be used to develop a health promotion programme. 
 
               
INSTRUCTIONS 
 
Select only one response unless instructed otherwise. 
 
Please tick the appropriate answer e.g.  □     or circle one correct answer where indicated. 
 
Thank you very much for your co-operation. 
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ID code _ _ _ _ _ __ _ _ 
Date: _ _ _ _ _ __ _ __ _ _ _ _ __ _ __ _ _ _ _ __ _ _ 
Community Health Centre: _ _ _ _ _ __ _ __ _ _ _ _ __ _ __ _ _ _ _ __ _  
 
PHASE I:  
 
(Q1 – Q7 are used for screening of MSD and CDL) 
 
1. Age:  _ _ __ _ _ _  years old  OR  Date of birth: _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ 
 
2a.  Do you have a diagnosed musculoskeletal problem in the joints or spine? 
□ No   □ Yes  
 
2b.  If yes, do you attend the rehabilitation/ exercise classes at physiotherapy? 
□ No   □ Yes  
 
3a.  Do you suffer from chronic diseases of lifestyle? 
□ No   □ Yes  
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3b.  If yes, please tick the chronic diseases that you suffer from. 
□ Cancer               □ Sugar (Diabetes Mellitus Type I)     
□ Cardio-vascular diseases (Coronary heart disease)  
□ Depression             □ Chronic respiratory disease          
□ High blood pressure (Hypertension) 
□ Other      
 
4. Do you attend the chronic care club at the day hospital? 
□ No   □ Yes  
 
5. Literacy in home language: 
□ Read only                          □ Read and write 
□ None               
 
6.  Do you suffer from any of the following acute illnesses/ injuries today? 
□ cold/ flu                □ gastroenteritis,                           
□ diarrhoea                □ infection  
□ acute musculoskeletal injuries (muscle pain, sprain)              
 
7.  Do you have any of the following conditions/ impairments: 
□ neurological conditions (stroke, spinal cord injury) □ fractures                           
□ intellectual/ cognitive impairments      
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THE FOLLOWING QUESTIONS ASK ABOUT YOUR PERSONAL DATA AND MEDICAL HISTORY  
 
DEMOGRAPHIC INFORMATION: 
 
8. Gender 
□ Male    □ Female 
 
9.  Home language:    
□ Afrikaans               □ English                
□ isiXhosa              □ Other  
 
10. Marital status: 
□ Single    □ Married               
□ Separated / divorced                □ Widowed  
□ Live with partner 
 
11.     Children: 
□ None    □ 1 child 
□ 2 children   □ 3 children 
□ More than 3 children 
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12. Highest level of education: 
□ No schooling                          □ Grades 10 to 12 
□ Grades R to 3   □ College, university or technicon 
□ Grades 4 to 6 
□ Grades 7 to 9 
 
13. Current job: 
□ Housewife   □ Teacher 
□ Desk job   □ Work at shop or business 
□ Factory worker  □ Domestic worker 
□ Military   □ Police 
□ Retired   □ Unemployed 
□ Other  
 
14.  If you are working, describe the nature of your work:  
□ Light  
□ Moderate  
□ Heavy  
□ Other 
 
15a.   If you are not working, did you stop working due to any illness/ injury?  
□ No   □ Yes   
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15b.  If Yes, please specify:  
□ Musculoskeletal condition (stiff joints/ spine)  □ Chronic diseases 
□ Accident/ traumatic Injury      □ Physical disability 
□ Other Illness 
 
16a.  Have you changed work due to any illness/ injury?  
□ No   □ Yes  
 
16b.  If Yes, please specify:  
□ Musculoskeletal condition (stiff joints/ spine)  □ Chronic diseases  
□ Accident/traumatic Injury      □ Physical disability 
□ Other Illness  
 
17. Do you receive a government pension or grant? 
□ Yes   □ No 
 
18. Monthly income: 
______________________________ 
 
19. Are you the only provider for the family (breadwinner)? 
□ Yes   □ No 
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20. History of smoking: 
□ Never smoked  □ Stopped smoking 
□ Currently smoke  
□ If smoking, how many cigarettes per day? _ _ _ _ _ _ _ _ _ _ __ _ _ _ _  
□ If smoking, at what age did you start?  _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _  
 
21. History of alcohol use: 
□ Never used alcohol   □ Currently drinking alcohol  
□ Stopped drinking alcohol    
□ If drinking alcohol, how many times per week do you drink? _ _ _ _ _ _ _ _ _ _ 
□ If drinking alcohol, at what age did you start?  _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _  
 
THE FOLLOWING QUESTIONS ASK ABOUT YOUR HEALTH: 
 
22. Have you been diagnosed with any of these chronic diseases? 
□ High blood (Hypertension)    □ Sugar (Diabetes Mellitus Type 2)                           
□ Obesity (overweight)     □ Cholesterol (hyperlipidaemia)             
   
 
23. How long (months/years) have you been diagnosed with these conditions? 
High blood _________     Sugar ________________                           
Obesity ___________   Cholesterol ___________           
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 24. Did you use medication for these chronic diseases in the last 3 months? 
□ Yes      □ No                           
 
25. If yes, what medication did you use? 
□ Over the counter pain killers                               
□ Prescribed medication for high blood pressure 
□ Prescribed medication for diabetes 
□ Prescribed medication for high cholesterol 
□ Natural remedies, herbs, supplements                           
□ Other  
 
26a. Do you use the prescribed medication on a regular basis as advised? 
□ Yes      □ No 
  
26b. If no, what is the reason for not taking the medication on time? 
□ I don’t like taking too many pills  
□ I forget  
□ Some tablets make me feel sick, drowsy or sleepy 
□ Other reason  
 
27a. Were you involved in a traumatic accident before? 
□ Yes      □ No 
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27b.  If yes, how did the accident occur?  
□ Vehicle    □ Agriculture / Field  
□ Industrial    □ Violence 
□ Fall     □ Other 
 
28a.  Nature of traumatic injury 
□ Fracture   □ Sprain 
□ Paralysis   □ Other 
 
28b.  Result of traumatic injury 
□ Cured   □ Disabled 
□ Chronic pain   □ Joint stiffness 
□ Deformity   □ Other 
 
29a. Has your doctor/ nurse ever told you to follow an exercise programme? 
□ Yes      □ No                            □ Not sure 
      
 
29b.  If yes, have you followed an exercise programme yet? 
□ Yes      □ No                           
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30a. During the last 3 months have you experienced pain, aching, swelling, stiffness 
(tightness) in or around your joints or back which is not related to an injury / 
accident? 
□ Yes      □ No                        □ Not sure 
 
 
30b. During the last 7 days have you experienced pain, aching, swelling, stiffness 
(tightness) in or around your joints or back which is not related to an injury / 
accident? 
□ Yes      □ No                         □ Not sure 
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ID code _ _ _ _ _ __ _ _ 
Date: _ _ _ _ _ __ _ __ _ _ _ _ __ _ __ _ _ _ _ __ _ _ 
Community Health Centre: _ _ _ _ _ __ _ __ _ _ _ _ __ _ __ _ _ _ _ __ _  
 
PHASE II: 
THE FOLLOWING QUESTIONS ASK ABOUT YOUR JOINT OR MUSCLE physical activityIN, 
STIFFNESS / TIGHTNESS OR SWELLING AROUND YOUR JOINTS, OR LESS MOVEMENT IN 
ANY JOINTS 
1a.  Please indicate on the figure below, with a  all the sites where you have 
experienced pain in the last 3 months and with a X all the sites where you have 
experienced swelling. 
 
Front     Back 
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1b.  Please indicate on the figure below, with a  all the sites where you have 
experienced pain in the last 7 days and with a X all the sites where you have 
experienced swelling. 
Front   Back 
 
 
 
 
 
 
 
2. When did your pain start? 
□ Less than 7 days ago     □ In the last 3 months                           
□ 3 months  to 1 year ago  □ More than 1 year ago              
  
3. How long does the episode of pain last? 
□ Few days    □ 4 to 6 weeks                           
□ 6 to 12 weeks              □ More than 3 months  
 
4. When is the pain most intense? 
□ In the morning      □ After an activity (doing something)                           
□ While resting at night            
□ Other  
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5a. During the last year have you experienced stiffness in your joints in the morning 
             after getting out of bed or after a long rest without movement? 
□ Yes      □ No               □ Not sure 
 
5b. If yes, indicate the site/s of stiffness in the following joints 
□ Neck   □ Upper Back   □ Toes 
□ Shoulder  □ Lower Back 
□ Elbow  □ Hip 
□ Wrist   □ Knee 
□ Fingers  □ Ankle 
 
6. Did the stiffness go away after exercise or movement of the joint? 
□ Yes      □ No                           
□ Not sure 
 
7. Have you been diagnosed with arthritis or other joint diseases like rheumatism? 
□ Yes      □ No                           
 
8. Have you been taking any medication for joint or back pain, not related to an 
injury, in the last 3 months? 
□ Yes      □ No                           
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9. If yes, what medication was used? 
□ Over the counter pain killers    □ Natural remedies, herbs, supplements                  
□ Over the counter anti-inflammatory drugs (NSAIDS’s)    
□ Prescribed anti-inflammatory drugs (NSAID’s)   
□ Injection                           
□ Other  
 
10. Did the medication reduce your joint pain or back pain? 
□ Yes      □ No  
 
11. Have you received any type of treatment, other than medication, for pain? 
□ Yes      □ No                           
 
12.  If yes, please specify the type of treatment that you received at the day hospital. 
 □ Exercise  □ Education  
□ Massage  □ Herbal/ natural 
□ Acupuncture  □ Electrotherapy machines 
□ Joint mobilizations □ Strapping/ bracing 
□ Other 
 
13. Did the above treatment reduce your joint pain or stiffness? 
□ Yes      □ No 
198 
 
14.  Which treatment worked best in reducing your pain and stiffness? 
 □ Exercise    □ Education  
□ Massage    □ Herbal/ natural 
□ Acupuncture    □ Electrotherapy machines 
□ Joint mobilizations   □ Strapping/ bracing 
□ Medication    □ Injection 
 
15. Are you easily depressed or get anxious because of the pain/ joint stiffness? 
 □ Yes      □ No                           
 
16. Do you experience abnormal sleeping patterns because of the pain /joint stiffness? 
 □ Yes      □ No                           
 
17. Do you feel physically tired due to the pain / joint stiffness (not able to manage 
everyday tasks)? 
 □ Yes      □ No                           
 
 
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE 
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8.7 Appendix VII: Brief Pain Inventory Questionnaire 
 
1. Throughout our lives, most of us have had pain from time to time (such as 
minor headaches, sprains, and toothaches). Have you had pain other than 
these everyday kinds of pain during the last week? 
□ Yes     □ No 
 
2. On the diagram, shade in the areas where you feel pain. Put an X on the 
area that hurts the most. 
 
 
 
 
 
 
 
 
 
 
 
 
3. Please rate your pain by circling the one number that best describes your 
pain at its worst in the last week. 
 
0   1   2 3 4   5 6          7           8         9         10 
No Pain      Pain as bad as you can imagine 
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4. Please rate your pain by circling the one number that best describes your 
pain at its least in the last week. 
 
0   1   2 3 4   5 6          7           8         9         10 
No Pain      Pain as bad as you can imagine 
   
5. Please rate your pain by circling the one number that best describes your pain on 
the average. 
 
0   1   2 3 4   5 6          7           8         9         10 
No Pain      Pain as bad as you can imagine 
         
6. Please rate your pain by circling the one number that tells how much pain 
you have right now. 
 
0   1   2 3 4   5 6          7           8         9         10 
No Pain      Pain as bad as you can imagine 
 
7. What treatments or medications are you receiving for your pain? 
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
________________________________________           ________________ 
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8. In the last week, how much relief have pain treatments or medications 
provided? Please circle the one percentage that most shows how much 
relief you have received. 
 
0%    10%    20%   30%   40%   50%   60%   70%   80%   90%   100% 
No Relief       Complete Relief 
 
9. Circle the one number that describes how much, during the past week, 
pain has interfered with your: 
A. General Activity 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
 
B. Mood 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
 
C. Walking Ability 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
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D. Normal Work (includes both work outside the home and housework) 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
 
E. Relations with other people 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
 
F. Sleep 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
 
G. Enjoyment of life 
 
0   1   2 3 4   5 6          7           8         9         10 
Does not interfere     Completely interferes 
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8.8 Appendix VIII: European Quality of Life-5 Dimensions 
 
 
 
 
 
 
 
 
 
 
Health Questionnaire 
South African English version 
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By placing a tick in one box in each group below, please indicate which statements best 
describe your own state of health TODAY. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
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Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
 
 
Compared with my general level of health over the past 12 months, my state of health 
today is: 
 
Better   PLEASE TICK 
Much the same  ONE 
Worse  BOX 
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To help people say how good or bad their state of health is, we have drawn a scale on 
which the best state you can imagine is marked 100 and the worst state you can imagine is 
marked 0. 
 
We would like you to indicate on this scale, in your 
opinion, how good or bad your own health is today. 
Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good 
or bad your state of health is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst imaginable 
state of health 
0 
Best imaginable 
state of health 
Your own 
state of health 
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Because all replies are anonymous, it will help us to understand your answers better if we 
have a little background data from everyone, as covered in the following questions. 
 
1. Have you experienced serious illness? Yes No 
  yourself   
  in your family   
  while caring for others   
 
2. What is your age in years ? 
 
3. Are you male or female? Male Female 
     
 
4. I smoke  
  I used to smoke  
  I have never smoked  
 
5. Do you now, or did you ever, work in Yes No 
 health services or social welfare?   
 
 If so, in what capacity? ........................................................................................  
 
 
PLEASE TICK 
APPROPRIATE BOXES 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
 
PLEASE TICK 
APPROPRIATE 
BOX 
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6. Which of the following best describes your main activity? 
  self employed  
  in formal employment   
  retired  
  homemaker/domestic worker  
  student  
  seeking work  
  other (please specify)   ..................................................  
 
    
7. What was the highest grade that you attained at school? ................................. 
 
  Yes No 
8. Do you have a diploma or equivalent?   
 
 
9. If you know the area/suburb in which you stay, please write it 
here................................. 
  
PLEASE TICK 
APPROPRIATE BOX  
 
PLEASE TICK 
APPROPRIATE BOX  
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8.9 Appendix IX: International Physical Activity Questionnaire 
(IPAQ) – Short Version 
 
We are interested in finding out about the kinds of physical activities 
that people do as part of their everyday lives. This is part of a large 
study being conducted in many countries around the world. Your 
answers will help us to understand how active we are compared with 
people in other countries. 
 
The questions are about the time you spent being physically active in 
the last 7 days. They include questions about activities you do at work, 
as part of your house and yard work, to get from place to place, and in 
your spare time for recreation, exercise or sport. 
Your answers are important. 
 
Please answer each question even if you do not consider yourself to 
be an active person. 
 
THANK YOU FOR PARTICIPATING. 
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In answering the following questions, 
 
 vigorous physical activities refer to activities that take hard 
physical effort and make you breathe much harder than normal. 
 moderate activities refer to activities that take moderate physical 
effort and make you breathe somewhat harder than normal. 
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1a.  During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling? 
 
Think about only those physical activities that you did for at least 10 minutes at a 
time. 
 
________ days per week     go to question 1b 
 
or 
 
 none  go to question 2a 
 
 
1b. How much time in total did you usually spend on one of those days doing vigorous 
physical activities? 
 
_____ hours ______ minutes 
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2a.  Again, think only about those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles tennis? Do 
not include walking. 
 
________ days per week   go to question 2b 
 
or 
 
     none  go question 3a 
 
 
 
2b.  How much time in total did you usually spend on one of those days doing 
moderate physical activities? 
 
_____ hours ______ minutes 
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3a.  During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time? This includes walking at work and at home, walking to travel from place to 
place, and any other walking that you did solely for recreation, sport, exercise or 
leisure. 
 
________ days per week   go to question 3b 
 
or 
 
     none  go to question 4 
 
3b.  How much time in total did you usually spend walking on one of those days? 
 
_____ hours ______ minutes 
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The last question is about the time you spent sitting on weekdays while at work, at 
home, while doing course work and during leisure time. This includes time spent sitting 
at a desk, visiting friends, reading travelling on a bus or sitting or lying down to watch 
television. 
 
4.  During the last 7 days, how much time in total did you usually spend sitting on a 
week day? 
 
____ hours ______ minutes 
 
 
This is the end of questionnaire, thank you for participating.  
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8.10 Appendix X: Anthropometric Measurements 
 
ID code _ _ _ _ _ __ _ _ 
Date: _ _ _ _ _ __ _ __ _ _ _ _ __ _ __ _ _ _ _ __ _ _ 
Community Health Centre: _ _ _ _ _ __ _ __ _ _ _ _ __ _ __ _ _ _ _ __ _  
 
Description First Second Third Average 
Height  (cm) 
– to nearest 0.1 cm 
    
Weight  (kg) 
– accurate to 0.05 kg 
    
Body Mass Index 
(weight in kg ÷ height in 
cm2) 
    
Waist measurement (cm) 
– to nearest 0.1 cm 
    
Hip measurement (cm) 
– to nearest 0.1 cm 
    
Waist-Hip Ratio 
(waist in cm ÷ hip in cm) 
    
 
